Page last updated: 2024-12-04

dimethyl sulfoxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID679
CHEMBL ID504
CHEBI ID28262
MeSH IDM0006456

Synonyms (225)

Synonym
BIDD:PXR0182
dimethyli sulfoxidum
s(o)me2
dimethyl sulfur oxide
(ch3)2so
dimethylsulfoxyde
CHEBI:28262 ,
sulfinylbis(methane)
dimetil sulfoxido
(methanesulfinyl)methane
dimethylsulfoxid
rimso-50
dms-90
dimexidum
caswell no. 381
ai3-26477
methyl sulfoxide (8ci)
ccris 943
dimethylsulfoxide
topsym
methane, sulfinylbis- (9ci)
nsc 763
epa pesticide chemical code 000177
sq-9453
sulfinyldimethane
kemsol
inchi=1/c2h6os/c1-4(2)3/h1-2h
c2h6os
dimethylsulfoxyde [inn-french]
rimso-5
dimethylsulphoxide
domoso (veterinary)
einecs 200-664-3
topsym (rescinded)
dimethylsulphinyl
hsdb 80
dimetilsolfossido [dcit]
dimethyli sulfoxidum [inn-latin]
dimetil sulfoxido [inn-spanish]
dms-70
dimethyl sulphoxide
nsc763
gamasol 90
durasorb
domoso
doligur
demasorb
demeso
dms 90
dimethyl sulfoxide
deltan
wln: os1&1
demavet
methane, sulfinylbis-
demsodrox
dipirartril-tropico
hyadur
methyl sulfoxide
67-68-5
somipront
DMSO ,
a 10846
infiltrina
dms 70
rimso 50
nsc-763
sulfinylbismethane
dimexide
dromisol
dolicur
m 176
syntexan
sq 9453
methylsulfinylmethane
sulfinylbis-methane
(dmso)
dermasorb
dimethyl sulfoxide, for molecular biology
dimethyl sulfoxide, aldrasorb(tm), 99.8%
dimethyl sulfoxide, >=99.5% (gc), plant cell culture tested
dimethyl sulfoxide, hybri-max(tm), sterile-filtered, bioreagent, suitable for hybridoma, >=99.7%
dimethyl sulfoxide, pcr reagent
dimethyl sulfoxide, >=99%
dimethyl sulfoxide, sterile-filtered, bioperformance certified, meets ep, usp testing specifications, suitable for hybridoma
DB01093
D01043
dimethyl sulfoxide (jan/usp/inn)
rimso-50 (tn)
dimethyl sulfoxide, acs spectrophotometric grade, >=99.9%
D1159
NCGC00163958-01
dtxsid2021735 ,
sulfoxide, dimethyl
sulphoxide, dimethyl
dimethyl sulfoxide, bioultra, for molecular biology, >=99.5% (gc)
dimethyl sulfoxide, puriss., absolute, over molecular sieve (h2o <=0.005%), >=99.5% (gc)
dimethyl sulfoxide, meets ep testing specifications, meets usp testing specifications
dimethyl sulfoxide, meets ep, usp testing specifications
dimethyl sulfoxide, anhydrous, >=99.9%
D0798
CHEMBL504 ,
(methanesulfinyl)methanedimethyl sulfoxide
bdbm50026472
AKOS000121107
NCGC00163958-03
NCGC00163958-02
methylsulfoxide
cas-67-68-5
tox21_300957
dtxcid401735
NCGC00254859-01
pharmakon1600-01506122
nsc-760436
nsc760436
dimethyl sulpoxide
methanesulfinylmethane
dimethyl sulfoxide [usan:usp:inn:ban]
dimetilsolfossido
methane, 1,1'-sulfinylbis-
yow8v9698h ,
unii-yow8v9698h
ec 200-664-3
FT-0625100
FT-0625099
dmso [inci]
dimethyl sulfoxide [vandf]
dimethyl sulfoxide [usp monograph]
dimethyl sulfoxide [who-dd]
dimethyl sulfoxide [orange book]
methyl sulphoxide
dimethyl sulfoxide [mi]
dimethyl sulfoxide [hsdb]
dimethyl sulfoxide [green book]
dimethyl sulfoxide [ii]
dimethyl sulfoxide [inn]
dimethyl sulfoxide [usan]
dimethyl sulfoxide [jan]
dimethyl sulfoxide [mart.]
dimethyl sulfoxide [ep monograph]
methylsulfinylmethane [fhfi]
dimethyl sulfoxide [usp-rs]
STL264194
(methylsulfinyl)methane
CCG-213615
dimethyl sulfoxide, acs reagent
dimethyl sulf oxide
dimethvlsulfoxide
dimethlysulfoxide
dimethyl-sulphoxide
dimethyl-sulfoxide
dimethyl-sulfoxyde
dimethy sulfoxide
dimethysulfoxide
dimethyl suiphoxide
dimethylsulphoxid
dimethyisulfoxide
dimethyl sulfoxyde
h3c-so-ch3
dirnethyl sulfoxide
dimetyl sulfoxide
dimethyisulphoxide
methylsulfmylmethane
dmso, sterile filtered
AB01563146_01
mfcd00002089
dimethyl sulfoxide, hplc grade
dimethyl sulfoxide, analytical standard
dimethyl sulfoxide, anhydrous
dimethyl sulfoxide, united states pharmacopeia (usp) reference standard
dimethyl sulfoxide, acs reagent, >=99.9%
dimethyl sulfoxide, >=99.6%, reagentplus(r)
dimethyl sulfoxide, >=99.0%, suitable for absorption spectrum analysis
dimethyl sulfoxide, puriss. p.a., acs reagent, >=99.9% (gc)
dimethyl sulfoxide, saj first grade, >=99.0%
dimethyl sulfoxide, for inorganic trace analysis, >=99.99995% (metals basis)
dimethyl sulfoxide, jis special grade, >=99.0%
dimethyl sulfoxide, >=99.5%
dimethyl sulfoxide, hplc grade, 99.9%
dimethyl sulfoxide, for hplc, >=99.7%
dimethyl sulfoxide, for hplc
dimethyl sulfoxide, puriss. p.a., dried, <=0.02% water
dimethyl sulfoxide, for hplc, >=99.5%
dimethyl sulfoxide, european pharmacopoeia (ep) reference standard
dimethyl sulfoxide, reagentplus(r), >=99.5%
dimethyl sulfoxixde
dimethyl sulfoxide, p.a., 99%
dimethyl sulfoxide, anhydrous, zero2(tm), >=99.9%
dimethyl sulfoxide, p.a., acs reagent, 99.9%
dimethyl sulfoxide, lr, >=99%
dimethyl sulfoxide, ar, >=99.5%
dimethyl sulfoxide, vetec(tm) reagent grade, 99%
methyl sulfoxide, >=99%, fg
dimethyl sulfoxide, vetec(tm) reagent grade, anhydrous, >=99.7%
dimethyl sulfoxide, uv hplc spectroscopic, 99.9%
MRF-0000764
dmso (sterile-filtered)
Q407927
HB3262
dmso (dimethyl sulfoxide)
103759-08-6
D5293
dimethyl sulfoxide [for spectrophotometry]
AMY14894
dimethyl sulfoxide (dmso)
dimethyl sulfoxide, 99%
CS-B1637
8070-53-9
HY-Y0320
EN300-24544
methyl-13c sulfoxide
dimethyl sulfoxide (ep monograph)
domoso solution
dimethylis sulfoxidum
usepa/opp pesticide code: 000177
dimethyl sulfoxide (ii)
dimethyl sulfoxide (usp-rs)
dimehtylsulfoxyde
dimethyl sulfoxide (usp monograph)
domoso gel
g04bx13
m02ax03
dimethyl sulfoxide (mart.)
dimethyl sulfoxide (dmso), cell culture reagent
Z199055774
dimethyl sulfoxide; aif; ce0; ms2dec

Research Excerpts

Overview

Dimethyl sulfoxide (DMSO) is a highly utilized small molecule that serves many purposes in scientific research. It is a universal water-soluble solvent widely used in many biotechnological and medical applications, such as cells cryopreservation, and for the treatment of different human diseases.

ExcerptReferenceRelevance
"Dimethyl sulfoxide (DMSO) is a highly reactive by-product of paper production in the form of an odorless, colorless liquid that has been studied since the 1860s. "( DMSO: an aid to combat pain and pruritus.
Anzelc, M; Burkhart, CG, 2021
)
2.06
"Dimethyl sulfoxide (DMSO) is a highly utilized small molecule that serves many purposes in scientific research. "( Low dose DMSO treatment induces oligomerization and accelerates aggregation of α-synuclein.
Baun, A; Gram, H; Haikal, C; Jensen, PH; Kovacs, G; Li, JY; Nielsen, J; Otzen, DE; Reimer, L; Ruesink, H; Theologidis, V, 2022
)
2.16
"Dimethyl sulfoxide (DMSO) is a commonly used cryoprotectant that may allow for better structural preservation of samples by impairing ice damage that occurs during plunge/snap freezing."( Chemical and cryo-collection of muscle samples for transmission electron microscopy using Methacarn and dimethyl sulfoxide
Fletcher, E; Ismaeel, A; Koutakis, P; Miserlis, D; Wilburn, D; Zechmann, B, 2022
)
1.66
"Dimethyl sulfoxide (DMSO) is a clear, odorless liquid, inexpensively produced as a by-product of the wood pulp industry. "( Dimethyl sulfoxide (DMSO): a solvent that may solve selected cutaneous clinical challenges.
Boikess, RS; Cohen, PJ; Karim, M; Schwartz, RA, 2023
)
3.8
"Dimethyl sulfoxide (DMSO) is a universal water-soluble solvent widely used in many biotechnological and medical applications, such as cells cryopreservation, and for the treatment of different human diseases (e.g. "( Solvation properties of raft-like model membranes.
Del Vecchio, P; Gironi, B; Morresi, A; Oliva, R; Paolantoni, M; Petraccone, L; Sassi, P, 2019
)
1.96
"Dimethyl sulfoxide (DMSO) is an excellent solvent for various types of anticancer drugs. "( Hyaluronic acid thiol modified injectable hydrogel: Synthesis, characterization, drug release, cellular drug uptake and anticancer activity.
Fan, D; Wei, S; Xu, K; Yao, H; Zhou, L, 2021
)
2.06
"Dimethyl sulfoxide (DMSO) is a well-known organic solvent that is often used to dissolve phase I reagents in toxicology and oxidative stress research experiments."( Dimethyl sulfoxide stimulates the AhR-Jdp2 axis to control ROS accumulation in mouse embryonic fibroblasts.
Chan, TF; Chen, HL; Hou, MF; Huang, SK; Kato, K; Kishikawa, S; Ku, CC; Kuo, KK; Lin, CS; Lin, YC; Liu, CJ; Nakade, K; Nakamura, Y; Noguchi, M; Pan, JB; Tsai, MH; Wu, DC; Wuputra, K; Yang, YH; Yokoyama, KK, 2022
)
2.89
"Dimethyl sulfoxide (DMSO) is a widely used solvent to dissolve hydrophobic substances for clinical uses and experimental in vivo purposes. "( Exposure to DMSO during infancy alters neurochemistry, social interactions, and brain morphology in long-evans rats.
Berman, R; Chan, J; Fan, S; Fiehn, O; Heil, H; Lechpammer, M; Martínez-Cerdeño, V; Morningstar, T; Nudler, E; Rabow, Z; Showalter, M; Thongphanh, K; Zagzag, D, 2021
)
2.06
"Dimethyl sulfoxide (DMSO) is an amphipathic molecule widely used as a solvent for water-insoluble substances, cryopreserving, and cell-biological therapies. "( Application of Dimethyl Sulfoxide as a Therapeutic Agent and Drug Vehicle for Eye Diseases.
Fang, W; Han, B; Hoang, BX; Hoang, C; Nguyen, AK; Nguyen, TQ; Tran, HD, 2021
)
2.42
"Dimethyl sulfoxide (DMSO) is a common additive used in such assays and enhances the solubility of assay components."( Dimethyl sulfoxide reduces the stability but enhances catalytic activity of the main SARS-CoV-2 protease 3CLpro.
Fadl, S; Ferreira, JC; Ilter, M; Pekel, H; Rabeh, WM; Rezgui, R; Sensoy, O, 2021
)
2.79
"Dimethyl sulfoxide (DMSO) is a universally used aprotic solvent with the ability to permeate biological membranes and thus is commonly used to achieve appropriate biological availability of hydrophobic toxicants. "( Unsuitable use of DMSO for assessing behavioral endpoints in aquatic model species.
Campana, O; Cartlidge, R; Huang, Y; Kaslin, J; Walpitagama, M; Wlodkowic, D, 2018
)
1.92
"Dimethyl sulfoxide (DMSO) is a polar organic solvent used in a wide range of biological applications. "( CD4
Bonifacio, E; Gavrisan, A; Holthaus, L; Jastroch, M; Lamp, D; Sharma, V; Ziegler, AG, 2018
)
1.92
"Dimethyl sulfoxide (DMSO) is a small molecule with polar, aprotic and amphiphilic properties. "( Low dose dimethyl sulfoxide driven gross molecular changes have the potential to interfere with various cellular processes.
Banerjee, S; Esenturk, O; Gurbanov, R; Sheraj, I; Solel, E; Tunçer, S, 2018
)
2.34
"Dimethyl sulfoxide (DMSO) is a dipolar aprotic solvent widely used in biological assays. "( Enhanced elevations of hypo-osmotic shock-induced cytosolic and nucleic calcium concentrations in tobacco cells by pretreatment with dimethyl sulfoxide.
Bouteau, F; Kawano, T; Kuse, M; Mazars, C; Nguyen, HTH, 2019
)
2.16
"Dimethyl sulfoxide (DMSO) is an effective radical scavenger and, when added to cells, reduces the initial number of radiation-induced DNA double-strand breaks (DSB). "( Impact of dimethyl sulfoxide on irradiation-related DNA double-strand-break induction, -repair and cell survival.
Debus, J; Hauswald, H; Huber, PE; Weber, KJ; Zwicker, F, 2019
)
2.36
"Dimethyl sulfoxide (DMSO) is an amphipathic molecule widely used to solubilize water-insoluble compounds. "( Antiepileptic effect of dimethyl sulfoxide in a rat model of temporal lobe epilepsy.
Cannizzaro, C; Carletti, F; Ferraro, G; Rizzo, V; Sardo, P, 2013
)
2.14
"Dimethyl sulfoxide (DMSO) is an important aprotic solvent that can solubilize a wide variety of otherwise poorly soluble polar and nonpolar molecules. "( Unexpected low-dose toxicity of the universal solvent DMSO.
Cordeiro, MF; Davis, B; Duchen, MR; Galvao, J; Normando, E; Tilley, M, 2014
)
1.85
"Dimethyl sulfoxide (DMSO) is an amphipathic molecule that is commonly/widely used as a solvent for biological compounds. "( Dimethyl sulfoxide inhibits NLRP3 inflammasome activation.
Ahn, H; Jeung, EB; Kim, J; Lee, GS, 2014
)
3.29
"Dimethyl sulfoxide (DMSO) is a commonly used penetration enhancer, which has anti‑inflammatory analgesic effects and is able to penetrate the skin."( Use of lipolanthionine peptide, a toll-like receptor 2 inhibitor, enhances transdermal delivery efficiency.
Chen, B; Liu, DL; Mao, QL; Pan, WY; Shou, JB; Wang, J; Wu, JH; Yang, XH, 2014
)
1.12
"Dimethyl sulfoxide (DMSO) is an amphipathic molecule with potential of delivering both lipophilic and hydrophilic agents into cells, also a common cryoprotectant for freezing of the cells."( The effect of dimethyl sulfoxide on hepatic differentiation of mesenchymal stem cells.
Akbarzadeh, A; Alizadeh, E; Barzegar, A; Eslaminejad, MB; Mohammadi, SA; Zarghami, N, 2016
)
1.52
"Dimethyl sulfoxide (DMSO) is a polar organic solvent that is used to dissolve neuroprotective or neurotoxic agents in neuroscience research. "( Dimethyl sulfoxide damages mitochondrial integrity and membrane potential in cultured astrocytes.
Bai, L; Cai, Z; Gao, J; Guo, J; Marshall, C; Wang, L; Xiao, M; Yuan, C, 2014
)
3.29
"Dimethyl sulfoxide (DMSO) is a solvent for organic and inorganic substances and an organ-conserving agent used in solid organ transplantations."( Dimethyl sulfoxide inhibits spontaneous diabetes and autoimmune recurrence in non-obese diabetic mice by inducing differentiation of regulatory T cells.
Chan, DC; Chang, HM; Chen, YW; Huang, SH; Kuo, YL; Lin, GJ; Sytwu, HK; Yu, CC; Yu, JC, 2015
)
2.58
"Dimethyl sulfoxide (DMSO) is an FDA-approved organosulfur solvent that is reported to have therapeutic value in osteoarthritis and osteopenia. "( Inhibition of differentiation and function of osteoclasts by dimethyl sulfoxide (DMSO).
Cui, Q; Dighe, AS; Du, X; Madhu, V; Thomas, C; Yang, C; Yang, X, 2015
)
2.1
"Dimethyl sulfoxide (DMSO) is a common solvent and biological additive possessing well-known utility in cellular cryoprotection and lipid membrane permeabilization, but the governing mechanisms at membrane interfaces remain poorly understood. "( Correlating steric hydration forces with water dynamics through surface force and diffusion NMR measurements in a lipid-DMSO-H2O system.
Cheng, CY; Donaldson, SH; Han, S; Israelachvili, JN; Lee, DW; Schrader, AM; Song, J, 2015
)
1.86
"Dimethyl sulfoxide (DMSO) is a solvent that is commonly used in medicine. "( Dimethyl sulfoxide attenuates nitric oxide generation via modulation of cationic amino acid transporter-1 in human umbilical vein endothelial cells.
Bentur, OS; Chernichovski, T; Ingbir, M; Schwartz, IF; Weinstein, T, 2016
)
3.32
"Dimethyl sulfoxide (DMSO) is a popular cryoprotective agent; however, its cytotoxicity cannot be ignored."( StemCell Keep™ Is Effective for Cryopreservation of Human Embryonic Stem Cells by Vitrification.
Hyon, SH; Lee, JJ; Matsumura, K; Ota, A; Sumi, S, 2017
)
1.18
"Dimethyl sulfoxide (DMSO) is a universal solvent widely used in many fields, from basic research to industrial applications. "( DMSO-induced perturbation of thermotropic properties of cholesterol-containing DPPC liposomes.
Del Vecchio, P; Morresi, A; Oliva, R; Paolantoni, M; Ricci, M; Sassi, P, 2016
)
1.88
"Dimethyl sulfoxide (DMSO) is a widely used solvent and vehicle for in vivo and in vitro administration of test compounds. "( Effects of dimethyl sulfoxide on the morphology and viability of primary cultured neurons and astrocytes.
Bing, G; Dai, H; Deng, Y; Tian, J; Zhang, C; Zhao, L; Zhou, W, 2017
)
2.29
"Dimethyl sulfoxide (DMSO) is a cryoprotective agent used in storage of frozen stem cells in stem cell transplantation. "( Neurotoxicity Associated With Dimethyl Sulfoxide Used in Allogeneic Stem Cell Transplantation.
Ataseven, E; Güleryüz, H; Ören, H; Tüfekçi, Ö; Yilmaz, Ş, 2017
)
2.19
"Dimethyl sulfoxide (DMSO) is an anti-inflammatory, antibacterial, analgesic drug widely used to treat several diseases as reported in the literature. "( Effects of DMSO on a rabbit ear hypertrophic scar model: A controlled randomized experimental study.
Bakar, B; Budak Yildiran, FA; Dincel, GC; Sari, E, 2017
)
1.9
"Dimethyl sulfoxide (DMSO) is a solvent that is routinely used as a cryopreservative in allogous bone marrow and organ transplantation. "( Dimethyl sulfoxide (DMSO) produces widespread apoptosis in the developing central nervous system.
Farber, NB; Hanslick, JL; Lau, K; Mennerick, S; Noguchi, KK; Olney, JW; Zorumski, CF, 2009
)
3.24
"Dimethyl sulfoxide (DMSO) is an organic compound widely used as solvent in biological studies and as vehicle for drug administration. "( Protective effect of dimethyl sulfoxide on acute myocardial infarction in rats.
Alfieri, A; Cicala, C; Mascolo, N; Mazzella, A; Mazzella, M; Parisi, A; Scognamiglio, G; Scognamiglio, M, 2010
)
2.12
"Dimethyl sulfoxide (DMSO) is a widely used vehicle for water-insoluble substances and exerts a wide range of pharmacologic effects including anti-inflammatory and free radical scavenging properties. "( Dimethyl sulfoxide prevents 7β-hydroxycholesterol-induced apoptosis by preserving lysosomes and mitochondria.
Laskar, A; Li, W; Yuan, XM, 2010
)
3.25
"Dimethyl sulfoxide (DMSO) is an important solvent that is widely used in industry and medical studies, as well as in the study of aging, in which it is used as a negative control for lifespan assays; however, our data showed that 0.5% and 2% DMSO extended the lifespan of Caenorhabditis elegans by 24.4% and 23.0% (the first trial), respectively. "( Lifespan extension in Caenorhabditis elegans by DMSO is dependent on sir-2.1 and daf-16.
Li, L; Wang, D; Wang, X, 2010
)
1.8
"Dimethyl sulfoxide (DMSO) is a naturally derived, inexpensive, non-toxic solvent and pharmaceutical agent that has been demonstrated to have numerous health enhancing and therapeutic benefits."( Dimethyl sulfoxide as an excitatory modulator and its possible role in cancer pain management.
Hoang, BX; Hoang, C; Levine, SA; Nguyen, PM; Pham, PT; Shaw, DG; Tran, DM; Tran, HD; Tran, HQ, 2010
)
2.52
"Dimethyl sulfoxide is an amphiphilic compound whose miscibility with water and its ability to dissolve lipophilic compounds make it an appreciated solvent in biomedical research. "( Antioxidant properties of dimethyl sulfoxide and its viability as a solvent in the evaluation of neuroprotective antioxidants.
Méndez-Álvarez, E; Sánchez-Sellero, I; Sanmartín-Suárez, C; Soto-Otero, R,
)
1.87
"Dimethyl sulfoxide is a very useful solvent that may be used at relatively low concentrations in the development of new antioxidants with neuroprotective properties."( Antioxidant properties of dimethyl sulfoxide and its viability as a solvent in the evaluation of neuroprotective antioxidants.
Méndez-Álvarez, E; Sánchez-Sellero, I; Sanmartín-Suárez, C; Soto-Otero, R,
)
1.87
"Dimethyl sulfoxide (DMSO) is a well-known organic solvent that can be used for biological applications. "( Hypersensitive luminescence of Eu3+ in dimethyl sulfoxide as a new probing for water measurement.
Chen, W; Yao, M, 2011
)
2.08
"Dimethyl sulfoxide (DMSO) is a widely used solvent for water-insoluble molecules and it has antioxidant, neuroprotective and cryopreservative effects. "( The effect of intraperitoneally administered dimethyl sulfoxide on absence-like epileptic activity of freely moving WAG/Rij rats.
Czurkó, A; Juhász, G; Kékesi, KA; Kovács, Z, 2011
)
2.07
"Dimethyl sulfoxide (DMSO) is a very common organic solvent used for dissolving lipophilic substances, for example for in vitro cell-based assays. "( Effects of DMSO on gene expression in human and rat hepatocytes.
Abe-Tomizawa, K; Aoki, M; Igarashi, Y; Matsushita, T; Ohno, Y; Sumida, K; Toritsuka, N; Urushidani, T; Yamada, H, 2011
)
1.81
"Dimethyl sulfoxide is a moderately cohesive solvent, reasonably dipolar/polarizable and strongly hydrogen-bond basic."( Models for liquid-liquid partition in the system dimethyl sulfoxide-organic solvent and their use for estimating descriptors for organic compounds.
Karunasekara, T; Poole, CF, 2011
)
1.34
"Dimethyl sulfoxide (DMSO) is a small amphipathic solvent molecule capable of stimulating cell differentiation."( Myocyte enhancer factor 2c, an osteoblast transcription factor identified by dimethyl sulfoxide (DMSO)-enhanced mineralization.
Bacic-Welsh, D; Hobbs, C; Hutmacher, DW; Morrison, NA; Stephens, AS; Stephens, SR; Woodruff, MA, 2011
)
1.32
"Dimethyl sulfoxide (DMSO) is a molecule with a long history in pharmaceutics and is now well established as a penetration enhancer in topical pharmaceutical formulations. "( Dimethyl sulfoxide: an effective penetration enhancer for topical administration of NSAIDs.
Marren, K, 2011
)
3.25
"Dimethyl sulfoxide (DMSO) is an amphipathic molecule that displays a diversity of antitumor activities. "( Dimethyl sulfoxide promotes the multiple functions of the tumor suppressor HLJ1 through activator protein-1 activation in NSCLC cells.
Chen, JJ; Hsu, YL; Lai, YH; Lin, SY; Liu, YJ; Wang, CC, 2012
)
3.26
"Dimethyl sulfoxide (DMSO) is a chemical of industrial significance with many important applications. "( Direct measurement of part-per-billion levels of dimethyl sulfoxide in water by gas chromatography with stacked injection and chemiluminescence detection.
Cortes, HJ; Gras, R; Luong, J; Shellie, RA, 2012
)
2.08
"Dimethyl sulfoxide (DMSO) is an efficient solvent for water-insoluble compounds, widely used in biological studies and as a vehicle for drug therapy, but few data on its neurotoxic or behavioural effects is available. "( Behavioural effects of dimethyl sulfoxide (DMSO): changes in sleep architecture in rats.
Beltrán, D; Cavas, M; Navarro, JF, 2005
)
2.08
"Dimethyl sulfoxide (DMSO) is a "universal" solvent in pharmaceutical sciences and cell biology. "( Dimethyl sulfoxide targets phage RNA polymerases to promote transcription.
Chen, Z; Zhang, Y, 2005
)
3.21
"Dimethyl sulfoxide (DMSO) is a widely used prototypical chemical inducer of cell differentiation. "( Dimethyl sulfoxide potentiates death receptor-mediated apoptosis in the human myeloid leukemia U937 cell line through enhancement of mitochondrial membrane depolarization.
Andrysík, Z; Chramostová, K; Hofmanová, J; Kozubík, A; Sheard, MA; Soucek, K; Vondrácek, J, 2006
)
3.22
"Dimethyl sulfoxide (DMSO) is a water miscible solvent that is used extensively for receptor ligands in osteoblast studies."( Dimethyl sulfoxide as an inducer of differentiation in preosteoblast MC3T3-E1 cells.
Cheung, WM; Kung, AW; Ng, WW, 2006
)
2.5
"Dimethyl Sulfoxide (DMSO) is a common solvent for pharmacological agents. "( Transient osmotic absorption of fluid in microvessels exposed to low concentrations of dimethyl sulfoxide.
Bates, DO; Glass, CA; Perrin, RM; Pocock, TM, 2006
)
2
"Dimethyl sulfoxide (DMSO) is a small amphiphilic molecule which is widely employed in cell biology as an effective penetration enhancer, cell fusogen, and cryoprotectant. "( Modulating the structure and properties of cell membranes: the molecular mechanism of action of dimethyl sulfoxide.
Anwar, J; Gurtovenko, AA, 2007
)
2
"Dimethyl sulfoxide (DMSO) is a well-tolerated, safe drug that is a powerful scavenger of the hydroxyl free radical."( Dimethyl sulfoxide increases the survival of primarily ischemic island skin flaps.
Angel, MF; Carpenter, RJ; Morgan, RF, 1994
)
2.45
"Dimethyl sulfoxide is a commonly used solvent which has been used therapeutically."( Posttranscriptional elevation of cytochrome P450 3A expression.
Hernandez, M; Novak, RF; Zangar, RC, 1997
)
1.02
"Dimethyl sulfoxide (DMSO) is a well-known hydroxyl radical scavenger, which is readily absorbed through biological membranes. "( Failure of topical DMSO to improve blood flow or evoked potentials in rat spinal cord injury.
Park, YK; Tator, CH, 1998
)
1.74
"Dimethyl sulfoxide (DMSO) is a chemical compound that is used to preserve haematopoietic stem cells during freezing at -180 degrees C. "( Quantification of residual dimethyl sulfoxide in supernatants of haematopoietic stem cells by capillary zone electrophoresis.
Anselme, M; Bousquet, B; Dal Cortivo, L; Gourmel, B; Houzé, P, 1999
)
2.04
"Dimethyl sulfoxide (DMSO) is a potent antioxidant which protects against endotoxemia and septic shock in animal models. "( Therapeutic effect of dimethyl sulfoxide on ICAM-1 gene expression and activation of NF-kappaB and AP-1 in septic rats.
Albarillo, MV; Chang, CK; Schumer, W, 2001
)
2.07
"Dimethyl sulfoxide is a more efficient hydroxyl radical scavenger than the other three scavengers and increased the formation of nitrogen dioxide from peroxynitrite."( Bactericidal activity of peroxynitrite.
Beckman, JS; Gunn, C; Zhu, L, 1992
)
1
"Dimethyl sulfoxide (DMSO) is an organic solvent with myriad biological actions, including actions on synaptic membrane transport processes. "( Opposite effects of dimethyl sulfoxide and ethanol on synaptic membrane fluidity.
Mrak, RE,
)
1.9
"Dimethyl sulfoxide (Me2SO) is a widely used cryoprotectant for biological structures such as membranes. "( Insights into the cryoprotective mechanism of dimethyl sulfoxide for phospholipid bilayers.
Anchordoguy, TJ; Cecchini, CA; Crowe, JH; Crowe, LM, 1991
)
1.98
"Dimethyl sulfoxide is a hydroxyl radical scavenger that readily penetrates cell membranes."( Dimethyl sulfoxide antagonizes hypotensive, metabolic, and pathologic responses induced by endotoxin.
Brackett, DJ; Lerner, MR; Wilson, MF, 1991
)
2.45
"Dimethyl sulfoxide (DMSO) is a dipolar organic compound commonly used as a solvent in studies of membrane transport. "( Dimethyl sulfoxide affects water flow through a nonosmolar action.
Kurtzman, NA; Lim, HK; Sabatini, S; Wharton, JC, 1989
)
3.16
"Dimethyl sulfoxide is a widely accepted and recommended solvent in which to dissolve compounds to be tested for mutagenicity via the Ames Salmonella/mammalian microsome assay. "( The involvement of dimethyl sulfoxide in a bacteriotoxic response of the Ames assay tester strains TA98 and TA100.
Baptista, JA; Krepinsky, JJ; Perdomo, GR; Vaughan, DJ, 1989
)
2.05
"Dimethyl sulfoxide (DMSO) is an inorganic compound with many interesting in vitro properties, including the ability to scavenge oxygen-free radicals. "( The effects of dimethyl sulfoxide on posttraumatic limb swelling and joint stiffness. A review and an experimental study in rabbits.
Dorey, FJ; Kabo, JM; Meals, RA; More, RC, 1988
)
2.07
"Dimethyl sulfoxide is a well-known differentiating agent that has been shown to inhibit tumor growth in vitro. "( Synergistic cytotoxicity between dimethyl sulfoxide and antineoplastic agents against ovarian cancer in vitro.
Fletcher, WS; Milo, G; Pommier, RF; Woltering, EA, 1988
)
2
"Dimethyl sulfoxide (DMSO) is a very simple compound that has stimulated much controversy in the scientific and popular literature. "( Dimethyl sulfoxide (DMSO): a review.
Brayton, CF, 1986
)
3.16

Effects

Dimethyl sulfoxide (DMSO) has a variety of biological actions that suggest efficacy as a neuroprotectant. DMSO has a significant, multi-faceted role in medicine, pharmacy, and biology as well as in biophysical chemistry and catalysis.

Dimethyl sulfoxide (DMSO) has been widely used in the treatment of arthritis and certain inflammatory diseases. It is also considered an alternative remedy for cancer even if not supported by concrete evidence.

ExcerptReferenceRelevance
"Dimethyl sulfoxide (DMSO) has a significant, multi-faceted role in medicine, pharmacy, and biology as well as in biophysical chemistry and catalysis. "( Unscrambling micro-solvation of -COOH and -NH groups in neat dimethyl sulfoxide: insights from
Boulougouris, GC; Melissas, VS; Papavasileiou, KD; Peristeras, LD; Takis, PG; Troganis, AN, 2017
)
2.14
"Dimethyl sulfoxide (DMSO) has a variety of biological actions that suggest efficacy as a neuroprotectant. "( Effects of intravenous dimethyl sulfoxide on ischemia evolution in a rat permanent occlusion model.
Bardutzky, J; Bouley, J; Duong, TQ; Fisher, M; Meng, X; Ratan, R, 2005
)
2.08
"Dimethyl sulfoxide (DMSO) has a variety of properties suggesting that it may be a useful agent in the management of central nervous system trauma and stroke. "( Effect of dimethyl sulfoxide on the cerebral and systemic circulations of the dog.
Boarini, DJ; Kassell, NF; Olin, JJ; Sprowell, JA, 1983
)
2.11
"Dimethyl sulfoxide (DMSO) has been used not only as an experimental solvent, but also as a therapeutic agent for interstitial cystitis. "( Dimethyl Sulfoxide Enhances Acetylcholine-Induced Contractions in Rat Urinary Bladder Smooth Muscle by Inhibiting Acetylcholinesterase Activities.
Abe, Y; Fujii, A; Ikegami, Y; Iwata, N; Matsuoka, Y; Obara, K; Tanaka, Y; Yoshioka, K, 2023
)
3.8
"Dimethyl sulfoxide (DMSO) has a significant, multi-faceted role in medicine, pharmacy, and biology as well as in biophysical chemistry and catalysis. "( Unscrambling micro-solvation of -COOH and -NH groups in neat dimethyl sulfoxide: insights from
Boulougouris, GC; Melissas, VS; Papavasileiou, KD; Peristeras, LD; Takis, PG; Troganis, AN, 2017
)
2.14
"Dimethyl sulfoxide (DMSO) has been known for almost 150 years, but its properties as a solvent and reaction medium are far from being understood. "( Self-association and picosecond dynamics in liquid dimethyl sulfoxide.
Ataev, MB; Gafurov, MM; Gorobets, MI; Kirillov, SA; Rabadanov, KSh, 2013
)
2.08
"Dimethyl sulfoxide (DMSO) has been suggested as a traditional chemical probe for assessing skin susceptibility and barrier function. "( Dimethyl sulfoxide could be a useful probe to evaluate unusual skin angioneurotic reaction and epidermal permeability.
Chen, SY; Dong, YQ; Gao, YR; Li, SY; Liu, XP; Liu, YQ; Wang, XM, 2014
)
3.29
"Dimethyl sulfoxide (DMSO) has been broadly used in biology as a cosolvent, a cryoprotectant, and an enhancer of membrane permeability, leading to the general assumption that DMSO-induced structural changes in cell membranes and their hydration water play important functional roles. "( DMSO induces dehydration near lipid membrane surfaces.
Cheng, CY; Han, S; Meijer, LH; Pas, J; Song, J, 2015
)
1.86
"Dimethyl sulfoxide (DMSO) has been used for years as a cryoprotectant agent; it acts by penetrating the cell and binding water molecules and it has been described as harmless for the individual who receives it in limited amounts."( Dimethyl sulfoxide-induced toxicity in cord blood stem cell transplantation: report of three cases and review of the literature.
Gómez-Almaguer, D; Hernández-Arizpe, A; López-Otero, A; Mancías-Guerra, C; Rodríguez-Romo, LN; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Tamez-Gómez, EL, 2009
)
2.52
"Dimethyl sulfoxide (DMSO) has recently been proposed as an anti-inflammatory and free radical scavenging agent. "( Dimethyl sulfoxide induces heme oxygenase-1 expression via JNKs and Nrf2 pathways in human umbilical vein endothelial cells.
Cang, J; Li, P; Liang, C; Wang, H; Xue, Z, 2011
)
3.25
"Dimethyl sulfoxide (DMSO) has the ability to penetrate living tissues without causing significant damage. "( Luminescence of lanthanide-dimethyl sulfoxide compound solutions.
Chen, W; Hossu, M; Joly, AG; Li, Y; Liu, Z; Yao, M, 2011
)
2.11
"Dimethyl sulfoxide (DMSO) has been known to enhance cell membrane permeability of drugs or DNA. "( Effects of dimethyl sulfoxide in cholesterol-containing lipid membranes: a comparative study of experiments in silico and with cells.
de Ménorval, MA; Fernández, ML; Mir, LM; Reigada, R, 2012
)
2.21
"Dimethyl sulfoxide (DMSO) has been shown to reduce the accumulation of PrP(Sc) in scrapie-infected (ScN2a) cells, and to inhibit its aggregation in vitro."( Dimethyl sulfoxide delays PrP sc accumulation and disease symptoms in prion-infected hamsters.
Avraham, I; Engelstein, R; Gabizon, R; Kahana, E; Shaked, GM, 2003
)
2.48
"Dimethyl sulfoxide (DMSO) has anti-inflammatory and analgesic properties and is the only intravesical agent approved by the FDA for the treatment of interstitial cystitis. "( Anti-angiogenic effects of dimethyl sulfoxide on endothelial cells.
Koizumi, K; Mayumi, T; Mukai, Y; Nakagawa, S; Okamoto, T; Tsutsumi, Y; Watanabe, M; Yoshioka, Y, 2003
)
2.06
"Dimethyl sulfoxide (DMSO) has been widely used in the treatment of arthritis and certain inflammatory diseases, and is also considered an alternative remedy for cancer even if not supported by concrete evidence. "( Massive intracranial hemorrhage associated with the ingestion of dimethyl sulfoxide.
Karcioglu, O; Niyazi Ozucelik, D; Oray, D; Ozsarac, M; Topacoglu, H; Tuncok, Y, 2004
)
2
"Dimethyl sulfoxide (DMSO) has been used as an intracellular cryoprotectant."( Simplified method for cryopreservation of islets using hydroxyethyl starch and dimethyl sulfoxide as cryoprotectants.
Arita, S; Iwashita, C; Kashiwabara, H; Kenmochi, T; Maruyama, M; Sakamoto, K, 2004
)
1.27
"Dimethyl sulfoxide (DMSO) has a variety of biological actions that suggest efficacy as a neuroprotectant. "( Effects of intravenous dimethyl sulfoxide on ischemia evolution in a rat permanent occlusion model.
Bardutzky, J; Bouley, J; Duong, TQ; Fisher, M; Meng, X; Ratan, R, 2005
)
2.08
"Dimethyl sulfoxide (DMSO) has been frequently used as carrier solvent in toxicological experiments where the most compelling DMSO attributes are its exceptionally low toxicity and environmental impact. "( Dimethyl sulfoxide is a potent modulator of estrogen receptor isoforms and xenoestrogen biomarker responses in primary culture of salmon hepatocytes.
Arukwe, A; Mortensen, AS, 2006
)
3.22
"Dimethyl sulfoxide (DMSO) has been shown to induce the differentiation of primary hepatocytes in vitro. "( Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells.
Chisari, FV; Sainz, B, 2006
)
1.78
"Dimethyl sulfoxide (DMSO) has long been used in studies as a vehicle to enhance the solubility and transport of ligands in biological systems. "( Modulation of brain metabolism by very low concentrations of the commonly used drug delivery vehicle dimethyl sulfoxide (DMSO).
Ball, GE; Garner, B; Nasrallah, FA; Rae, C, 2008
)
2
"Dimethyl sulfoxide (DMSO) has shown promise as a drug for the treatment of intracranial hypertension. "( Dimethyl sulfoxide for the treatment of intracranial hypertension: a preliminary trial.
Bowers, SA; Camp, PE; Marshall, LF, 1984
)
3.15
"Dimethyl sulfoxide (DMSO) has been reported to have beneficial effects in the treatment of central nervous system trauma, possibly due to its reported anti-inflammatory, antiedemic, anticoagulate, diuretic, hypothermic, vasodilatory, and respiratory stimulatory effects as well as an ability to correct membrane instability and penetrate the blood-brain barrier. "( Treatment of cerebral infarction with dimethyl sulfoxide in the mongolian gerbil.
McGraw, CP, 1983
)
1.98
"Dimethyl sulfoxide (DMSO) has been shown to reverse the effects of cerebral ischemia in the primate model."( The effect of hyaluronidase and dimethyl sulfoxide (DMSO) on experimental skin flap survival.
Dinner, MI; Dowden, RV; Grossman, JA; McGonagle, BA, 1983
)
1.27
"Dimethyl sulfoxide has been used as a nonaqueous organic solvent in haloperoxidase reactions. "( DMSO is a substrate for chloroperoxidase.
Dalietos, DJ; DeWitt, SK; Geigert, J; Lee, G; Moreland, M; Neidleman, SL, 1983
)
1.71
"Dimethyl sulfoxide (DMSO) has a variety of properties suggesting that it may be a useful agent in the management of central nervous system trauma and stroke. "( Effect of dimethyl sulfoxide on the cerebral and systemic circulations of the dog.
Boarini, DJ; Kassell, NF; Olin, JJ; Sprowell, JA, 1983
)
2.11
"Dimethyl sulfoxide has practical applications in the management of vesicant extravasation."( Dimethyl sulfoxide therapy in the treatment of vesicant extravasation: two case presentations.
D'Amato, S; Houlihan, N; St Germain, B,
)
2.3
"Dimethyl sulfoxide has been shown to modulate cell differentiation in cultured human cells."( Actin, tropomyosin and alpha-actinin as markers of differentiation in human rhabdomyosarcoma cell lines induced with dimethyl sulfoxide.
Alvarez, L; Aranega, A; Aranega, AE; Fernandez, JE; Melguizo, C; Prados, J, 1993
)
1.22
"Dimethyl sulfoxide (DMSO) has previously been reported to protect against hepatotoxicity resulting from chloroform (CHCl3) or bromobenzene (BB) when given 10 hr after the toxicant. "( Hepatoprotection by dimethyl sulfoxide. I. Protection when given twenty-four hours after chloroform or bromobenzene.
Gandolfi, AJ; Lind, RC,
)
1.9
"Dimethyl sulfoxide (DMSO) has previously been shown to attenuate chloroform (CHCl3) and bromobenzene (BB) induced hepatotoxicity in the rat when a dose of 2.0 ml/kg is given 24 hr after the toxicants. "( Hepatoprotection by dimethyl sulfoxide. II. Characterization of optimal dose and the latest time of administration for effective protection against chloroform and bromobenzene induced injury.
Gandolfi, AJ; Lind, RC, 1999
)
2.07
"Dimethyl sulfoxide (DMSO) has previously been shown to have the ability to attenuate chloroform (CHCl(3))-induced liver injury in the naive rat even when administered 24 h after the toxicant. "( Hepatoprotection by dimethyl sulfoxide. III. Role of inhibition of the bioactivation and covalent bonding of chloroform.
Begay, CK; Gandolfi, AJ; Lind, RC, 2000
)
2.07
"Dimethyl sulfoxide injection has limited stress-induced stimulation of LPO."( Lipid peroxidation in the heart of adult and old rats during immobilization stress.
Davydov, VV; Shvets, VN, 2001
)
1.03
"Dimethyl sulfoxide has cryoprotective and radioprotective properties. "( Effect of dimethyl sulfoxide (DMSO) on radiation-induced heteroallelic reversion in diploid yeast.
Krishnan, D; Mahajan, JM; Singh, DR, 1976
)
2.1
"Dimethyl sulfoxide has been tested in various experimental injuries of the central nervous system in relation to other therapies. "( Dimethyl sulfoxide in central nervous system trauma.
de la Torre, JC; Goode, DJ; Johnson, CM; Kajihara, K; Kawanaga, HM; Mullan, S, 1975
)
3.14
"Dimethyl sulfoxide has opposite effects on these two phosphotransferase activities: it enhances ATP hydrolysis and inhibits glucose phosphorylation."( Effect of dimethyl sulfoxide on phosphoryl transfer catalyzed by yeast hexokinase.
Montero-Lomelí, M, 1992
)
1.41
"Dimethyl sulfoxide (DMSO) has previously been shown to protect against acetaminophen (APAP)-induced hepatotoxicity, but the mechanism of this effect was not clear. "( Prevention of acetaminophen-induced hepatotoxicity by dimethyl sulfoxide.
Combs, AB; Kehrer, JP; Park, Y; Smith, RD, 1988
)
1.97
"Dimethyl sulfoxide (DMSO) has been demonstrated to suppress the in vitro microbicidal activity of neutrophils. "( Effects of dimethyl sulfoxide on the oxidative function of human neutrophils.
Beilke, MA; Collins-Lech, C; Sohnle, PG, 1987
)
2.11
"Dimethyl sulfoxide (DMSO) has previously been shown to increase the surface expression of H-2K and H-2D antigens on cultured line 1 carcinoma cells. "( Enhanced immune recognition of H-2 antigen-deficient murine lung carcinoma cells following treatment with dimethyl sulfoxide.
Bahler, DW; Lord, EM, 1985
)
1.93

Actions

Dimethyl sulfoxide (DMSO) plays no redox role in the chemistry, and kinetic experiments identify the turnover-limiting step as DMSO-promoted oxidation of palladium(0) by molecular oxygen. Dimethyl sulfoxy and ouabain suppress the complete expression of activity but do not inhibit the subsequent decay.

ExcerptReferenceRelevance
"Dimethyl sulfoxide (DMSO) plays no redox role in the chemistry, and kinetic experiments identify the turnover-limiting step as DMSO-promoted oxidation of palladium(0) by molecular oxygen."( Mechanistic study of alcohol oxidation by the Pd(OAc)(2)/O(2)/DMSO catalyst system and implications for the development of improved aerobic oxidation catalysts.
Fix, SR; Stahl, SS; Steinhoff, BA, 2002
)
1.04
"Dimethyl sulfoxide and ouabain suppress the complete expression of activity but do not inhibit the subsequent decay."( Tissue factor in cultured cells: pharmacologic effects.
Fintel, DJ; Maynard, JR; Nemerson, Y; Pitlick, FA, 1976
)
0.98
"Dimethyl sulfoxide was found to inhibit histamine release induced by compound 48/80 at concentrations ranging from 0.6 to 10%. "( Dimethyl sulfoxide inhibits histamine release induced by various chemicals.
Baldini, L; Bevilacqua, S; Candussio, L; Decorti, G; Klugmann, FB, 1987
)
3.16

Treatment

Dimethyl sulfoxide (DMSO) treatment altered the expression of genes involved in lipid (FAS, ACC1, ACC2, DGAT1, DGat2, SCD) and glucose (PEPCK, G6Pase) metabolism as well as liver functionality. The dim methyl sulfoxide treatment cannot prevent the migration of caspase-9 into the nuclei when it is added to primary hepatocytes immediately after isolation.

ExcerptReferenceRelevance
"Dimethyl sulfoxide treatment altered the expression of genes involved in lipid (FAS, ACC1, ACC2, DGAT1, DGAT2, SCD) and glucose (PEPCK, G6Pase) metabolism as well as liver functionality (albumin, alpha-1-antitrypsin, AFP)."( Optimizing human hepatocyte models for metabolic phenotype and function: effects of treatment with dimethyl sulfoxide (DMSO).
Green, CJ; Gunn, PJ; Hodson, L; Nikolaou, N; Tomlinson, JW, 2016
)
1.37
"The dimethyl sulfoxide (DMSO) treatment cannot prevent the migration of caspase-9 into the nuclei when it is added to primary hepatocytes immediately after isolation; however, it can trigger redistribution of caspase-9 from the nuclei into the cytosol when added 1 day post-isolation."( DMSO modulates the pathway of apoptosis triggering.
Banič, B; Milisav, I; Nipič, D; Suput, D, 2011
)
0.85
"Dimethyl sulfoxide treatment decreased the level of persistence at early time points after wounding and ablated temporal dependencies observed in untreated embryos."( P38 and JNK have opposing effects on persistence of in vivo leukocyte migration in zebrafish.
Barthen, C; Brown, SB; Bugeon, L; Dallman, MJ; Huvet, M; Kirk, PD; Lamb, JR; Liepe, J; Stumpf, MP; Taylor, HB, 2013
)
1.11
"Dimethyl sulfoxide treatment of HL-60 that causes differentiation with G0/G1 cell cycle arrest decreased the expression of ClC-5 mRNA."( Expression and roles of Cl- channel ClC-5 in cell cycles of myeloid cells.
Hattori, N; Inagaki, C; Jiang, B; Kitagawa, K; Liu, B; Nakayama, Y; Sumita, K, 2004
)
1.04
"Dimethyl sulfoxide (DMSO) treatment, which rigidifies the cell membrane, also activates the HOG pathway in both SLN1 branch- and SHO1 branch-dependent manners."( Activation of the HOG pathway upon cold stress in Saccharomyces cerevisiae.
Hayashi, M; Maeda, T, 2006
)
1.06
"Dimethyl sulfoxide treatment (2 to 4%) resulted in a dose-related decrease (less than 10% of control at 4% DMSO) in AFP, albumin, and transferrin production by 7777, but in 8994, DMSO (1 to 2%) resulted in an increase (up to sixfold) in albumin and transferrin production, without affecting AFP production."( Differential effects of dimethyl sulfoxide and sodium butyrate on alpha-fetoprotein, albumin, and transferrin production by rat hepatomas in culture.
Hughes, EH; Schut, HA; Thorgeirsson, SS, 1981
)
1.29
"Dimethyl sulfoxide-treated P-29 cells were trapped in the lung more than untreated cells and were cleared from the lungs more slowly than untreated cells."( Enhanced metastatic potential of cloned low-metastatic Lewis lung carcinoma cells treated in vitro with dimethyl sulfoxide.
Takenaga, K, 1984
)
1.2
"Upon dimethyl sulfoxide treatment, the cells differentiated along the erythroid pathway as shown by morphological evidence and by their increased synthesis of hemoglobin and spectrin."( Cytochemical characteristics of leukopoietic differentiation in murine erythroleukemic (Friend) cells.
Bertolini, L; Fioritoni, G; Revoltella, R; Torlontano, G, 1980
)
0.72
"The dimethyl sulfoxide treated enzymes were passed over phosphocellulose to purify and characterize the dissociated subunits as well as to remove the dimethyl sulfoxide."( Dissociation of alpha beta DNA polymerase of avian myeloblastosis virus by dimethyl sulfoxide.
Grandgenett, DP, 1976
)
0.97
"Dimethyl sulfoxide-treated hybrid cells accumulate polyribosomal globin mRNA to levels comparable to those of the parental erythroleukemic cells under the same conditions."( Negative control of hemoglobin production in somatic cell hybrids due to heme deficiency.
Benoff, S; Bruce, SA; Skoultchi, AI, 1978
)
0.98
"Dimethyl sulfoxide treatment led to a decrease in the number of dexamethasone binding sites on the cells induced to differentiate."( Detection of glucocorticoid receptors on Friend erythroleukemia cells.
Bersch, N; Friend, C; Golde, DW; Lippman, ME, 1979
)
0.98
"Dimethyl sulfoxide treatment caused no significant difference in the mean serum concentration of SMZ or in the mean CSF concentrations of TMP or SMZ."( Concentrations of trimethoprim and sulfamethoxazole in cerebrospinal fluid and serum in mares with and without a dimethyl sulfoxide pretreatment.
Brown, MP; Green, SL; Gronwall, RR; Mayhew, IG; Montieth, G, 1990
)
1.21
"Dimethyl sulfoxide (DMSO) treatment of human HepG2 hepatoma cells increases the activity and the concentration of delta-aminolevulinic acid dehydratase (ALAD) to a comparable degree. "( Regulation of heme synthesis in HepG2 human hepatoma cells by dimethyl sulfoxide.
Fujita, H; Galbraith, RA; Sassa, S, 1988
)
1.96
"Dimethyl sulfoxide (DMSO) treatment of the Friend erythroleukemia cell line GM 979 markedly increased its susceptibility to natural cytotoxicity by splenocytes from normal inbred DBA/2 mice. "( Macrophage-mediated natural cytotoxicity of dimethyl sulfoxide-treated Friend erythroleukemia cells.
Friedman, H; Hsu, KH, 1985
)
1.97
"The treatment was: Dimethyl sulfoxide (DIMSO) and Pentosan Polysulfate."( [Experience in the treatment of interstitial cystitis: review of 17 cases].
Flores-Carreras, O; González-Ruiz, MI; Martínez-Espinoza, CJ, 2011
)
0.69
"Treatment with dimethyl sulfoxide, glycerol, or sucrose did not enhance gene transfer."( Phage particle-mediated gene transfer to cultured mammalian cells.
Hamada, Y; Hirose, S; Ishiura, M; Okada, Y; Suzuki, Y; Uchida, T, 1982
)
0.6
"Untreated and dimethyl sulfoxide-treated cells were incubated with L-[3H]leucine and the incorporation of radioactivity into total trichloroacetic acid-insoluble proteins and into proteins immunoprecipitated with a multivalent rabbit antibody to mouse erythrocyte membranes was determined."( Biosynthesis of mouse erythrocyte membrane proteins by Friend erythroleukemia cells.
Pfeffer, SR; Redman, CM, 1981
)
0.61
"When treated with dimethyl sulfoxide (DMSO), MEL cells grown on a fibronectin matrix become committed to erythroid differentiation asynchronously, with 90% of cells becoming committed by Day 3 of treatment."( Phosphatidylinositol 3-kinase activity in murine erythroleukemia cells during DMSO-induced differentiation.
Ai, Z; Cohen, CM; Misra, S; Susa, M; Varticovski, L, 1995
)
0.61
"Treatment with dimethyl sulfoxide (1%) or colchicine (0.5 microM) increased percentages of cells in G0 (24.8 +/- 20.0) or G2+M (37.4 +/- 4.6), respectively."( Flow cytometric cell cycle analysis of cultured porcine fetal fibroblast cells.
Boquest, AC; Day, BN; Prather, RS, 1999
)
0.64
"Treatment with dimethyl sulfoxide, extracellular glutathione, or N-acetyl-L-cysteine (NAC) decreased cristobalite-induced tumor necrosis factor (TNF)-alpha mRNA levels by 40%, 20%, and 42%, respectively."( Antioxidant treatment attenuates cytokine and chemokine levels in murine macrophages following silica exposure.
Barrett, EG; Finkelstein, JN; Johnston, C; Oberdörster, G, 1999
)
0.64
"Treatment with dimethyl sulfoxide induces granulocytic differentiation in the both types of cells."( Loss of irreversibility of granulocytic differentiation induced by dimethyl sulfoxide in HL-60 sublines with a homogeneously staining region.
Haque, M; Hirano, T; Kitajima, K; Nakamura, H; Utiyama, H, 2001
)
0.89
"Treatment of dimethyl sulfoxide-stimulated Friend erythroleukemic cells (clone 745) with mouse interferon (50 U/ml) led to the following changes: (i) a net decrease (40 to 60%) in both the total number of apparently newly synthesized virion particles per cell section and in the average number of cell sections containing one or more virion particles; (ii) a large decrease (80 to 90%) in the number of particles released into the supernatant fluid, as assayed by reverse transcriptase activity; (iii) an initial increase in the number of "immature" or "enveloped A-type" virions followed by an increase in the accumulation of empty, core shell-like particles; and (iv) a decrease in the number of cytoplasmic vacuolar structures, which have been implicated as a major site of virus production and which we show here by serial sectioning to be, in several instances, invaginations of the plasma membrane. "( Effect of interferon on dimethyl sulfoxide-stimulated Friend erythroleukemic cells: ultrastructural and biochemical study.
Conscience, JF; Luftig, RB; McMillan, P; Revel, M; Ruddle, FH; Skoultchi, A, 1977
)
0.93
"Treatment with dimethyl sulfoxide (DMSO) decreased (p less than 0.05) neutrophil alveolitis and lung leak in hamsters given FNLP intratracheally."( Dimethyl sulfoxide decreases lung neutrophil sequestration and lung leak.
Ahmed, NK; Day, CE; Leff, JA; McCarty, EC; Oppegard, MA; Patton, LM; Repine, JE; Shanley, PF; Wilke, CP, 1992
)
2.07
"Treatment with dimethyl sulfoxide (6.5 g/kg; i.p.) evoked significant decreases in cardiac output, stroke volume, and central venous pressure and increases in heart rate, systemic vascular resistance, mean aortic pressure, respiration rate, and concentrations of blood glucose and plasma lactate."( Dimethyl sulfoxide antagonizes hypotensive, metabolic, and pathologic responses induced by endotoxin.
Brackett, DJ; Lerner, MR; Wilson, MF, 1991
)
2.06
"Treatment of dimethyl sulfoxide with butyllithium leads to rapid formation of lithium methylsulfinyl carbanion. "( A convenient method for methylation of glycoprotein glycans in small amounts by using lithium methylsulfinyl carbanion.
Cardon, P; Fournet, B; Leroy, Y; Montreuil, J; Parente, JP; Ricart, G, 1985
)
0.64

Toxicity

Dimethyl sulfoxide (DMSO) can be toxic to test organisms and has species-specific sensitivity. HSC products also contain various cells and plasma components. A simple generic toxicity method (test) is proposed using baker's yeast.

ExcerptReferenceRelevance
" This indicates less conjugation of the toxic metabolites of paracetamol and bromobenzene to liver glutathione (G-SH) in the presence of DMSO."( Antidotal effects of dimethyl sulphoxide against paracetamol-, bromobenzene-, and thioacetamide-induced hepatotoxicity.
Siegers, CP, 1978
)
0.26
" The results are tabulated as LD50 ml/kg with 95% confidence limits."( Acute toxicity of various solvents in the mouse and rat. LD50 of ethanol, diethylacetamide, dimethylformamide, dimethylsulfoxide, glycerine, N-methylpyrrolidone, polyethylene glycol 400, 1,2-propanediol and Tween 20.
Bartsch, W; Dietmann, K; Fuchs, G; Sponer, G, 1976
)
0.26
" The microtubule-disruptive agents colchicine (10-4 M), vinblastine (10-5 M) and colcemid (10-6 M) did not influence antibody-dependent cytotoxicity at concentrations which were not toxic to the effector cells."( Antibody-dependent cytotoxicity: modulation by the cytochalasins and microtubule-disruptive agents.
Gelfand, EW; Morris, SA; Resch, K, 1975
)
0.25
" Although dimethyl sulfoxide is not highly flammable, normal safety precautions used with any flammable solvent are the minimal requirements for safe use of this drug."( The safe use of dimethyl sulfoxide in the laboratory.
Cotter, DA, 1975
)
1
" A broad spectrum of model toxic compounds was evaluated for toxicity on mouse skin JB6 cells in culture."( Studies of skin toxicity in vitro: dose-response studies on JB6 cells.
Berezesky, IK; Fitzpatrick, MJ; Jain, PT; Phelps, PC; Trump, BF, 1992
)
0.28
" It was concluded that the only form of AmB toxic to human erythrocytes is the water-soluble self-associated form (in contrast with fungal cells on which the monomeric form is also active)."( Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes.
Bolard, J; Cohen, BE; Legrand, P; Romero, EA, 1992
)
0.28
"Leishmania must survive despite exposure to the toxic oxidant hydrogen peroxide (H2O2) during phagocytosis by macrophages."( Hydrogen peroxide-mediated toxicity for Leishmania donovani chagasi promastigotes. Role of hydroxyl radical and protection by heat shock.
Britigan, BE; Wilson, ME; Zarley, JH, 1991
)
0.28
" These results demonstrate that the most toxic substance for growing fibroblasts was the solvent DMSO."( Toxicity in vital fluorescence microscopy: effect of dimethylsulfoxide, rhodamine-123, and DiI-low density lipoprotein on fibroblast growth in vitro.
Braunwald, NS; Crawford, JM, 1991
)
0.28
"It has been suggested that the generation of toxic radicals plays an important role in toxicity by Adriamycin (ADR) on cancer cell lines and in vivo."( Cytotoxic effect of adriamycin and agarose-coupled adriamycin on glomerular epithelial cells: role of free radicals.
Bertelli, R; Ghiggeri, GM; Ginevri, F; Gusmano, R, 1991
)
0.28
" Using the same protocol, six pesticides applied in dimethyl sulfoxide (DMSO) at doses of 1/8, 1/16, and 1/32 of the dermal LD50 were investigated."( Comparison of the activity of topically applied pesticides and the herbicide 2,4-D in two short-term in vivo assays of genotoxicity in the mouse.
Goldberg, MT; Hardy, MH; Schop, RN, 1990
)
0.53
" Desethylamiodarone was more toxic than amiodarone in the cultured hepatocytes."( Amiodarone- and desethylamiodarone-induced myelinoid inclusion bodies and toxicity in cultured rat hepatocytes.
Bandyopadhyay, S; Gross, SA; Klaunig, JE; Somani, P, 1990
)
0.28
" The concentration of toxic thresholds varied from cell type to cell type."( Psychosine cytotoxicity in rat neural cell cultures and protection by phorbol ester and dimethyl sulfoxide.
Eto, Y; Ida, H; Kim, SU; Sugama, S, 1990
)
0.5
" On the other hand, sodium valproate and isoniazid was, respectively, seven and 100 times more toxic for embryos than adults, thus indicating that these pharmaceuticals might pose developmental hazards to mammalian development."( In vitro testing for developmental toxicity using the Hydra attenuata assay.
Støttum, A; Wiger, R, 1985
)
0.27
" Although the ozonation products of pyrene were not toxic under the conditions of this study, phenanthrene products were more hepatotoxic than was phenanthrene itself."( Toxicity of polycyclic aromatic hydrocarbons. I. Effect of phenanthrene, pyrene, and their ozonized products on blood chemistry in rats.
Church, DF; Flory, W; Giamalva, D; Pryor, WA; Ruhr, LP; Yoshikawa, T, 1985
)
0.27
"A mouse hepatoma cell line, Hepa-1, is highly sensitive to the toxic effects of Aflatoxin B1 (AFB1)."( Mechanism of cytotoxicity of aflatoxin B1: role of cytochrome P1-450.
Kärenlampi, SO, 1987
)
0.27
" The relative toxic potential of the drug congeners (CsG greater than CsA greater than CsH = CsF = CsA/M17) correlated well with the degree of their accumulation in the hepatocytes during exposure to equimolar drug concentrations."( In vitro toxicity assessment of cyclosporin A and its analogs in a primary rat hepatocyte culture model.
Boelsterli, UA; Bouis, P; Brouillard, JF; Donatsch, P, 1988
)
0.27
" The accumulation of platinum on the proteins of Chinese hamster or African green monkey kidney cells treated with cis- or trans-DDP was also consistent with the respective toxic effects of the two isomers."( Differential toxicity of cis- and trans-diamminedichloroplatinum(II) toward mammalian cells: lack of influence of any difference in the rates of loss of their DNA-bound adducts.
Friedlos, F; Roberts, JJ, 1987
)
0.27
" Our results suggest that the intravitreal administration of vidarabine dissolved in DMSO may be a safe and effective means of drug therapy."( Ocular toxicity of intravitreal vidarabine solubilized in dimethyl sulfoxide.
Meyers-Elliott, R; Niizawa, JM; Yoshizumi, MO, 1986
)
0.52
" Both types of conjugates caused considerable toxicity: allyl isothiocyanate conjugates gave effects comparable to the parent compound, but benzyl isothiocyanate was more toxic than its conjugates."( Glutathione- and cysteine-mediated cytotoxicity of allyl and benzyl isothiocyanate.
Bruggeman, IM; Temmink, JH; van Bladeren, PJ, 1986
)
0.27
" sanguis, O2- can exert a toxic effect independent of the production of OH."( Oxygen toxicity in Streptococcus sanguis. The relative importance of superoxide and hydroxyl radicals.
DiGuiseppi, J; Fridovich, I, 1982
)
0.26
" The latter results are in good agreement with data reported by others who suggested that DMSO could act as a scavenger of TNF-induced toxic radical formation."( Polar agents with differentiation inducing capacity potentiate tumor necrosis factor-mediated cytotoxicity in human myeloid cell lines.
Depraetere, S; Fiers, W; Joniau, M; Vanhaesebroeck, B; Willems, J, 1995
)
0.29
"We evaluated the toxic effects of four currently used chemolytic solvents--dimethyl sulfoxide (DMSO, 99%), ethyl propionate (EP, 99%), tetrasodium ethyl-dimethyl tetraacetate (4Na-EDTA, 2%, pH 11), and methyl tert-butyl ether (MTBE, purity = 99."( Toxic effects of cholelitholytic solvents on gallbladder and liver. A piglet model study.
Chang, KK; Chen, CY; Chou, TC; Chow, NH; Leow, TC; Lin, XZ, 1995
)
0.52
"These results support and extend a previous study that bone marrow hematopoietic progenitor cells, including burst-forming units--erythroid, colony-forming units--granulocyte/macrophage, and colony-forming units--granulocyte/erythrocyte/macrophage/megakaryocyte are resistant to any toxic effects of 8- to 10-percent (vol/vol) DMSO during at least 2 hours of DMSO exposure."( Hematopoietic progenitor cells are resistant to dimethyl sulfoxide toxicity.
Branch, DR; Calderwood, S; Cecutti, MA; Herst, R; Solh, H, 1994
)
0.54
"Studies on the antagonism of toxicity can provide information about toxic mechanisms and suggest chemotherapeutic strategies."( Antagonism of cadmium cytotoxicity by differentiation inducers.
Shopsis, C, 1994
)
0.29
" The single tested solvents did not show any major differences in acute toxicity in the three tested strains with the exclusion of DMSO (less toxic in CD2F1) and BeOH and EtOH (less toxic in B6D2F1)."( Acute intravenous toxicity of dimethyl sulfoxide, polyethylene glycol 400, dimethylformamide, absolute ethanol, and benzyl alcohol in inbred mouse strains.
Cavalletti, E; Melloni, E; Montaguti, P, 1994
)
0.58
" It is concluded that a) plasma membrane indicator dyes, not neutral red, might be better indicators of cytotoxicity occurring during cryopreservation; b) DMSO might be toxic to lysosomes during cryopreservation of cultured cells; and c) although [Ca+2]e can contribute to cytotoxicity, the presence of [Ca+2]e might not influence cryopreservation-induced cytotoxicity."( Extracellular calcium does not contribute to cryopreservation-induced cytotoxicity.
Baust, J; Danks, AM; Im, J; Isaacson, RL; Rhoads, LS; Van Buskirk, RG; Warner, A, 1993
)
0.29
"The toxic effect of ethylene glycol (EG) on the pattern of dynamic insulin release from rat pancreatic islets with or without freezing was investigated in comparison with that of dimethyl sulfoxide (Me2SO)."( Cryopreservation of isolated rat islets of Langerhans in the presence of ethylene glycol or dimethyl sulfoxide: evaluation of toxicity and the dynamic pattern of subsequent insulin release in vitro.
Inayoshi, Y; Nakaichi, M; Nakama, S; Sakonju, I; Suzuki, T; Takimoto, K; Taura, Y, 1996
)
0.71
" Iron has been implicated to play an important role in several models of tissue injury, presumably through the generation of hydroxyl radicals via the Haber-Weiss reaction or other highly toxic free radicals."( In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity.
Baliga, M; Baliga, R; Shah, SV; Ueda, N; Zhang, Z, 1998
)
0.3
"Eleven patients (50%) experienced symptoms related to graft infusion, nausea and vomiting being the most common adverse events."( Clinical toxicity of cryopreserved circulating progenitor cells infusion.
Cuomo, A; Da Prada, G; Miotti, D; Pedrazzoli, P; Perotti, C; Poggi, G; Preti, P; Robustelli della Cuna, G; Zambelli, A,
)
0.13
" Cisplatin reduced body weight gain and spleen weight during treatment and was much more toxic than NAMI-A on liver sinusoids, kidney tubules, and lung epithelium."( In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.
Alessio, E; Bergamo, A; Furlani, A; Gagliardi, R; Mestroni, G; Sava, G; Scarcia, V, 1999
)
0.3
" No adverse clinical sequelae were noted."( A reexamination of the angiotoxicity of superselective injection of DMSO in the swine rete embolization model.
Alderman, J; Chaloupka, JC; Fink, S; Hammond, R; Huddle, DC; Vinters, HV, 1999
)
0.3
" Among possible metabolites from mancozeb breakdown, neither Mn2+ nor ethylenethiourea (ETU) is particularly toxic even at 10% of the optimum mancozeb dosage."( The toxicity of dithiocarbamate fungicides to soil nematodes, assessed using a stress-inducible transgenic strain of Caenorhabditis elegans.
Allender, R; Avramides, S; de Pomerai, DI; Guven, K; Power, RS, 1999
)
0.3
" When lipid peroxidation was suppressed by DPPD or BHA cell viability remained high even in the presence of toxic Al concentrations."( The role of lipid peroxidation in aluminium toxicity in soybean cell suspension cultures.
Barz, W; Rath, I,
)
0.13
"The toxic effects of DNA-incorporated 5-[(125)I]iodo-2'-deoxyuridine ((125)IdUrd) were assessed by the colony-forming assay with cells incubated in medium containing serum and/or dimethyl sulphoxide (DMSO)."( Chemical modification of 5-[125I]iodo-2'-deoxyuridine toxicity in mammalian cells in vitro.
Adelstein, SJ; Kassis, AI; Walicka, MA, 2001
)
0.31
" This study also examined possible adverse reactions associated with methylsulfonylmethane supplementation."( A multicentered, open-label trial on the safety and efficacy of methylsulfonylmethane in the treatment of seasonal allergic rhinitis.
Barrager, E; Schauss, AG; Schiller, RN; Veltmann, JR, 2002
)
0.31
" MSM administered in a single gavage dose of 2 g/kg resulted in no adverse events or mortality."( Toxicity of methylsulfonylmethane in rats.
Financsek, I; Glávits, R; Horváth, K; Noker, PE; Schauss, AG; Somfai-Relle, S, 2002
)
0.31
" Topical DMSO is considered an effective and safe antidote to be used with topical cooling after extravasations of vesicant drugs."( Toxicity to topical dimethyl sulfoxide (DMSO) when used as an extravasation antidote.
Codina, C; Creus, N; Massó, J; Mateu, J; Ribas, J, 2002
)
0.64
" AH Plus was also shown to be toxic in concentrations of 16."( Examination of cytotoxicity and mutagenicity of AH26 and AH Plus sealers.
Anić, I; Garaj-Vrhovac, V; Jukić, S; Miletić, I; Osmak, M; Zeljezić, D, 2003
)
0.32
" Furthermore, it leads to a safe and sustained engraftment."( The role of depletion of dimethyl sulfoxide before autografting: on hematologic recovery, side effects, and toxicity.
Bewick, M; Chadderton, T; Glück, S; Porter, K; Stewart, D; Syme, R, 2004
)
0.63
"House dust is an important source of different toxic metabolites as well as allergens, including those of fungal origin, in the indoor environment."( Airway toxicity of house dust and its fungal composition.
Piecková, E; Wilkins, K, 2004
)
0.32
" A topical NSAID formulation may provide symptom relief with fewer adverse effects."( Efficacy and safety of a topical diclofenac solution (pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial.
Roth, SH; Shainhouse, JZ, 2004
)
0.32
" We assessed safety by evaluation of adverse events, vital signs, and irritation at the application site."( Efficacy and safety of a topical diclofenac solution (pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial.
Roth, SH; Shainhouse, JZ, 2004
)
0.32
" There was no significant difference between groups in NSAID-related gastrointestinal tract complaints or in dropouts due to study-related adverse effects."( Efficacy and safety of a topical diclofenac solution (pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial.
Roth, SH; Shainhouse, JZ, 2004
)
0.32
"Topical diclofenac is effective in the treatment of the symptoms of primary OA of the knee, with only minor local irritation and no significant systemic adverse events."( Efficacy and safety of a topical diclofenac solution (pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial.
Roth, SH; Shainhouse, JZ, 2004
)
0.32
" Results showed that the toxic effect of cryoprotectant on oocytes generally increased with increasing concentration."( Studies on cryoprotectant toxicity to zebrafish (Danio rerio) oocytes.
Plachinta, M; Rawson, DM; Zhang, T,
)
0.13
" No changes implicating toxic reactions were observed during DMSO and Onyx injections."( A contribution to the controversy over dimethyl sulfoxide toxicity: anesthesia monitoring results in patients treated with Onyx embolization for intracranial aneurysms.
Aypar, U; Cekirge, HS; Pamuk, AG; Saatci, I, 2005
)
0.6
" This study aimed to select the least toxic among the cryoprotectants dimethyl sulfoxide (Me2SO), propylene glycol (PG), and methanol (MET) based on their toxicological effects on Crassostrea rhizophorae gametes and trochophores."( Selection of cryoprotectants based on their toxic effects on oyster gametes and embryos.
do Espírito Santo, EM; Leite, MB; Nascimento, IA; Pereira, SA; Sampaio de Araújo, MM; Sansone, G, 2005
)
0.56
" Nine adverse events occurred in 7 patients during 8 procedures (16%), one causing a permanent deficit."( Endovascular treatment of intracerebral arteriovenous malformations: procedural safety, complications, and results evaluated by MR imaging, including diffusion and perfusion imaging.
Brandt, L; Cronqvist, M; Holtås, S; Larsson, EM; Nilsson, O; Ramgren, B; Romner, B; Säveland, H; Wirestam, R, 2006
)
0.33
"Endovascular procedures are rather safe but are associated with more ischemic events and followed by less hemodynamic disturbances than previously understood."( Endovascular treatment of intracerebral arteriovenous malformations: procedural safety, complications, and results evaluated by MR imaging, including diffusion and perfusion imaging.
Brandt, L; Cronqvist, M; Holtås, S; Larsson, EM; Nilsson, O; Ramgren, B; Romner, B; Säveland, H; Wirestam, R, 2006
)
0.33
" Because the embryos reared in the 96-well microtiter plates never showed increased adverse effects (as compared to the bottle-reared embryos) at any DMSO concentration, we conclude that the 96-well microtiter plate assay provides a rapid and efficient alternative for developmental toxicity screens that utilize fish embryos."( Adapting the medaka embryo assay to a high-throughput approach for developmental toxicity testing.
Cowden, J; Hinton, DE; Oxendine, SL; Padilla, S, 2006
)
0.33
" These limitations have prompted a search for more effective and less toxic metal-based antitumor agents."( DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec, V; Nováková, O, 2006
)
0.33
" We found that DMSO is toxic to planarians at concentrations above 5% (705 mM), with an LD(50) of 10% (1."( Toxicity and behavioral effects of dimethylsulfoxide in planaria.
Pagán, OR; Rowlands, AL; Urban, KR, 2006
)
0.33
" This experiment established a method to examine systematically toxicity parameters for chondrocytes in situ and this data can be used to tailor vitrification protocols by limiting exposure temperature and time or lowering DMSO concentrations below toxic levels recorded."( Dimethyl sulfoxide toxicity kinetics in intact articular cartilage.
Elliott, JA; Elmoazzen, HY; Jomha, NM; Law, GK; McGann, LE; Poovadan, A, 2007
)
1.78
"25%) side effect events during and after the infusion period."( Clinical side effects during peripheral blood progenitor cell infusion.
Cagirgan, S; Donmez, A; Gungor, A; Saydam, G; Soyer, N; Tombuloglu, M, 2007
)
0.34
" In all patients, mild non-neurological side effects occurred but besides the reported seizure no other severe adverse events were observed upon PBSC-infusion."( Neurotoxicity upon infusion of dimethylsulfoxide-cryopreserved peripheral blood stem cells in patients with and without pre-existing cerebral disease.
Behre, G; Christopeit, M; Grothe, W; Guenther, S; Mueller, LP; Muetherig, A; Theurich, S; Weber, T, 2007
)
0.34
" Furthermore adding cryoprotectant solution at low temperature of 4 degrees C significantly reduced the toxic effect on the tissue-engineered dermal equivalent."( Cryopreservation of tissue-engineered dermal replacement in Me2SO: Toxicity study and effects of concentration and cooling rates on cell viability.
Cao, Y; Hua, TC; Liu, B; Sun, DW; Wang, X; Yang, G, 2007
)
0.34
"The acute toxicity of six quinoxaline 1,4-di-N-oxides has been evaluated in an attempt to determine: a) the feasibility of testing systemic toxicity of these compounds in a very preliminary phase without an adequate formulation for in vivo administration, b) the LD50 range and the toxic target organ of these compounds in order to have an approximation of the structure-activity relationship."( Comparative acute systemic toxicity of several quinoxaline 1,4-di-N-oxides in Wistar rats.
Azqueta, A; Cia, F; de Cerain, AL; García-Jalón, JA; García-Rodríguez, A; Gil, AG; Monge, A; Zarranz, B, 2007
)
0.34
" This study aimed to identify possible toxic mechanisms using primary cell cultures from vascular tissue: these were exposed to the cryoprotectant at room temperature to avoid any possibility of hypothermic injury."( Reduction of cryoprotectant toxicity in cells in suspension by use of a sodium-free vehicle solution.
Hunds, N; Pegg, DE; Rauen, U; Simmonds, J; Wusteman, M, 2008
)
0.35
" In vitro toxicity studies in neurons and cancer cells and in vivo toxicity studies in rats were used to determine both the cancer chemotherapeutic and toxic effects of the identified compound."( Cisplatin and dimethyl sulfoxide react to form an adducted compound with reduced cytotoxicity and neurotoxicity.
Benson, LM; Fauq, A; Fischer, SJ; Naylor, S; Windebank, AJ, 2008
)
0.71
" Considering the presence of high levels of potentially toxic substances, such as metals and chlorinated organic compounds, aqueous and organic extracts were used to assess toxicity in sediments by using the photo-luminescent bacteria Vibrio fischeri (Microtox) as screening response variable."( Estimating the environmental impact of micro-pollutants in the low Ebro River (Spain): an approach based on screening toxicity with Vibrio fischeri.
Domingo, JL; Ferré-Huguet, N; Ocampo-Duque, W; Schuhmacher, M; Sierra, J, 2008
)
0.35
" This study aimed to determine the least toxic cryoprotective agent for Haliotis midae embryos."( Preliminary investigation to determine the cytotoxicity of various cryoprotectants on southern African abalone (Haliotis midae) embryos.
Roodt-Wilding, R; Roux, A; Sandenbergh, L, 2008
)
0.35
" Unfortunately cryoprotectants can be toxic for cells."( Studies on cryoprotectant toxicity to early stage zebrafish (Danio rerio) ovarian follicles.
Rawson, DM; Tsai, S; Zhang, T,
)
0.13
" The commonest adverse event associated with TDiclo was dry skin (18."( Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis.
Bookman, AAM; Grierson, LM; Naseer, Z; Shainhouse, ZJ; Simon, LS, 2009
)
0.6
" First convincingly introduced by Baxter and Lathe in 1971, the concept that certain amides can block toxic effects of dimethyl sulfoxide (Me(2)SO) was contradicted by direct experiments in 1990."( Cryoprotectant toxicity neutralization.
Fahy, GM, 2010
)
0.57
" The absence of a specific treatment and the necessity of effective and safe drugs against these etiologic agents have stimulated the search for new antiprotozoal drugs with high activity, low toxicity to the animal, and low cost."( Cytotoxicity of solubilization vehicles for Trichomonas gallinae and Tritrichomonas foetus measured by the resazurin microtiter assay.
Carli, GA; Duarte, M; Giordani, RB; Macedo, AJ; Tasca, T; Zuanazzi, JA, 2009
)
0.35
"The toxic effects of onyx, its solvent dimethyl sulphoxide (DMSO), and n-butyl 2-cyanoacrylate (NBCA) were evaluated after infusion into the subaracnoid space of a rabbit model."( Evaluation of the toxicity of onyx compared with n-butyl 2-cyanoacrylate in the subarachnoid space of a rabbit model: an experimental research.
Atilla, P; Bakar, B; Hazer, BD; Kilic, K; Muftuoglu, SF; Oruckaptan, HH; Saatci, I, 2010
)
0.36
"This experimental study suggests that NBCA, and various concentrations of onyx and DMSO have toxic effects on the neural tissues of rabbits when infused into the subarachnoid space."( Evaluation of the toxicity of onyx compared with n-butyl 2-cyanoacrylate in the subarachnoid space of a rabbit model: an experimental research.
Atilla, P; Bakar, B; Hazer, BD; Kilic, K; Muftuoglu, SF; Oruckaptan, HH; Saatci, I, 2010
)
0.36
" Safety assessment included adverse events, skin irritation scores of the treated knee(s), ocular examinations, and routine laboratory tests."( A long-term, open-label study to confirm the safety of topical diclofenac solution containing dimethyl sulfoxide in the treatment of the osteoarthritic knee.
Grierson, LM; Naseer, Z; Shainhouse, JZ,
)
0.35
"Vitrification requires high concentrations of cryoprotectants that may induce long-term toxic effects on cells."( Assessment of the genotoxicity of three cryoprotectants used for human oocyte vitrification: dimethyl sulfoxide, ethylene glycol and propylene glycol.
Aye, M; Botta, A; Courbiere, B; De Mo, M; Di Giorgio, C; Perrin, J, 2010
)
0.58
" Isoxyl microparticles and controls in concentrations up to 100microg/ml were not toxic to macrophages."( Isoxyl particles for pulmonary delivery: In vitro cytotoxicity and potency.
Hickey, AJ; Wang, C, 2010
)
0.36
" A cellular assay with rat CGN cultures was established to study the neurotoxicity of compounds in order to filter out toxic compounds at an early phase of drug development."( An imaging assay to analyze primary neurons for cellular neurotoxicity.
Gabriel, D; Glickman, JF; Götte, M; Hofmann, G; Michou-Gallani, AI; Wishart, W, 2010
)
0.36
" Owing to the delayed occurrence of these adverse effects, the optimal time of surgical intervention after Onyx embolization should be discussed and perhaps expedited."( Early side effects after embolization of a carotid body tumor using Onyx.
Bien, S; Chapot, R; Kureck, I; Sesterhenn, AM; Werner, JA; Wiegand, S, 2010
)
0.36
"Until now, the adverse effects of toner powders on humans have been considered to be minimal."( Genotoxic effects of three selected black toner powders and their dimethyl sulfoxide extracts in cultured human epithelial A549 lung cells in vitro.
Decker, K; Ebner, W; Gieré, R; Gminski, R; Goldenberg, E; Grobéty, B; Heinz, C; Könczöl, M; Mersch-Sundermann, V; Seidel, A, 2011
)
0.61
" Further acute toxicity evaluation indicated low toxic effect of the (N-dodecylcarbamoyl)methyl enone glyceroside α-anomer and of the carbamoylmethyl dienepyranosides N-protected with propargyl or benzyl groups."( Synthesis of sugars embodying conjugated carbonyl systems and related triazole derivatives from carboxymethyl glycoside lactones. Evaluation of their antimicrobial activity and toxicity.
Chambert, S; Goulart, M; Justino, J; Neves, A; Queneau, Y; Rauter, AP; Xavier, NM, 2011
)
0.37
" It represents a practical and safe cyanation method."( The palladium-catalyzed cyanation of indole C-H bonds with the combination of NH4HCO3 and DMSO as a safe cyanide source.
Chen, F; Chen, J; Cheng, J; Ren, X, 2011
)
0.37
"This experimental study suggested that DMSO has no toxic effect on the neural and arterial tissues of rats when it is slowly infused into the carotid artery."( Evaluation of the neurotoxicity of DMSO infused into the carotid artery of rat.
Alhan, A; Bakar, B; Keskil, IS; Kilinc, K; Kose, EA; Sonal, S, 2012
)
0.38
" However, serious gastrointestinal and cardiovascular systemic adverse events (AEs) are associated with oral NSAIDs and can be treatment limiting."( Diclofenac sodium topical solution 1.5% w/w with dimethyl sulfoxide compared with placebo for the treatment of osteoarthritis: pooled safety results.
Fuller, P; Roth, SH, 2011
)
0.62
" According to the time dependent IC50 values, the CIB could provide dynamic information that can be used to identify maximum toxicity of cigarette smoke and reversibility of the toxic effects which are difficult to achieve by the endpoint assays."( Evaluation of the cytotoxicity of cigarette smoke condensate by a cellular impedance biosensor.
Chen, H; Cui, L; Hou, HW; Hu, QY; Jiang, JH; Jiang, XY; Pang, YQ; Tang, GL, 2012
)
0.38
" These recommendations are based on evidence of adverse solvent effects in apical level tests."( Implications of the solvent vehicles dimethylformamide and dimethylsulfoxide for establishing transcriptomic endpoints in the zebrafish embryo toxicity test.
Cossins, A; Fenske, M; Sawle, A; Turner, C, 2012
)
0.38
"Multiple-CPA solutions were significantly less toxic than single-CPA solutions (P<0."( Cryoprotective agent toxicity interactions in human articular chondrocytes.
Almansoori, KA; Elliott, JA; Forbes, JF; Jomha, NM; Law, GK; McGann, LE; Prasad, V, 2012
)
0.38
" PG was the most toxic CPA when used in combinations."( Cryoprotective agent toxicity interactions in human articular chondrocytes.
Almansoori, KA; Elliott, JA; Forbes, JF; Jomha, NM; Law, GK; McGann, LE; Prasad, V, 2012
)
0.38
"Products cryopreserved with dimethyl sulfoxide (DMSO) in stem cell transplant (SCT) often cause many adverse effects during their infusion (major cardiovascular events, dyspnea … even death)."( An automatic wash method for dimethyl sulfoxide removal in autologous hematopoietic stem cell transplantation decreases the adverse effects related to infusion.
Blanquer, M; Cabañas-Perianes, V; García-Hernández, A; Gómez-Espuch, J; Insausti, CL; Majado, MJ; Menchón, P; Monserrat, J; Moraleda, JM; Morales, A; Sánchez-Ibáñez, MV; Sánchez-Salinas, A, 2012
)
0.96
" One adverse event, abdominal pain, occurred during the washed cells infusions."( An automatic wash method for dimethyl sulfoxide removal in autologous hematopoietic stem cell transplantation decreases the adverse effects related to infusion.
Blanquer, M; Cabañas-Perianes, V; García-Hernández, A; Gómez-Espuch, J; Insausti, CL; Majado, MJ; Menchón, P; Monserrat, J; Moraleda, JM; Morales, A; Sánchez-Ibáñez, MV; Sánchez-Salinas, A, 2012
)
0.67
" In the first experiment, only xylol was highly toxic at the concentrations tested, causing mortality above 90% for larvae of both species."( Toxicity of solvents and surfactants to Amblyomma cajennense (Fabricius, 1787) (Acari: Ixodidae) and Dermacentor nitens (Neumann, 1897) (Acari: Ixodidae) larvae.
Daemon, E; Ferreira Rodrigues, AF; Maturano, R; Monteiro, CM; Prata, MC; Resende, JD, 2012
)
0.38
"The most common adverse events involved the skin or subcutaneous tissue, primarily at the application site."( Pooled safety analysis of diclofenac sodium topical solution 1.5% (w/w) in the treatment of osteoarthritis in patients aged 75 years or older.
Fuller, P; Roth, SH, 2012
)
0.38
" Using sensitive indices of neural damage, we found a wide range of toxicities, with median toxic concentrations ranging from 2 to 10,000 ng/ml."( Antiretroviral neurotoxicity.
Liner, J; Meeker, RB; Robertson, K, 2012
)
0.38
" These data support the toxic accumulation of NAMI-A or of its products of transformation in the kidneys and stress the need of at least 14 days washout between two treatment cycles when the drug is given daily for 6 consecutive days."( Features and full reversibility of the renal toxicity of the ruthenium-based drug NAMI-A in mice.
Cocchietto, M; Pacor, S; Sava, G; Vadori, M; Vita, F; Zorzet, S, 2013
)
0.39
" LD50 values of iodogen/DMSO were 59."( A safety study on single intravenous dose of tetrachloro-diphenyl glycoluril [iodogen] dissolved in dimethyl sulphoxide (DMSO).
Alpizar, YA; Chen, F; Cona, MM; de Witte, P; Feng, Y; Li, J; Ni, Y; Oyen, R; Sun, Z; Talavera, K; Vanstapel, F; Verbruggen, A, 2013
)
0.39
" A comparison of the MERA with the conventional isobologram and the extended toxic unit summation revealed that the MERA characterizes the degree of toxicity interaction in the view of effect, with less limitation by different concentration ratios or effect levels."( [Characterizing the toxicity interaction of the binary mixture between DMSO and pesticide by the multi-effect residual analysis (MERA)].
Huo, XC; Liu, SS; Zhang, J, 2013
)
0.39
" A variety of adverse events (AEs) of varying severity have been noted during HPC infusions."( Infusion technique of hematopoietic progenitor cells and related adverse events (CME).
Bryant, SC; Gastineau, DA; Greiner, CW; Hogan, WJ; Jacob, EK; Lingineni, RK; Mohr, A; Mulay, SB; Padley, D, 2014
)
0.4
" MET was less toxic among the tested cryoprotectants and concentrations did not allow the determination of its LC50-24h."( Toxicity of cryoprotectants agents in freshwater prawn embryos of Macrobrachium amazonicum.
Barbosa, MS; Castro, EJ; de Araújo Neto, MP; de Sousa, ML; de Souza Sampaio, CM; Ferreira, AV; Filho, AA, 2015
)
0.42
" However, few studies have investigated the involvement of IGF-I during states of extreme shock, such as those induced by potently toxic cryoprotective agents (CPAs) or low temperature conditions, in bivalves."( Influence of the toxicity of cryoprotective agents on the involvement of insulin-like growth factor-I receptor in surf clam (Spisula sachalinensis) larvae.
Choi, YH; Nam, TJ,
)
0.13
" Dimethyl sulphoxide (DMSO) is commonly used at a concentration of 10% (v/v); however, there is evidence to suggest this chemical is toxic to cells as well as to patients after infusion."( Assessing the toxic effects of DMSO on cord blood to determine exposure time limits and the optimum concentration for cryopreservation.
Fry, LJ; Gomez, SG; Madrigal, JA; McArdle, S; Querol, S; Rees, R, 2015
)
0.42
"The toxic effects of DMSO were assessed through cell viability and in vitro functional assays in fresh and post-thaw CB samples before determining the maximum exposure time and optimal concentration for cryopreservation."( Assessing the toxic effects of DMSO on cord blood to determine exposure time limits and the optimum concentration for cryopreservation.
Fry, LJ; Gomez, SG; Madrigal, JA; McArdle, S; Querol, S; Rees, R, 2015
)
0.42
" In fresh and post-thaw analysis, minimal toxic effect was observed when cryopreservation was delayed for up to 1 h after 10% DMSO addition."( Assessing the toxic effects of DMSO on cord blood to determine exposure time limits and the optimum concentration for cryopreservation.
Fry, LJ; Gomez, SG; Madrigal, JA; McArdle, S; Querol, S; Rees, R, 2015
)
0.42
" The aim of sharing these data, including adverse findings, is to provide meaningful information for vehicle selection, thereby avoiding repetition of animal experimentation."( Safety data on 19 vehicles for use in 1 month oral rodent pre-clinical studies: administration of hydroxypropyl-ß-cyclodextrin causes renal toxicity.
Burdett, L; Cotton, P; Finney, R; Garner, C; Hargreaves, A; Harris, J; Healing, G; Kirk, S; Pivette, P; Schramm, C; Sulemann, T, 2016
)
0.43
"Dimethyl sulfoxide (DMSO), a widely used carrier solvent, can be toxic to test organisms and has species-specific sensitivity."( Comparative Developmental Toxicity and Stress Protein Responses of Dimethyl Sulfoxide to Rare Minnow and Zebrafish Embryos/Larvae.
Luo, S; Wang, J; Wu, B; Xiong, X, 2017
)
2.13
" We selected 44 compounds that exhibited toxic effects on HEL cells in the dividing phase from a chemical library containing 325 anticancer drugs and enzyme inhibitors."( Dividing phase-dependent cytotoxicity profiling of human embryonic lung fibroblast identifies candidate anticancer reagents.
Inagaki, Y; Matsumoto, Y; Sekimizu, K; Tang, W,
)
0.13
" At least one adverse event was reported in 14."( A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis.
Cervigni, M; Ciani, O; Frangione, V; Giammò, A; Ostardo, E; Pappagallo, GL; Porru, D; Sommariva, M; Tarricone, R; Tenaglia, R; Trevisan, S, 2017
)
0.66
" As a Generally Recognized As Safe (GRAS) approved substance, MSM is well-tolerated by most individuals at dosages of up to four grams daily, with few known and mild side effects."( Methylsulfonylmethane: Applications and Safety of a Novel Dietary Supplement.
Benjamin, RL; Bloomer, RJ; Butawan, M, 2017
)
0.46
" We evaluated the factors contributing to the occurrence of adverse events (AEs) of cryopreserved HPC-A infusion."( Adverse events of cryopreserved hematopoietic stem cell infusions in adults: a single-center observational study.
Carey, S; Grossman, BJ; Otrock, ZK; Sempek, DS, 2017
)
0.46
"TVE with liquid embolic agents is a safe and effective salvage method for VGAMs with restricted transarterial access, previously considered as poor candidates for endovascular treatment."( Superselective transvenous embolization with Onyx and n-BCA for vein of Galen aneurysmal malformations with restricted transarterial access: safety, efficacy, and technical aspects.
Berestov, V; Gorbatykh, A; Kislitsin, D; Orlov, K; Seleznev, P; Shayakhmetov, T; Strelnikov, N, 2017
)
0.46
" Patients were monitored for adverse events (AEs), coagulation markers, PLT responses, and hemostatic efficacy."( Safety and efficacy of cryopreserved platelets in bleeding patients with thrombocytopenia.
Cancelas, JA; Dumont, LJ; Dunbar, NM; Gernsheimer, TB; Hmel, P; Housler, G; Jones, M; Kinne, B; Macdonald, VW; Medlin, S; Prakash, G; Ransom, JH; Rugg, N; Slichter, SJ; Szczepiorkowski, ZM; Valiyaveettil, M, 2018
)
0.48
"Cryopreserved PLT transfusions appear to be safe and effective when given to bleeding patients with thrombocytopenia."( Safety and efficacy of cryopreserved platelets in bleeding patients with thrombocytopenia.
Cancelas, JA; Dumont, LJ; Dunbar, NM; Gernsheimer, TB; Hmel, P; Housler, G; Jones, M; Kinne, B; Macdonald, VW; Medlin, S; Prakash, G; Ransom, JH; Rugg, N; Slichter, SJ; Szczepiorkowski, ZM; Valiyaveettil, M, 2018
)
0.48
" elegans are more resistant to the toxic effect of M22 compared to wild-type worms."( Cryoprotectant toxicity in Caenorhabditis elegans.
Johnson, TE; Schumacher, GJ; Tedesco, PM, 2019
)
0.51
"A simple generic toxicity method (test) is proposed using baker's yeast to mediate the reduction of the colourless triphenyltetrazolium chloride (TTC) to red, 1,3,5-triphenyl formazan, which can be extracted by dimethyl sulfoxide (DMSO), enabling the identification of reducible toxic compounds (e."( YTOX: a rapid toxicity test based on the dehydrogenase activity of Saccharomyces cerevisiae for detection of contaminants in water samples.
Andrino, FG; da Silva, APM; de Lira, SP; Duarte, KMR; Ferrarezi, JA; Gomes, LH; Kamogawa, MY; Laguna, SE; Tavares, ACL, 2019
)
0.7
" In conclusion, oral MSM at either acute (single dose at 1,000 to 2,000 mg/kg BW) or sub-chronic (1,500 mg/kg BW daily for 21 D) concentrations did not cause any adverse effects on growth or clinical outcomes and appeared to be absorbed and distributed throughout the body."( Toxicity and tissue distribution of methylsulfonylmethane following oral gavage in broilers.
Abdul Rasheed, MS; Bauer, LL; Dilger, RN; Oelschlager, ML; Smith, BN; Whelan, RA, 2019
)
0.51
"To ensure that 16 weeks of methylsulfonylmethane (MSM) does not cause adverse effects in patients with the musculoskeletal disorders of osteoarthritis and back pain."( Methylsulfonylmethane for treatment of low back pain: A safety analysis of a randomized, controlled trial.
Crawford, A; Crawford, P; Lystrup, R; Nielson, F, 2019
)
0.51
"Carrier solvents are used frequently in toxicity testing to assist hydrophobic chemicals into solution, but such solvents may have toxic effects on test subjects."( Assessment of sublethal ecotoxicity of solvents on larvae of a model native amphibian (Lithobates pipiens).
Forbes, MR; Gavel, MJ; Gutierrez-Villagomez, JM; Robinson, SA; Young, SD, 2020
)
0.56
"It was found that Onyx embolization is safe and represents a good option for an initial treatment approach, in a sequential treatment strategy for pediatric ruptured brain AVMs."( First Line Onyx Embolization in Ruptured Pediatric Arteriovenous Malformations : Safety and Efficacy.
Alias, Q; Beccaria, K; Benichi, S; Blauwblomme, T; Boddaert, N; Boulouis, G; Brunelle, F; Gariel, F; Garzelli, L; Kossorotoff, M; Meyer, P; Naggara, O, 2021
)
0.62
"Hematopoietic cell infusion-related adverse events (HCI-AEs) in hematopoietic stem cell transplantations (HSCTs) have been largely attributed to toxicity of dimethyl sulfoxide (DMSO) for cryopreservation, but HSC products also contain various cells and plasma components."( Hematopoietic cell infusion-related adverse events in pediatric/small recipients in a prospective/multicenter study.
Ashida, T; Fujii, N; Fujiwara, SI; Hirose, A; Ikeda, K; Iseki, T; Kameda, K; Kanamori, H; Kanda, J; Kasama, K; Minakawa, K; Mori, T; Muroi, K; Nagai, K; Nagamura-Inoue, T; Ohto, H; Okuyama, Y; Takahashi, T; Tanosaki, R; Yamada-Fujiwara, M, 2020
)
0.76
" These treatments would not have taken place without suitable sources of DMSO that enabled stable and safe storage of bone marrow and blood cells until needed for transfusion."( Dimethyl sulfoxide: a central player since the dawn of cryobiology, is efficacy balanced by toxicity?
Awan, M; Buriak, I; Fleck, R; Fuller, B; Goltsev, A; Kerby, J; Lowdell, M; Mericka, P; Petrenko, A; Petrenko, Y; Rogulska, O; Stacey, GN; Stolzing, A, 2020
)
2
"Percutaneous direct sac embolization using Onyx in combination or not with microcoils represents a safe and valid technique to solve post-EVAR type II endoleaks."( Direct percutaneous embolization of aneurysm sac: a safe and effective procedure to treat post-EVAR type II endoleaks.
Cannavale, A; Chisci, E; Citone, M; Falcone, GM; Fanelli, F; Michelagnoli, S; Miele, V, 2021
)
0.62
" To address this challenge, we previously developed a mathematical approach to design less toxic CPA equilibration methods based on the minimization of a toxicity cost function."( Rapid quantification of multi-cryoprotectant toxicity using an automated liquid handling method.
Ampo, E; Benson, JD; Eroglu, A; Higgins, AZ; Nelson, D; Warner, RM, 2021
)
0.62
" The primary endpoint was any catheter-related adverse event (AE) at 30 days, such as unintentional tip detachment or malfunction with clinical sequelae, or retained catheter."( Safety of the APOLLO Onyx delivery microcatheter for embolization of brain arteriovenous malformations: results from a prospective post-market study.
Aziz-Sultan, MA; Bellon, RJ; Chitale, RV; Cockroft, KM; Deshmukh, VR; Diaz, O; Fifi, JT; Fiorella, D; Given, CA; Gonzalez, LF; Hanel, RA; Huddle, D; Jagadeesan, BD; Kan, P; Kvamme, P; Meyers, PM; Miller, TR; Mokin, M; Morrow, JT; Polifka, AJ; Puri, AS; Seinfeld, J; Singer, J; Wakhloo, AK; Woo, HH; Yao, TL; Zomorodi, AR, 2021
)
0.62
" The adverse drug reactions were mild to moderate, and manageable."( Efficacy and safety of intravesical instillation of KRP-116D (50% dimethyl sulfoxide solution) for interstitial cystitis/bladder pain syndrome in Japanese patients: A multicenter, randomized, double-blind, placebo-controlled, clinical study.
Akiyama, Y; Ameda, K; Homma, Y; Kageyama, S; Kajiwara, M; Kitta, T; Kobayashi, S; Kokura, K; Masumori, N; Mitsui, T; Muraki, O; Namima, T; Nanri, M; Niimi, A; Ohashi, Y; Ohinata, A; Okazoe, H; Otsuka, A; Sakamoto, S; Sekiguchi, Y; Shishido, T; Takei, M; Tomoe, H; Ueda, T; Uno, T; Watanabe, T; Yamaguchi, A; Yamanishi, T; Yoshimura, N, 2021
)
0.86
" Adverse events were monitored weekly."( Efficacy and safety of a supplement combination on hand pain among people with symptomatic hand osteoarthritis an internet-based, randomised clinical trial the RADIANT study.
Deveza, LA; Eyles, J; Fedorova, T; Hunter, DJ; Liu, X; McLachlan, AJ; Robbins, S; Virk, S, 2021
)
0.62
" The literature describes it as selectively toxic to neoplastic cells but safe for normal cells."( High cytotoxicity of betulin towards fish and murine fibroblasts: Is betulin safe for nonneoplastic cells?
Kaczorek-Łukowska, E; Kazuń, B; Małaczewska, J, 2021
)
0.62
" However, dimethylsulfoxide contained in cryopreserved grafts can cause adverse events (AEs)."( Washing transplants with Sepax 2 reduces the incidence of side effects associated with autologous transplantation and increases patients' comfort.
Černá, L; Grebeníček, L; Hájek, R; Huvarová, L; Jelínek, T; Kořístek, Z; Michalíková, M; Navrátil, M; Smejkalová, J; Tvrdá, I, 2021
)
0.62
" The aim of this study was to determine whether washing out dimethyl sulfoxide (DMSO) from transplants using the Sepax 2 (S-100) device is safe and reduces the incidence of DMSO-associated AEs."( Washing transplants with Sepax 2 reduces the incidence of side effects associated with autologous transplantation and increases patients' comfort.
Černá, L; Grebeníček, L; Hájek, R; Huvarová, L; Jelínek, T; Kořístek, Z; Michalíková, M; Navrátil, M; Smejkalová, J; Tvrdá, I, 2021
)
0.86
" No adverse events were observed."( Effectiveness and safety of topical amphotericin B in 30% dimethyl sulfoxide cream versus 30% dimethyl sulfoxide cream for nondermatophyte onychomycosis treatment: A pilot study.
Bunyaratavej, S; Kiratiwongwan, R; Komesmuneeborirak, P; Leeyaphan, C; Prasong, W; Suiwongsa, B; Supcharoenkul, S; Wongdama, S,
)
0.38
" The main concern about vitrification is how much potentially toxic residual cryoprotectant remains in the warmed tissues at the time of transplantation."( Quantification of residual cryoprotectants and cytotoxicity in thawed bovine ovarian tissues after slow freezing or vitrification.
Edashige, K; Furuyama, S; Koike, J; Koizumi, T; Kubota, M; Meng, L; Migitaka-Igarashi, J; Natsuki, Y; Nishimura, S; Seino, H; Sugishita, Y; Suzuki, N; Suzuki-Takahashi, Y; Tozawa-Ono, A; Uekawa, A, 2022
)
0.72
" This washing did not affect the tissue integrity or significantly elevate the percentage of AC3 and γH2AX positive cells, indicating that tissues are safe and of good quality for transplantation."( Quantification of residual cryoprotectants and cytotoxicity in thawed bovine ovarian tissues after slow freezing or vitrification.
Edashige, K; Furuyama, S; Koike, J; Koizumi, T; Kubota, M; Meng, L; Migitaka-Igarashi, J; Natsuki, Y; Nishimura, S; Seino, H; Sugishita, Y; Suzuki, N; Suzuki-Takahashi, Y; Tozawa-Ono, A; Uekawa, A, 2022
)
0.72
"The standard cryoprotectant for human cellular products is dimethyl sulfoxide (DMSO), which is associated with hematopoietic cell infusion-related adverse events (HCI-AEs) in hematopoietic stem cell transplantation including peripheral blood stem cell (PBSC) transplantation (PBSCT)."( Comparison of cryoprotectants in hematopoietic cell infusion-related adverse events.
Ashida, T; Fujii, N; Fujiwara, SI; Hirose, A; Ikeda, K; Iseki, T; Kameda, K; Kanamori, H; Minakawa, K; Nagai, K; Nagamura-Inoue, T; Ohto, H; Okuyama, Y; Takahashi, T; Tanosaki, R; Ueda, K; Yamada-Fujiwara, M; Yamahara, K; Yamazaki, R, 2022
)
0.96
" These observed changes in developmental endpoints, hormonal level, and alteration in mRNA expression of component genes involved in neurodevelopmental pathways could be part of the possible mechanism of the observed toxic effects of TBBPA-DHEE exposure on zebrafish."( Transcriptomic sequencing reveals the potential molecular mechanism by which Tetrabromobisphenol A bis (2-hydroxyethyl ether) exposure exerts developmental neurotoxicity in developing zebrafish (Danio rerio).
Che, J; Chen, Y; Ding, Y; Feng, W; Mao, G; Okeke, ES; Qian, X; Wu, X; Xu, H; Zeng, Z, 2022
)
0.72
" The present study further widens our insights into the adverse effects of TCS."( Adverse effects of triclosan on kidney in mice: Implication of lipid metabolism disorders.
Cai, Z; Cao, G; Chen, D; Chen, Y; Deng, C; Huang, W; Wang, T, 2023
)
0.91
" The concept of green solvents focuses on protecting the environment by reducing or even eliminating the use of toxic solvents."( Combining environmental, health, and safety features with a conductor like Screening Model for selecting green solvents for antibiotic analyses.
Abbas, T; Jones-Lepp, TL; Kaewlom, P; Khan, E; Masrura, SU, 2023
)
0.91
"5, or 5 mg/kg of AdipoRon without adverse effects."( The Safety of Adiponectin Receptor Agonist AdipoRon in a Rabbit Model of Arthrofibrosis.
Abdel, MP; Berry, DJ; Bettencourt, JW; Carstens, MF; Dudakovic, A; Gow, C; Limberg, AK; Morrey, ME; Payne, AN; Salmons, HI; Sanchez-Sotelo, J, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" Model-independent pharmacokinetic analysis (statistical moment theory) revealed a significant dependence of plasma clearance and mean residence time on the dose administered in both conditions."( Medroxyprogesterone acetate plasma pharmacokinetics after intravenous administration in rabbits.
Camaggi, CM; Comparsi, R; Pannuti, F; Strocchi, E, 1987
)
0.27
"A series of toxicologic and pharmacokinetic studies were performed in BALB/c mice administered intradermal (ID) mitomycin C (MMC) at doses of ."( Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide.
Dorr, RT; Keller, JH; Liddil, JD; Soble, MJ, 1986
)
0.49
" Model-dependent and model-independent pharmacokinetic parameters for theophylline were compared on the basis of the solvent used in the dosage form administered."( Effect of organic vehicles on the pharmacokinetics of aminophylline administered intravenously to goats.
Bevill, RF; Davis, LE; Koritz, GD; Langston, VC; Munsiff, IJ; Neff-Davis, CA; Sharma, GC, 1987
)
0.27
" Pharmacokinetic parameters for volume of the central compartment (Vc), maximum velocity (Vmax), and Michaels-Menten constant (Km) were 37."( Plasma concentrations and pharmacokinetics of dimethylsulfoxide and its metabolites in patients undergoing peripheral-blood stem-cell transplants.
Cottler-Fox, M; Egorin, MJ; Rosen, DM; Sensenbrenner, L; Sridhara, R, 1998
)
0.3
" Pharmacokinetic parameters in individual patients have been related to short-term toxicity and risk of relapse after HSCT."( Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation.
Deeg, J; Ehninger, G; Ehrsam, M; Schmidt, H; Schneider, A; Schuler, US, 1998
)
0.3
" In this report, we applied the analytical method to obtain new pharmacokinetic information about ISBN."( Analysis of isobutyl nitrite inhalant in rat and human blood: application for pharmacokinetic investigations.
Bauer, JA; Fung, HL; Kielbasa, WB, 1999
)
0.3
" The compound also showed a desirable in vivo pharmacokinetic profile in rats, suggesting that the SMR study on the confirmed in vitro and in vivo correlation is essential to the optimization."( [High throughput screening of pharmacokinetics and metabolism in drug discovery (II)--investigation on in vitro and in vivo correlation in drug metabolism screening].
Ano, R; Kawahara, I; Komura, H; Matsuda, K; Moriwaki, T; Murayama, Y; Shigemoto, Y; Yoshida, NH, 2005
)
0.33
" The objective of this study was to evaluate the pharmacokinetic profile and distribution of radiolabeled MSM in rats."( Pharmacokinetics and distribution of [35S]methylsulfonylmethane following oral administration to rats.
Ames, GB; Appleton, J; Magnuson, BA, 2007
)
0.34
" Simulations using a physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for CPF are consistent with these possibilities."( Comparative chlorpyrifos pharmacokinetics via multiple routes of exposure and vehicles of administration in the adult rat.
Barr, DB; Busby-Hjerpe, AL; Campbell, JA; Lee, S; Poet, TS; Smith, JN; Timchalk, C, 2009
)
0.35
" The method has then been applied to a pharmacokinetic study in cynomolgus monkeys."( Reduction of matrix interferences by the combination of chaotropic salt and DMSO in a broadly applicable target-based ELISA for pharmacokinetic studies of therapeutic monoclonal antibodies.
Avrameas, A; Canadi, J; Deckert-Salva, F; Doucet, J; Kalis, C; Legay, F; Marrony, S; Valentin, MA, 2009
)
0.35
" Enzyme kinetic parameters (K(m) and V(max)) and pharmacokinetic properties of three probe drugs were compared using wild-type and humanized UGT1 mice that express the Gilbert's UGT1A1*28 allele [Tg(UGT1(A1*28)) Ugt1(-/-) mice]."( A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation.
Cai, H; Chen, S; Hotz, K; La Placa, DB; Nguyen, N; Peterkin, V; Stevens, JC; Tukey, RH; Yang, YS, 2010
)
0.36
" The aim of this study was to clarify differences in outcomes owing to different dosing regimens and the pharmacokinetic profile of progesterone, particularly in relation to brain levels."( Progesterone pharmacokinetics in the mouse: implications for potential stroke therapy.
Kendall, DA; Ray, D; Wong, R, 2012
)
0.38
" Progesterone concentrations were measured by an enzyme-linked immunoassay and pharmacokinetic profiles were constructed."( Progesterone pharmacokinetics in the mouse: implications for potential stroke therapy.
Kendall, DA; Ray, D; Wong, R, 2012
)
0.38
" Modern high-throughput small molecule drug discovery requires rapid screening of the pharmacokinetic parameters of multiple candidate molecules in parallel."( Solvent-based formulations for intravenous mouse pharmacokinetic studies: tolerability and recommended solvent dose limits.
Bowman, T; Dean, B; Messick, K; Sambrone, A; Schweiger, M; Thackaberry, EA; Valle, N; Wang, X; Xie, M, 2014
)
0.4
" It is important to understand whether any pharmacokinetic interactions are among the major constituents of these supplements so as to provide information when considering the combination use of these supplements."( Pharmacokinetic assessment of constituents of Boswellia serrata, pine bark extracts, curcumin in combination including methylsulfonylmethane in healthy volunteers.
Adiwidjaja, J; Eagles, SK; Eyles, J; Hunter, DJ; Liu, X; McLachlan, AJ; Wang, X, 2020
)
0.56
"The pharmacokinetics of each constituent was characterized, and there were no significant differences in the pharmacokinetic profiles of the constituents when administered as a combination, relative to the constituents when administered alone (P > 0."( Pharmacokinetic assessment of constituents of Boswellia serrata, pine bark extracts, curcumin in combination including methylsulfonylmethane in healthy volunteers.
Adiwidjaja, J; Eagles, SK; Eyles, J; Hunter, DJ; Liu, X; McLachlan, AJ; Wang, X, 2020
)
0.56
"These data suggest that interactions between the major constituents of this supplement combination are unlikely and therefore could be investigated to manage patients with osteoarthritis without significant concerns for possible pharmacokinetic interactions."( Pharmacokinetic assessment of constituents of Boswellia serrata, pine bark extracts, curcumin in combination including methylsulfonylmethane in healthy volunteers.
Adiwidjaja, J; Eagles, SK; Eyles, J; Hunter, DJ; Liu, X; McLachlan, AJ; Wang, X, 2020
)
0.56

Compound-Compound Interactions

The aim of this study was to investigate the possible synergistic effect of royal jelly in combination with glycerol and dimethyl sulfoxide (DMSO) in sperm cryopreservation extender of Romanov ram.

ExcerptReferenceRelevance
"Bicarbonate-buffered HTF medium, Medicult, and T6 are as effective as PB1 medium when used in combination with DMSO in ultrarapid freezing of two-cell mouse embryos."( The evaluation of various culture media in combination with dimethylsulfoxide for ultrarapid freezing of murine embryos.
Bongso, A; Edirisinghe, R; Ng, SC; Ratnam, S; Vasuthevan, S, 1992
)
0.28
" These data suggest that differentiation agents may provide additional antineoplastic benefits when administered in combination with selected chemotherapeutic agents in the management of prostatic cancer."( Conventional chemotherapeutic agents combined with DMSO or DFMO in treatment of rat prostate carcinoma.
Carvalho, L; Foulkes, K; Mickey, DD, 1989
)
0.28
"A course of 4-5 intra-articular injections was given to 25 children aged 4-15 years with juvenile rheumatoid arthritis: 20% dimexide++ solution in combination with hydrocortisone (2 ml) was administered into the right knee joint and hydrocortisone (12."( [Effectiveness of intra-articular dimexide in combination with hydrocortisone and hydrocortisone in patients with juvenile rheumatoid arthritis].
Melikhova, NI; Mura'vev, IuV; Sigidin, IaA, 1989
)
0.28
" Glucose deprivation induced by insulin, and combined with the inhibition of oxidative phosphorylation, produces an additive depression of tumor energetics."( Inhibition of tumor high-energy phosphate metabolism by insulin combined with rhodamine 123.
Arbeit, JM; Hubesch, A; Karczmar, GS; Toy, BJ; Weiner, MW, 1988
)
0.27
"The [K+]/[Na+] ratio of rabbit renal cortical slices was used to examine, at 25 degrees C, the effects on viability of three cryoprotectant agents (CPA) (dimethyl sulfoxide (Me2SO), ethylene glycol, and glycerol) in combination with three vehicle solutions (Krebs-Henseleit (K-H), solution A, and RPS-2)."( Factors influencing renal cryopreservation. II. Toxic effects of three cryoprotectants in combination with three vehicle solutions in nonfrozen rabbit cortical slices.
Clark, P; Fahy, GM; Karow, AM, 1984
)
0.47
" This megazol gel, when used in combination with melarsoprol (3."( Topical chemotherapy for experimental African trypanosomiasis with cerebral involvement: the use of melarsoprol combined with the 5-nitroimidazole, megazol.
Chauvière, G; Jennings, FW; Murray, M; Viode, C, 1996
)
0.29
" Polyen antibiotics combined with DMSO also demonstrated antineoplastic activity at the animals treated with carcinogenic agent--diethyl nitrosoamine (DENA)."( [Radioprotective and antineoplastic activity of polyene antibiotics combined with dimethyl sulfoxide].
Aliev, DI; Ibragimova, VKh, 2002
)
0.54
"To study the safety and potential health benefits of soy isoflavones, a rapid and simple method based on liquid chromatography combined with mass spectrometry (LC/MS) and photodiode array detector (PDA) was developed for the determination of isoflavones in rat plasma."( An accurate and reproducible method for the quantitative analysis of isoflavones and their metabolites in rat plasma using liquid chromatography/mass spectrometry combined with photodiode array detection.
Cooke, G; Gilani, GS; Lau, BP; Robertson, P; Sepehr, E,
)
0.13
"This study was aimed to investigate the protective effects of dimethylsulfoxide (DMSO) combined with trehalose on the cryopreserved platelets."( [Protection of cryopreserved platelets by dimethyl sulfoxide combined with trehalose].
Dian, ZJ; Ouyang, HM; Shen, SY; Shen, XM; Yang, TH; Zhao, RB, 2009
)
0.62
" Therefore, we tested metal chelation by means of ethylenediaminetetraacetic acid (EDTA) combined with the permeability enhancer methylsulfonylmethane (MSM) applied topically on the eye to determine if this noninvasive treatment is neuroprotective in rat optic nerve and retinal ganglion cells exposed to oxidative stress induced by elevated IOP."( Metal chelator combined with permeability enhancer ameliorates oxidative stress-associated neurodegeneration in rat eyes with elevated intraocular pressure.
Ansari, NH; Campbell, GA; Hogan, D; Liu, P; Shoeb, M; Syed, MF; Tang, L; Wang, CZ; Zhang, M, 2014
)
0.4
" The aim of this study was to investigate the possible synergistic effect of royal jelly in combination with glycerol and dimethyl sulfoxide (DMSO) in sperm cryopreservation extender of Romanov ram."( Synergistic effect of royal jelly in combination with glycerol and dimethyl sulfoxide on cryoprotection of Romanov ram sperm.
Namvar, Z; Noghani, AE; Pashapour, S; Saberivand, A, 2022
)
1.16
"Microchip capillary electrophoresis in mixed hydro-organic solvent combined with laser-induced fluorescence detection was developed for the separation and detection of physcion and rhein in rhubarb."( Determination of rhein and physcion in rhubarb by microchip capillary electrophoresis in mixed hydro-organic solvent combined with laser-induced fluorescence detection.
Chen, S; He, Y; Li, Y; Liang, Y; Sun, Y, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of topically administered beta APN was determined by measuring the degree of collagen cross-linking inhibition in the underlying granuloma tissue."( Effect of topically applied beta-aminopropionitrile on granuloma tissue biochemistry.
Chvapil, M; Dhar, SC; Gibeault, JD; Gowri, C; Lata, A, 1988
)
0.27
" Only low platinum (Pt)-concentrations of about 1 microgram/ml could be detected in the serum using unmodified Cisplatinum solutions for instillation in the rat bladder indicating a rather low absorption rate for Cisplatinum."( Serum and tissue levels of platinum after cisplatinum instillation of the rat bladder.
Engelmann, U; Groebe, G; Wagner, HA, 1988
)
0.27
" Such a process of absorption was different of that described for prednisolone acetate suspension for which rate of absorption was slower."( [Pharmacokinetics of prednisolone administered to cows in the form of a prednisolone acetate solution in dimethyl sulfoxide in association with antibiotics].
Alvinerie, M; Oukessou, M; Toutain, PL, 1987
)
0.49
" The absorption rate of busulfan tablets in our model was as unpredictable as documented in clinical trials."( Use of a water-soluble busulfan formulation--pharmacokinetic studies in a canine model.
Blanz, J; Deeg, HJ; Ehninger, G; Ehrsam, M; Renner, U; Schuler, U; Storb, R; Zeller, KP, 1995
)
0.29
" The compounds examined ranged from well- to poorly-absorbed and included compounds absorbed by active and passive mechanisms."( Use of everted intestinal rings for in vitro examination of oral absorption potential.
Fix, JA; Leppert, PS, 1994
)
0.29
" The presence of MNA in both vehicles blunted the absorption rate curves without significantly changing total absorption."( The use of mechanistically defined chemical mixtures (MDCM) to assess component effects on the percutaneous absorption and cutaneous disposition of topically exposed chemicals. I. Studies with parathion mixtures in isolated perfused porcine skin.
Baynes, RE; Brooks, JD; Monteiro-Riviere, NA; Qiao, GL; Riviere, JE; Williams, PL, 1996
)
0.29
" These data indicated that NAMI-A is well absorbed after oral administration although there is no connection between lung concentration and the antimetastatic activity."( Comparison of the effects of the antimetastatic compound ImH[trans-RuCl4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice.
Alessio, E; Capozzi, I; Clerici, K; Cocchietto, M; Gagliardi, R; Marrella, M; Mestroni, G; Milanino, R; Sava, G, 1998
)
0.3
" Bioavailability of BU powder capsules was on average 70% (range, 44-94%)."( Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation.
Deeg, J; Ehninger, G; Ehrsam, M; Schmidt, H; Schneider, A; Schuler, US, 1998
)
0.3
" Papp of IDM was greater than that of TAT, indicating that the order corresponded with that of in vivo bioavailability after oral administration of their PEG 600 solutions."( Evaluation of absorbability of poorly water-soluble drugs: validity of the use of additives.
Hayashi, M; Sudo, R; Takahashi, M; Watanabe, E, 2000
)
0.31
" The oral bioavailability of monoHER is <1%."( Stability of monoHER in an aqueous formulation for i.v. administration.
Abou El Hassan, MA; Bast, A; Touw, DJ; van der Vijgh, WJ; Wilhelm, AJ, 2000
)
0.31
" Overall, the present results suggest that binding to plasma proteins causes a drastic decrease of NAMI-A bioavailability and a subsequent reduction of its biological activity, implying that association to plasma proteins essentially represents a mechanism of drug inactivation."( Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin.
Bergamo, A; Cocchietto, M; Messori, L; Piccioli, F; Sava, G, 2003
)
0.32
" The interindividual variability value of the Vm could explain, at least in part, the variability in absorption rate constants observed."( Use of nonlinear mixed effect modeling for the intestinal absorption data: application to ritonavir in the rat.
Casabó, VG; Lledó-García, R; Máñez-Castillejo, FJ; Merino-Sanjuán, M; Muñoz, MJ; Nácher, A, 2005
)
0.33
"We validated the application of the surface plasmon resonance (SPR) technique to reliably determine adhesion of drugs to the intestinal wall using heparin-DOCA conjugates, developed to enhance the oral absorption of poorly absorbed heparin."( Evaluation of absorption of heparin-DOCA conjugates on the intestinal wall using a surface plasmon resonance.
Byun, Y; Choi, K; Kim, CY; Kim, K; Kim, SK; Kwon, IC; Lee, S; Park, JH; Park, K, 2005
)
0.33
" In this study, the use of the sodium salt diclazuril to increase the apparent bioavailability of diclazuril for the treatment and prophylaxis of EPM and various other Apicomplexan mediated diseases is described."( New therapeutic approaches for equine protozoal myeloencephalitis: pharmacokinetics of diclazuril sodium salts in horses.
Atkinson, A; Boyles, J; Dirikolu, L; Granstrom, DE; Harkins, JD; Hughes, C; Karpiesiuk, W; Lehner, AF; Tobin, T; Woods, WE, 2006
)
0.33
"5 microM genistein, a broad-spectrum tyrosine kinase inhibitor, virtually eliminates the CO(2) sensitivity of HCO(3)(-) absorption rate (J(HCO(3)))."( Role of a tyrosine kinase in the CO2-induced stimulation of HCO3- reabsorption by rabbit S2 proximal tubules.
Boron, WF; Bouyer, P; Zhou, Y, 2006
)
0.33
" As bioavailability is a key issue for potential in vivo effects, the tissue accumulation and biliary elimination of 5,7-DMF and its non-methylated analog chrysin were examined in a small fish model (Fundulus heteroclitus)."( Accumulation and metabolism of the anticancer flavonoid 5,7-dimethoxyflavone compared to its unmethylated analog chrysin in the Atlantic killifish.
Tsuji, PA; Walle, T; Winn, RN, 2006
)
0.33
" LHD was pre-formulated with dimethyl sulfoxide (DMSO) as solubilizer to further improve its oral bioavailability (9."( Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant.
Byun, Y; Kim, CY; Kim, SK; Lee, DY; Lee, E; Lee, YK; Moon, HT, 2007
)
0.63
" The main reason is that the drug's hydrophobicity hinders its bioavailability in the body fluids."( Fenretinide-polyvinylalcohol conjugates: new systems allowing fenretinide intravenous administration.
Bergamante, V; Carosio, R; Cilli, M; Gotti, R; Montaldo, PG; Orienti, I; Zuccari, G, 2007
)
0.34
" Moreover, the early qualitative prediction of bioavailability and absorption of orally administered drugs require more and more biorelevant solubility values in drug discovery programs."( High throughput UV method for the estimation of thermodynamic solubility and the determination of the solubility in biorelevant media.
Bard, B; Carrupt, PA; Martel, S, 2008
)
0.35
"The results allowed us to predict that these coumarins are well absorbed in the gut lumen and efflux is not limiting the absorption."( Coumarins permeability in Caco-2 cell model.
Fallarero, A; Galkin, A; Vuorela, PM, 2009
)
0.35
" The present results add important information on the bioavailability of unmodified linear peptides in moths, clearly indicate that linear hydrophilic peptides can penetrate the cuticle by contact application in aqueous solutions and in organic solvents very efficiently, reach their target organ and activate it."( Bioavailability of insect neuropeptides: the PK/PBAN family as a case study.
Altstein, M; Ben-Aziz, O; Davidovitch, M; Hariton, A; Nachman, RJ, 2009
)
0.35
"Triazine-based antiprotozoal agents are known for their lipophylic characteristics and may therefore be expected to be well absorbed following oral administration."( Synthesis and detection of toltrazuril sulfone and its pharmacokinetics in horses following administration in dimethylsulfoxide.
Dirikolu, L; Granstrom, DE; Hughes, C; Karpiesiuk, W; Lehner, AF; Tobin, T, 2009
)
0.35
" In this article we compare the two main methods of dissolving FAs for work in vitro, (i) dissolution in dimethylsulfoxide (DMSO) and (ii) conjugation with bovine serum albumin (BSA), and describe the effects of the solvent on cytotoxicity (determination of viability) and bioavailability (as shown by the impact on the gene expression of TNF-alpha)."( Effect of solvent on cytotoxicity and bioavailability of fatty acids.
Hosek, J; Kollar, P; Zavalova, V, 2010
)
0.36
" The results indicated that the concentrations of 2ME2 had no influence on absorption rate constant (ka) of 2ME2 and the small intestinal absorption of 2ME2 was a first-order process with passive diffusion mechanism within the concentration tested."( An investigation on intestinal absorption of a new anticancer drug, 2-methoxyestradiol.
Cui, FD; Du, B; Guo, XH; Zhang, N; Zhang, ZZ, 2009
)
0.35
" Hence, our data support that the synthetic 4'-dimethylamino-7,8-dihydroxyflavone and its lead both are orally bioavailable TrkB agonists and possess potent antidepressant effects."( A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect.
Chan, CB; France, S; He, K; Huang, J; Jang, SW; Jia, Y; Liu, X; Luo, HR; Phun, LH; Pradoldej, S; Xiao, G; Ye, K, 2010
)
0.36
"Particle size reduction is a suitable method to enhance the bioavailability of poorly soluble drugs."( Process optimization of a novel production method for nanosuspensions using design of experiments (DoE).
Heinzerling, O; Möschwitzer, JP; Müller, RH; Salazar, J, 2011
)
0.37
"Nanosizing is a non-specific approach to improve the oral bioavailability of poorly soluble drugs."( Nanocrystals: comparison of the size reduction effectiveness of a novel combinative method with conventional top-down approaches.
Ghanem, A; Möschwitzer, JP; Müller, RH; Salazar, J, 2012
)
0.38
" Indeed, high protein concentrations are often required to achieve acceptable bioavailability and efficacy for many indications."( Polar solvents decrease the viscosity of high concentration IgG1 solutions through hydrophobic solvation and interaction: formulation and biocompatibility considerations.
Danilenko, DM; Gokarn, YR; Kamerzell, TJ; Li, M; McDowell, M; Pace, AL; Wang, YJ, 2013
)
0.39
" We conclude that C6-Cer complexed to CholPC increased the bioavailability of the short-chain ceramide for cells, and potentiated its effects in comparison to solvent-dissolved C6-Cer."( Complexation of c6-ceramide with cholesteryl phosphocholine - a potent solvent-free ceramide delivery formulation for cells in culture.
Långvik, O; Lönnfors, M; Pulli, I; Slotte, JP; Sukumaran, P; Törnquist, K, 2013
)
0.39
" Being highly insoluble, DSN bioavailability suffers from high inter-subject variation due to variable degrees of permeation."( Lyophilized phytosomal nanocarriers as platforms for enhanced diosmin delivery: optimization and ex vivo permeation.
Abdallah, OY; Elnaggar, YS; Freag, MS, 2013
)
0.39
" In vivo pharmacokinetics in rats showed an increase in bioavailability of micronised simvastatin (3."( Micronisation of simvastatin by the supercritical antisolvent technique: in vitro-in vivo evaluation.
Patel, JK; Sutariya, VB, 2015
)
0.42
" The project team was able to improve the bioavailability by reducing efflux through systematic modifications to the strength of the HBA by changing the electronic properties of neighboring groups, whilst maintaining sufficient acceptor strength for potency."( Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering.
Eisman, MS; Gu, C; Harrison, RA; Hu, H; Johannes, JW; Kazmirski, S; Lamb, ML; Lyne, PD; Mikule, K; Peng, B; Scott, DA; Su, N; Sylvester, MA; Wang, W; Ye, Q; Zheng, X, 2016
)
0.43
" In vivo pharmacokinetic study revealed noticeable enhancement of bioavailability and plasma circulation time of the drugs when encapsulated in the carrier system."( Folate receptor-targeted hybrid lipid-core nanocapsules for sequential delivery of doxorubicin and tanespimycin.
Choi, HG; Gautam, M; Gupta, B; Jeong, JH; Kim, JO; Lee, JS; Pathak, S; Poudel, BK; Regmi, S; Ruttala, HB; Yong, CS, 2017
)
0.46
" In mice, orally delivered liquid and lyophilized Mef-Lipo displayed comparable absorption with bioavailability (BA) of 81-86%, while the absorption of the standard Mef suspension was significantly lower with BA of 70% and 20% decreased maximal plasma concentration and area under the curve."( Development of a Rapidly Dissolvable Oral Pediatric Formulation for Mefloquine Using Liposomes.
Chen, WC; Diako, C; Li, SD; Ross, CF; Tang, WH; Tang, WL, 2017
)
0.46
" RO-2 as one of the potent and orally bioavailable compounds was evaluated in various models of autoimmune disorder."( Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.
Bala, M; Bhuniya, D; Gavhane, R; Iyer, JP; Jamdar, V; Joshi, S; Kandikere, V; Kulkarni, B; Lohote, M; Meru, A; Mookhtiar, KA; Mukhopadhyay, PP; Munot, YS; Nagaraj, R; Petla, R; Raje, AA; Reddy, S; Rouduri, S; Shaikh, NS; Sherkar, P; Umrani, D, 2019
)
0.51
"In mass casualty events involving radiation exposure, there is a substantial unmet need for identifying and developing an orally bioavailable agent that can be used to protect the hematopoietic stem cell pool and regenerate hematopoiesis after radiation injury."( Dimethyl sulfoxide, a potent oral radioprotective agent, confers radioprotection of hematopoietic stem and progenitor cells independent of apoptosis.
Cong, Y; Liu, X; Peng, R; Shan, Y; Tang, Y; Wang, L; Yu, Z; Zhang, W; Zuo, Z, 2020
)
2
"Among polymeric nanocarriers, nanogels are especially promising non-irritating delivery vehicles to increase dermal bioavailability of therapeutics."( Sulfoxide-functionalized nanogels inspired by the skin penetration properties of DMSO.
Guo, X; Hedtrich, S; Işık, D; Joshi, AA; Klinger, D; Klossek, A; Rancan, F; Rühl, E; Vogt, A, 2021
)
0.62
"To maximize the biological activity of branched-chain amino acids (BCAAs), it is necessary to find a new excipient agent to increase the bioavailability of BCAAs in protein mixtures."( Impact of soy lecithin, zinc oxide, and methylsulfonylmethane, as excipient ingredients, on the bioaccessibility and intestinal transport of branched-chain amino acids from animal and plant protein mixtures.
Lee, CY; Lee, DY; Oh, JH; Shim, SM; Shin, JN, 2021
)
0.62
" In this open-label, phase 1, single-dose, randomized, 2-treatment, 2-period crossover study in healthy volunteers, bioavailability of a single 2-mg tablet of trametinib containing 9% DMSO (test formulation), corresponding to the lowest DMSO content in the tablet after storage at 25°C for 36 months, was evaluated vs bioavailability of a 2-mg tablet containing 11% DMSO (reference formulation)."( Comparative Bioavailability of a Single Dose of Trametinib (TMT212) Containing 9% vs 11% Dimethyl Sulfoxide in Randomized Healthy Volunteers to Assess Long-Term Storage at Room Temperature.
Chiparus, O; Choudhury, S; Ilankumaran, P; Kim, C; Lau, M; Tan, EY; Ziltener, C, 2022
)
0.94
" At the same time, increased loading of DMY and sustained release of DMY were achieved, improving bioavailability of hydrophobic drug DMY."( Injectable redox albumin-based hydrogel with in-situ loaded dihydromyricetin.
Chen, X; Cheng, W; Deng, L; Xia, T; Yang, M; Zhu, W, 2022
)
0.72

Dosage Studied

The epidermal surfaces were dosed with [3H]T-2 dissolved in dimethyl sulfoxide (DMSO) The elevation in aneuploidy frequency induced by high doses of these compounds was reduced in a dose-response manner.

ExcerptRelevanceReference
" These results explain several previous, discordant reports on the presence or absence of an effect of A23187 on cellular secretory events, on differing dose-response relationships, and on cytotoxic versus noncytotoxic mechanisms of action."( Effect of solvent on the histamine-releasing, enzyme-releasing, and mitogenic properties of the calcium ionophore A23187.
Dorsey, NK; Findlay, SR; Lichtenstein, LM; Plaut, M; Thomas, LL, 1979
)
0.26
" It is concluded that gene dosage is effective in increasing the proportion of hemoglobin inducible hybrids, but hybrid morphology is the phenotype characteristic that correlates most closely with expression of hemoglobin inducibility."( Maintenance of hemoglobin inducibility in somatic cell hybrids of tetraploid (2S) mouse erythroleukemia cells with mouse or human fibroblasts.
Anderson, WF; Axelrod, DE; Gopalakrishnan, TV; Willing, M, 1978
)
0.26
" By this method the position of the ascending slope of the dose-response curve, at several different effector to target cell ratios, is compared between fresh and frozen-thawed cells."( Curve -shift analysis of cryopreserved killer T cell function.
Bradley, BA; Farrant, J; van Lambalgen, R, 1979
)
0.26
"5% rifampin according to two dosage schedules."( Corneal penetration of rifampin.
Feldman, MF; Moses, RA, 1977
)
0.26
" In the presence of DMSO, the addition of NGF resulted in a general shift of the dose-response curve."( The effects of dimethyl sulfoxide on neurite development in vitro.
Roisen, FJ, 1975
)
0.61
" When the percent ovulation response was transformed to probits and plotted against the logarithm of the LH-RH dose an approximately linear log dose-response was obtained; the same relationship also held true for ovulation induction following sc LH-RH administration."( Stimulation of LH release and ovulation in the rat by cutaneous application of luteinizing hormone-releasing hormone (LH-RH) in dimethyl sulfoxide (DMSO).
Dermody, WC; Humphrey, RR; Reel, JR; Vaitkus, JW, 1975
)
0.46
" Dogs were dosed for approximately 2 years and pigs for 1 year, although half the animals of both species were dosed for only 18 weeks."( The toxicity of dimethyl sulphoxide (DMSO) for the dog, pig, rat and rabbit.
Barnett, KC; Davies, RE; Jolly, DW; Leahy, JS; Mawdesley-Thomas, LE; Noel, PR; Shillam, KW; Squires, PF; Street, AE; Tucker, WC; Worden, AN, 1975
)
0.25
" In the second experiment, rats were dosed with riboflavin and divided into four groups: no further treatment; aflatoxin (LD50); irradiation (1-2 hr); or aflatoxin plus irradiation."( Some interactions of light, riboflavin, and aflatoxin B1 in vivo and in vitro.
Findley, M; Joseph-Bravo, PI; Newberne, PM, 1976
)
0.26
" Dose-response studies showed an optimal increase of cellular proliferation when cells were incubated with 5 mM lithium for 5 days (127 +/- 5% of DMSO only treated cells)."( Effects of lithium on dimethyl sulfoxide induced differentiation of HL-60 promyelocytic leukemia cells.
Becker, RW; Tyobeka, EM, 1992
)
0.6
" Me2SO alone gave a cooperative dose-response curve, with inhibition changing from almost zero below 10% Me2SO to 80% at 20% Me2SO with either substrate."( Genistein inhibits protein histidine kinase.
Huang, J; Kim, Y; Matthews, HR; Nasr, M, 1992
)
0.28
" The dose-response to f-Met-Leu-Phe in TNF-primed cells demonstrated the same half-maximal and maximal concentrations of f-Met-Leu-Phe as seen in untreated cells."( Priming of the HL-60 cell respiratory burst response by tumor necrosis factor-alpha.
Klein, JB; McLeish, KR; Sonnenfeld, G, 1991
)
0.28
" Thirdly, the Epo dose-response curve was left-shifted approximately 20-fold."( Potentiation of the erythropoietin response by dimethyl sulfoxide priming of erythroleukemia cells: evidence for interaction of two signaling pathways.
Chern, Y; Sytkowski, AJ; Yonekura, S, 1990
)
0.54
" The test relies on a gene dosage selection system in which hyperploidy is detected by the simultaneous increase in copy number of two alleles residing on the right arm of chromosome VIII: arg4-8 and cup1S (Rockmill and Fogel."( The detection of mitotic and meiotic chromosome gain in the yeast Saccharomyces cerevisiae: effects of methyl benzimidazol-2-yl carbamate, methyl methanesulfonate, ethyl methanesulfonate, dimethyl sulfoxide, propionitrile and cyclophosphamide monohydrate.
Fogel, S; Maloney, DH; Moser, SF; Piegorsch, WW; Resnick, MA; Whittaker, SG, 1990
)
0.47
"01) elevations in plasma corticosterone concentrations were seen 24 and 48 hr following dosing of SAD in NaHCO3 with concentrations reaching a peak just prior to the onset of shelf elevation and fusion."( Role of maternal plasma corticosterone elevation in the teratogenicity of secalonic acid D in mice.
Eldeib, MM; Reddy, CS, 1990
)
0.28
"Each of seven mares was given an intravenous (IV) injection of 40% dimethyl sulfoxide (DMSO) at a dosage of 1 g/kg, over 35 min, immediately followed by a single IV injection of a trimethoprim (TMP) and sulfamethoxazole (SMZ) combination (SMZ 83%, TMP 17%) at a combined dosage of 44 mg/kg (7."( Concentrations of trimethoprim and sulfamethoxazole in cerebrospinal fluid and serum in mares with and without a dimethyl sulfoxide pretreatment.
Brown, MP; Green, SL; Gronwall, RR; Mayhew, IG; Montieth, G, 1990
)
0.73
"Previous studies have shown that after dosing with tri-o-cresyl phosphate (TOCP), the testis contains more active intermediate (saligenin cyclic-o-tolyl phosphate; SCOTP) than do other organs or blood."( The interaction of Sertoli and Leydig cells in the testicular toxicity of tri-o-cresyl phosphate.
Burka, LT; Chapin, RE; Heindel, JJ; Phelps, JL; Somkuti, SG, 1990
)
0.28
" This enhancement is particularly striking at decreased effector:target ratios (as low as one effector per five targets) and is also demonstrated by a shift to lower concentrations of the phorbol diester dose-response curve."( Enhancement of phorbol diester-induced HL-60-mediated cytotoxicity by retinoic acid, dimethyl sulfoxide, and 5-azacytidine.
Hall, RE; Leftwich, JA, 1986
)
0.5
" The vehicle used in RA dosing was also shown to be a major factor in the incidence of RA-induced cleft palate."( Etiology of retinoic acid-induced cleft palate varies with the embryonic stage.
Abbott, BD; Birnbaum, LS; Harris, MW, 1989
)
0.28
" In addition, a dose-response curve was established for eight concentrations of benzo[alpha]pyrene."( The micronucleus test in Xenopus: a new and simple 'in vivo' technique for detection of mutagens in fresh water.
Jaylet, A; Kirsch-Volders, M; Paulussen, J; Van Hummelen, P; Zoll, C, 1989
)
0.28
" To resolve this discrepancy, we investigated the dose-response to phorbol esters of both baseline and potentiated granule cell responses elicited with perforant path stimulation."( Dose-dependent phorbol ester facilitation or blockade of hippocampal long-term potentiation: relation to membrane/cytosol distribution of protein kinase C activity.
Colley, PA; Routtenberg, A; Sheu, FS, 1989
)
0.28
" Five of six chemicals tested yielded statistically significant and generally linear dose-response curves."( Assay of mutagens in aqueous fecal extracts with a modified ames Salmonella test.
Andrews, AW; Riggs, CW; Shaw, R, 1985
)
0.27
" The dose-response curve for HL-60 differentiation was consistent with the published 50% inhibitory dose for inhibition of calmodulin-activated phosphodiesterase and with the calmodulin drug-binding potential of N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide and N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide and their less active congeners, N-(6-aminohexyl)-1-naphthalenesulfonamide and N-(4-aminobutyl)-2-naphthalenesulfonamide."( Induction of myeloid differentiation of HL-60 cells with naphthalene sulfonamide calmodulin antagonists.
Branch, ME; Niedel, J; Sedwick, WD; Veigl, ML, 1986
)
0.27
" Under optimal conditions, the yield of colonies resistant to the neomycin analog, G418, increased linearly at the rate of 10 clones/ng of input (native form I pSV2neo) DNA up to a plasmid concentration of 50 ng, whereupon the dose-response for colony recovery became semilogarithmic."( Factors influencing efficiency and reproducibility of polybrene-assisted gene transfer.
Aubin, RJ; Paterson, MC; Weinfeld, M, 1988
)
0.27
" Dose-response curves of phorbol-12,13-dibutyrate-induced muscle tension and -stimulated kinase activity and receptor binding indicate that these responses are mediated by the same system."( Schistosoma mansoni: evidence for protein kinase-C-like modulation of muscle activity.
Bennett, JL; Blair, KL; Pax, RA, 1988
)
0.27
" The initial dosage was 40 mg/kg/day, which was then increased progressively to 60 mg/kg/day."( Remarkable response of lipoid proteinosis to oral dimethyl sulphoxide.
Lin, CS; Wong, CK, 1988
)
0.27
" In the liver of the DL-buthionine-(S,R)-sulfoximine (BSO)-treated rats dosed with m-DCB, both of 2,4- and 3,5-DCPSO2Mes were present at significantly lower concentrations than in non-BSO-treated rats."( Contribution of methylsulfonyl metabolites of m-dichlorobenzene to the heme metabolic enzyme induction by the parent compound in rat liver.
Kato, Y; Kimura, R; Kogure, T; Sato, M, 1988
)
0.27
"98 Gy in the absence of DMSO is adequately described by the linear-quadratic dose-response function Y = alpha D + beta D2."( Modulation of radiation-induced chromosome aberrations by DMSO, an OH radical scavenger. 1: Dose-response studies in human lymphocytes exposed to 220 kV X-rays.
Colyer, SP; Frome, EL; Joiner, EE; Littlefield, LG; Sayer, AM, 1988
)
0.27
" The elevation in aneuploidy frequency induced by high doses of these compounds was reduced in a dose-response manner in the presence of increasing concentrations of dimethyl sulfoxide."( Aneuploidy induced by nocodazole or ethyl acetate is suppressed by dimethyl sulfoxide.
Goin, CJ; Mayer, VW, 1987
)
0.7
" A dose-response relationship was observed 12 days post-drug treatment in all monitored estrogen activities which showed CDS-E2 is more potent compared to equimolar E2."( A novel redox system for CNS-directed delivery of estradiol causes sustained LH suppression in castrate rats.
Bodor, N; Brewster, ME; Estes, KS; Simpkins, JW, 1987
)
0.27
" Model-dependent and model-independent pharmacokinetic parameters for theophylline were compared on the basis of the solvent used in the dosage form administered."( Effect of organic vehicles on the pharmacokinetics of aminophylline administered intravenously to goats.
Bevill, RF; Davis, LE; Koritz, GD; Langston, VC; Munsiff, IJ; Neff-Davis, CA; Sharma, GC, 1987
)
0.27
" While onset of growth arrest and differentiation occur together when the cells are exposed for 48 h to retinoic acid, the present results indicate that their occurrence can be uncoupled by this split dosage to inducers."( Precommitment states induced during HL-60 myeloid differentiation: possible similarities of retinoic acid- and DMSO-induced early events.
Brown, D; Fishbaugh, J; Yen, A, 1987
)
0.27
" We also studied the relationship between the clinical efficacy of different dosing frequencies and the amount of IDU in the stratum corneum."( Measurement of the stratum corneum drug reservoir to predict the therapeutic efficacy of topical iododeoxyuridine for herpes simplex virus infection.
McKeough, MB; Sheth, NV; Spruance, SL, 1987
)
0.27
"Tremor dose-response curves were determined for mice dosed with the ryegrass neurotoxin lolitrem B, and the tremor-genic mycotoxin aflatrem."( The potent tremorgenic neurotoxins lolitrem B and aflatrem: a comparison of the tremor response in mice.
Gallagher, RT; Hawkes, AD, 1986
)
0.27
" The epidermal surfaces were dosed with [3H]T-2 dissolved in dimethyl sulfoxide (DMSO)."( Evaluation of monkey skin as a model for in vitro percutaneous penetration and metabolism of [3H]T-2 toxin in human skin.
Hoerr, FJ; Joyave, J; Kemppainen, BW; Pace, JG; Riley, RT, 1986
)
0.51
" On a semilogarithmic plot, the dose-response curves for all these compounds were approximately parallel."( Mode of action of butylated hydroxyanisole (BHA) and other phenols in preventing loss of 11 beta-hydroxylase activity in cultured bovine adrenocortical cells.
Aldern, KA; Harris, SE; Hornsby, PJ, 1985
)
0.27
" Behavioral testing, 2 days to 4 mo post-treatment, indicated that DMSO and/or 50 mg/kg of BPAU retarded habituation of spontaneous exploratory activity, impaired acquisition of conditioned (auto-shaped) behavior, and changed the dose-response relationship ford-amphetamine-induced suppression of operant (fixed ratio 32) responding."( Long lasting behavioral effects of dimethyl sulfoxide and the "peripheral" toxicant p-bromophenylacetylurea.
Fossom, LH; Messing, RB; Sparber, SB, 1985
)
0.55
" Time course experiments and dose-response experiments indicated that an increase in the microsomal oxidation of alcohols could be observed 24 hr after a single treatment with 200 mg/kg body weight of either pyrazole or 4-methylpyrazole, and after 2 or 3 days of treatment with 50 mg/kg of either of these compounds."( Interaction of pyrazole and 4-methylpyrazole with hepatic microsomes: effect on cytochrome P-450 content, microsomal oxidation of alcohols, and binding spectra.
Cederbaum, AI; Feierman, DE,
)
0.13
" The dose-response of both substances reveal saturation curves."( Osmotica, dimethyl sulfoxide, parahydroxymercuribenzoate, and cyanide change the period of the circadian clock in the pulvini of Phaseolus coccineus L.
Flach, D; Maier, M; Mayer, WE, 1985
)
0.67
" The 3-methylcholanthrene-dependent increases in 2- and 3-hydroxylation appear due to induction of a single form of cytochrome P-450, as indicated by similar dose-response relationships and similar changes in sensitivity to the inhibitors."( Biphenyl metabolism by rat liver microsomes: regioselective effects of inducers, inhibitors, and solvents.
Haugen, DA,
)
0.13
" The time-dependent increase of TAA after administration of 100 mg/kg acetylsalicylic acid is demonstrated; the dosage finally delayed TAA to longer than 360 seconds."( Platelet aggregation induced in the hamster cheek pouch by a photochemical process with excited fluorescein isothiocyanate-dextran.
Herrmann, KS, 1983
)
0.27
"Several cohorts of cancerous mice were continuously dosed with 2,2'-bipyridyl dibutyltin dichloride, 1,10-phenanthroline dibutyltin and histidine dibutyltin; presented at 1 ppm and 10 ppm in drinking water."( Organotin implications in anticarcinogenesis. Effects of several organotins on tumour growth rate in mice.
Cardarelli, BM; Cardarelli, NF; Dobbins, E; Libby, EP, 1984
)
0.27
" Increasing the dosage of DNA or chromosomes resulted in an almost linear increase in the number of transformants."( Parameters governing the transfer of the genes for thymidine kinase and dihydrofolate reductase into mouse cells using metaphase chromosomes or DNA.
Lewis, WH; Siminovitch, L; Srinivasan, PR; Stokoe, N, 1980
)
0.26
" Unusual dose-response curves were obtained in that toxicity and genetic activity decreased at the higher concentrations examined."( The genetic activity of dinitropyrenes in yeast: unusual dose response curves for induced mitotic gene conversion.
Parry, JM; Wilcox, P, 1981
)
0.26
" APPA inhibits as well the maternal as by diaplacental passage the fetal hemostasis in dependence on the dosage till the incoagulability."( [Diaplacental inhibition of fetal blood coagulation in pregnant sheep (author's transl)].
Hofmann, KD; Jäger, K; Kukuk, G; Laube, R; Niedner, W; Weller, E, 1980
)
0.26
" Furthermore, the level of APP-695 decreased to 82% with low dosage of RA and 75% at high dosage of the total APP transcripts."( Altered levels and splicing of the amyloid precursor protein in the adult rat hippocampus after treatment with DMSO or retinoic acid.
Giordano, T; Monteggia, LM; Pan, JB, 1993
)
0.29
" The dose-response curves for SSBs due to glycerol radicals are predominantly "one-hit" over the entire glycerol concentration range where they were observable (> or = 75 mM)."( Role of scavenger-derived radicals in the induction of double-strand and single-strand breaks in irradiated DNA.
Ayene, IS; Koch, CJ; Krisch, RE, 1995
)
0.29
" The impressive antimalarial activity of Taxol, at a dosage that has been tolerated in humans, establishes its potential utility for treatment of severe, drug-resistant human malaria."( Taxol arrests the development of blood-stage Plasmodium falciparum in vitro and Plasmodium chabaudi adami in malaria-infected mice.
Farley, PJ; Long, CA; Pouvelle, B; Taraschi, TF, 1994
)
0.29
" Exposure times and dose-response relationships should be explored to optimize future clinical applications of this drug."( Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines.
Adler, LM; Herzog, TJ; Mutch, DG; Rader, JS; Williams, S, 1994
)
0.29
"05) higher CA-derived radioactivity was seen in maternal brain, carcass and heart as well as placenta and fetal heads and bodies 6 hr after dosing with CA in DMSO compared to CA in DW."( Alteration in the tissue retention of [14C]-caffeine in pregnant mice by dimethylsulfoxide.
Gross, SM; Reddy, CS; Reddy, RV, 1993
)
0.29
" Liver tumors (nodular hyperplasia) appeared only in FA-treated males but no dose-response relationship was evident."( Induction of lung and liver tumors by fluoranthene in a preweanling CD-1 mouse bioassay.
Busby, WF; Wang, JS, 1993
)
0.29
" This inexpensive and comparatively unsophisticated method afforded clear dose-response relationships and good discriminating power."( Measurement of skin-fold thickness in the guinea pig. Assessment of edema-inducing capacity of cutting fluids, acids, alkalis, formalin and dimethyl sulfoxide.
Wahlberg, JE, 1993
)
0.49
" Dose-response curves (DRCs) to the pigment-concentrating hormone PCH were determined under control and experimental conditions to evaluate the effects elicited by the cytoskeleton-affecting drugs."( Cytoskeleton and PCH-induced pigment aggregation in Macrobrachium potiuna erythrophores.
Castrucci, AM; Josefsson, L; Tuma, MC, 1995
)
0.29
" Neither heparin nor nedocromil sodium affected the dose-response curve or the maximum response to Ach."( Protective effect of heparin on immunologically induced tracheal smooth muscle contraction in vitro.
Abraham, MK; Abraham, WM; Ahmed, T, 1996
)
0.29
" Fifty percent effective doses (ED50) to block propagated compound action potentials (AP's) were obtained by examining dose-response relations for each solute."( An analysis of dimethylsulfoxide-induced action potential block: a comparative study of DMSO and other aliphatic water soluble solutes.
Gasser, K; Hahin, R; Larsen, J, 1996
)
0.29
" Using acetone or dimethylsulfoxide (DMSO) (80% in water) as a vehicle, percutaneous absorption and cutaneous disposition of parathion (PA) were studied following PA (40 microg/cm2) dosing on isolated perfused porcine skin as mechanistically defined chemical mixtures (MDCM) consisting of the surfactant sodium lauryl sulfate (SLS), the rubefacient methyl nicotinate (MNA), and the reducing agent stannous chloride (SnCl2)."( The use of mechanistically defined chemical mixtures (MDCM) to assess component effects on the percutaneous absorption and cutaneous disposition of topically exposed chemicals. I. Studies with parathion mixtures in isolated perfused porcine skin.
Baynes, RE; Brooks, JD; Monteiro-Riviere, NA; Qiao, GL; Riviere, JE; Williams, PL, 1996
)
0.29
" The extent of benzidine absorption in skin sections dosed with either B + A (0."( In vitro percutaneous absorption of benzidine in complex mechanistically defined chemical mixtures.
Baynes, RE; Brownie, C; Freeman, H; Riviere, JE, 1996
)
0.29
" A dose-response relationship of NAAC values was observed in the livers of M10 mice when treated with AFB1 at different doses ranging from 1 to 16 mg/kg body weight, whereas in nontransgenic mice, only slight but not statistically significant increases of NAAC values were observed."( In vivo activation of aflatoxin B1 in C57BL/6N mice carrying a human fetus-specific CYP3A7 gene.
Groopman, JD; Kamataki, T; Katsuki, M; Li, Y; Wang, JS; Yokoi, T, 1997
)
0.3
" H4IIE cells were dosed with three micrograms of UL-14C-PCB77/plate dissolved in DMSO or isooctane, and were harvested at sequential time periods for 4 days."( Carrier effects of dosing the H4IIE cells with 3,3',4,4'-tetrachlorobiphenyl (PCB77) in dimethyl sulfoxide or isooctane.
Burton, GA; Fisher, JW; Tillitt, DE; Yu, KO, 1997
)
0.52
"In this 8-hour in vitro flow-through diffusion study, porcine skin sections were dosed with 40 micrograms of CA/cm2 of surface area, different amounts of solvents (40 or 80% acetone or dimethyl sulfoxide [DMSO]), different amounts of a surfactant (0, 1, or 5% sodium lauryl sulfate [SLS]), an insect repellent (0 or 15% diethyl-m-toluamide [DEET]), an insecticide synergist (0 or 2% piperonyl butoxide [PB]), and a CA metabolite (40 micrograms/cm2 1-naphthol [1-NA])."( Influence of inert ingredients in pesticide formulations on dermal absorption of carbaryl.
Baynes, RE; Riviere, JE, 1998
)
0.49
" Irrespective of the solvent, increasing water content in pesticide dosing mixtures significantly increased CA absorption from SLS mixtures only."( Influence of inert ingredients in pesticide formulations on dermal absorption of carbaryl.
Baynes, RE; Riviere, JE, 1998
)
0.3
" CT-3 was devoid of GI ulceration when administered with DMSO either acutely at doses below 100 mg/kg or chronically at a dosage of 30 mg/kg/day for 5 days."( 1',1'-Dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties.
Dajani, EZ; Dajani, NE; Dayton, MT; Larsen, KR; Mir, GN; Neeleman, SD; Shahwan, TG; Taylor, J; Taylor, MS, 1999
)
0.3
"0 ml/kg DMSO at 24 hr after toxicant dosing and then killing the animals at 48 hr."( Hepatoprotection by dimethyl sulfoxide. II. Characterization of optimal dose and the latest time of administration for effective protection against chloroform and bromobenzene induced injury.
Gandolfi, AJ; Lind, RC, 1999
)
0.63
" Sixty minutes after dosing in rats, most of the labeled material was in the form of a (125)I-rhNGF/HMW complex."( Stability and interactions of recombinant human nerve growth factor in different biological matrices: in vitro and in vivo studies.
Escandón, E; Hotaling, TE; Mendoza-Ramirez, JL; Nguyen, CB; Sadick, MD; Szönyi, E, 2000
)
0.31
" Plasma ALT activities and quantitation of liver injury by light microscopy at 48 h after CHCl(3) dosing indicated that all three treatments were equally effective at protecting the liver."( Hepatoprotection by dimethyl sulfoxide. III. Role of inhibition of the bioactivation and covalent bonding of chloroform.
Begay, CK; Gandolfi, AJ; Lind, RC, 2000
)
0.63
" Isometric contraction studies demonstrated that both colchicine and nocodazole caused an upward shift in the phenylephrine (10(-8) to 10(-5) M) dose-response curve while taxol caused no significant change when compared to the control group."( Influence of microtubules on vascular smooth muscle contraction.
Jin, N; Rhoades, RA; Swartz, DR; Yancey, KW; Zhang, D, 2000
)
0.31
" We have studied the carcinogenic effects of heavy ions at the cellular and molecular levels and have obtained quantitative data on dose-response curves and on the repair of oncogenic lesions for heavy particles with various charges and energies."( DNA damage and repair in oncogenic transformation by heavy ion radiation.
Craise, LM; George, KA; Mei, M; Yang, TC, 1996
)
0.29
" In two separate experiments, genistein in a dimethyl sulfoxide/acetone (1:9) solution was applied to SKH-1 female mice 1 h post 8-methoxy-psoralen dosing and 1 h prior to UVA irradiation."( Effects of the isoflavone 4',5,7-trihydroxyisoflavone (genistein) on psoralen plus ultraviolet A radiation (PUVA)-induced photodamage.
Austin, LM; Lazinsky, A; Lebwohl, M; Lu, Y; Phelps, RG; Saladi, RN; Shyong, EQ; Wei, H, 2002
)
0.57
" This greater exposure to the mixture also reduced penetration in a dose-response manner and affected polyspermy."( An environmentally relevant organochlorine mixture impairs sperm function and embryo development in the porcine model.
Ayotte, P; Bailey, JL; Campagna, C; Guillemette, C; Paradis, R; Sirard, MA, 2002
)
0.31
" Dose-response analyses were performed with dinitrobenzene sulfonic acid (DNBS) and formaldehyde formulated either in water, 1% L92, dimethyl sulfoxide (DMSO) or dimethyl formamide (DMF)."( Examination of a vehicle for use with water soluble materials in the murine local lymph node assay.
Cruse, LW; Dearman, RJ; Gerberick, GF; Kimber, I; Ryan, CA; Skinner, RA, 2002
)
0.52
"This paper describes the development of a stable pharmaceutical dosage form for NAMI-A, a novel antimetastatic ruthenium complex, for Phase I testing."( Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.
Beijnen, JH; Bouma, M; Bult, A; Flaibani, A; Kettenes-van den Bosch, JJ; Nuijen, B; Perbellini, A; Sava, G; Talsma, H; van Steenbergen, MJ, 2002
)
0.31
" Interestingly, a bimodal H2O2 dose-response relationship in cell toxicity has been reported for Escherichia coli deficient in DNA repair as well as Chinese hamster ovary (CHO) cells."( Micromolar concentrations of hydrogen peroxide induce oxidative DNA lesions more efficiently than millimolar concentrations in mammalian cells.
Nakamura, J; Purvis, ER; Swenberg, JA, 2003
)
0.32
" Evidence of systemic toxicity was observed in animals dosed chronically with pyrimethamine or amiloride, but no skin papillomas were observed in mice treated with amiloride, dipyridamole, or pyrimethamine for 26 weeks."( Evaluation of the Tg.AC assay: specificity testing with three noncarcinogenic pharmaceuticals that induce selected stress gene promoters in vitro and the inhibitory effects of solvent components.
Lin, KK; Rosenzweig, BA; Sistare, FD; Thompson, KL; Weaver, JL; Zhang, J, 2003
)
0.32
" An increase in the dosage of phage particles, up to at least 5 x 10(7) phage particles per 100-mm dish, resulted in a linear increase in the number of transformants."( Phage particle-mediated gene transfer to cultured mammalian cells.
Hamada, Y; Hirose, S; Ishiura, M; Okada, Y; Suzuki, Y; Uchida, T, 1982
)
0.26
" Antimicrobial activity of propolis varied depending on propolis sample, dosage of propolis, and the extraction solvents for all test microorganisms."( An in vitro study on antimicrobial activity of propolis from Mugla province of Turkey.
Arslan, T; Ugur, A, 2004
)
0.32
" A dose-response was examined with each of these solvents."( The effects of organic solvents on poly(ADP-ribose) polymerase-1 activity: implications for neurotoxicity.
Banasik, M; Persad, AS; Stedeford, T; Strosznajder, RP; Tanaka, S; Ueda, K, 2004
)
0.32
" For the scheduled phase I clinical trials a stable, sterile, injectable pharmaceutical dosage form containing 100 mg Imexon was required."( Pharmaceutical development of a lyophilised dosage form for the investigational anticancer agent Imexon using dimethyl sulfoxide as solubilising and stabilising agent.
Beijnen, JH; den Brok, MW; Lutz, C; Nuijen, B; Opitz, HG, 2005
)
0.54
" All other differences from controls, including those which attained a level of statistical significance, were minor or not dosage related in degree, or were not consistent over time and are, therefore, considered to be of little toxicological importance."( The effects of solvents on embryonic stem cell differentiation.
Adler, S; Bremer, S; Hartung, T; Paparella, M; Pellizzer, C, 2006
)
0.33
" The method has been successfully applied to the determination of perindopril in commercial dosage forms."( Optimized and validated initial-rate method for the determination of perindopril erbumine in tablets.
Anwar, N; Kashif, M; Rahman, N, 2006
)
0.33
" Oral aspirin has a repertoire of gastrointestinal side effects even at low doses and requires high frequent dosing because it undergoes extensive presystemic metabolism."( Design of a transdermal delivery system for aspirin as an antithrombotic drug.
Ammar, HO; El-Nahhas, SA; Ghorab, M; Kamel, R, 2006
)
0.33
" Further, administration of DMSO could be delayed by up to 4 h after MK-801 dosing and still achieve between 80 and 86% reduction in neuronal loss."( Antioxidants attenuate MK-801-induced cortical neurotoxicity in the rat.
Ray, DE; Willis, CL, 2007
)
0.34
" The effect of t-butanol addition and ozone gas flow dosage on the degradation rate was evaluated."( Degradation of DMSO by ozone-based advanced oxidation processes.
Chen, SH; Muruganandham, M; Wu, JJ, 2007
)
0.34
" zymosan at a dosage of 100 mg/kg to induce the production of free radicals by stimulating NADPH oxidase in polymorphonuclear leukocytes."( The effect of zymosan and the protective effect of various antioxidants on fracture healing in rats.
Duygulu, F; Karahan, OI; Karaoglu, S; Kutlubay, R; Ozturk, A; Yakan, B, 2007
)
0.34
" We propose a new orally active heparin, Db-LHD, in a solid dosage form to effectively prevent DVT and PE."( A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study.
Byun, Y; Kim, CY; Kim, SK; Lee, DY; Moon, HT; Nam, JH, 2007
)
0.34
" Depending on dosage (0."( A dietary supplement for female sexual dysfunction, Avlimil, stimulates the growth of estrogen-dependent breast tumors (MCF-7) implanted in ovariectomized athymic nude mice.
Doerge, DR; Helferich, WG; Ju, YH, 2008
)
0.35
" A similar rightward shift in the morphine dose-response curve was caused by morphine tolerance."( Microinjection of the vehicle dimethyl sulfoxide (DMSO) into the periaqueductal gray modulates morphine antinociception.
Fossum, EN; Ingram, SL; Lisowski, MJ; Macey, TA; Morgan, MM, 2008
)
0.63
" Two of the four DMSO trials, and both MSM trials reported significant improvement in pain outcomes in the treatment group compared to comparator treatments, however, methodological issues and concerns over optimal dosage and treatment period, were highlighted."( Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis.
Bashir, N; Brien, S; Lewith, G; Lewith, H; Prescott, P, 2008
)
0.6
" Further studies are now required to identify both the optimum dosage and longer-term safety of MSM and DMSO, and definitive efficacy trials."( Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis.
Bashir, N; Brien, S; Lewith, G; Lewith, H; Prescott, P, 2008
)
0.6
"AE can provide protection for human fetal hepatocytes in cryopreservation, and the best performance concentration level of its is 60 mg/L; the preservation dosage of DMSO can be reduced when combined with AE in the preservation solution, which shows that AE has a synergistic effect with DMSO."( [The protective effect of Astragalus membranaceus extraction on cryopreserved primary-cultured human fetal hepatocytes].
Gao, Y; Lin, JM; Wang, Y; Zhang, ZY; Zhu, YQ, 2007
)
0.34
" The effects of stability, solubility and loss through the perfusion apparatus on actual dosing concentrations were investigated."( Test article concentrations in the hERG assay: losses through the perfusion, solubility and stability.
Brimecombe, JC; Brown, AM; Kirsch, GE,
)
0.13
" The formulation was optimized for skin permeation enhancers, pH of the system, and dosage strength using in vitro and in vivo techniques."( Ketorolac tromethamine transdermal gel: development, in vitro and in vivo evaluation.
Bommagani, M; Dubey, R; Karnati, HR; Menon, VC; Mullangi, R; Thammera, RK; Venkateswarlu, V, 2009
)
0.35
" A number of toxicity and mechanistic studies have been conducted in animals, where CPF has been administered via a variety of different exposure routes and dosing vehicles."( Comparative chlorpyrifos pharmacokinetics via multiple routes of exposure and vehicles of administration in the adult rat.
Barr, DB; Busby-Hjerpe, AL; Campbell, JA; Lee, S; Poet, TS; Smith, JN; Timchalk, C, 2009
)
0.35
" The successful validation and implementation challenges of this technology for direct dosing onto cells in cell-based screening is discussed."( Achieving accurate compound concentration in cell-based screening: validation of acoustic droplet ejection technology.
Grant, RJ; Hodgson, C; Jones, DC; Pointon, C; Roberts, K; Tang, E; Womersley, L, 2009
)
0.35
"More accurate dose-response curves can be constructed by eliminating aqueous serial dilution of compounds."( Gradient, contact-free volume transfers minimize compound loss in dose-response experiments.
Datwani, S; Ellson, R; Harris, D; Olechno, J, 2010
)
0.36
" In long-term treatments (>24 h), the cytotoxicity test for ASTA showed a sigmoidal dose-response curve (LC50 = 11."( Astaxanthin prevents in vitro auto-oxidative injury in human lymphocytes.
Barros, MP; Bolin, AP; Macedo, RC; Marin, DP; Otton, R, 2010
)
0.36
"Serial dilution of compounds solubilized in dimethylsulfoxide (DMSO) for dose-response curves is a common method for efficacy analysis of potential drug candidates."( An inline QC method for determining serial dilution performance of DMSO-based systems.
Walling, LA, 2011
)
0.37
"125 grams 3 times daily for 12 weeks and the other received a placebo in the same dosing frequency."( Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study.
Agar, G; Beer, Y; Debbi, EM; Debi, R; Elbaz, A; Fichman, G; Halperin, N; Kardosh, R; Ziv, YB, 2011
)
0.37
" The formalin test showed that III was effective in acute chemical pain (phase I, 0-5 min after injection), but was not effective for II at the same dosage compared to the PCP and control groups."( Synthesis and analgesic effects of new pyrrole derivatives of phencyclidine in mice.
Ahmadi, A; Hajikhani, R; Pakzad, S; Solati, J, 2011
)
0.37
" As inkjet printing is an inherently scalable technology, this proof of principal work with single deposited micro-spot formulations demonstrates the potential of this approach to print practical dosage forms (e."( Inkjet printing as a novel medicine formulation technique.
Alexander, MR; Gellert, PR; Roberts, CJ; Scoutaris, N, 2011
)
0.37
" The current studies evaluated the direct effects of 15 antiretroviral compounds on neurons to begin to provide basic neurotoxicity data that will serve as a foundation for the development of dosing and drug selection guidelines."( Antiretroviral neurotoxicity.
Liner, J; Meeker, RB; Robertson, K, 2012
)
0.38
" We studied the effect of oral dosing with corn oil, carboxymethyl cellulose, dimethyl sulfoxide, and polysorbate-80 on the progression of Mycobacterium tuberculosis infection in mice."( Influence of vehicles used for oral dosing of test molecules on the progression of Mycobacterium tuberculosis infection in mice.
Chaturvedi, V; Dwivedi, R; Singh, S, 2012
)
0.61
" The assay was validated by performing dose-response testing of rapamycin and cyclosporine A, which had previously been reported to inhibit IL-17, and determining, for the first time, their in vitro potencies (IC(50)s of 80 ± 23 pM and 223 ± 52 nM, respectively)."( Development of a high-throughput cell-based assay for identification of IL-17 inhibitors.
Carr, GJ; Dobritsa, SV; Kuok, IT; Morley, T; Nguyen, H; Spragg, AM; Webster, JC, 2013
)
0.39
" The aim of this study was to clarify differences in outcomes owing to different dosing regimens and the pharmacokinetic profile of progesterone, particularly in relation to brain levels."( Progesterone pharmacokinetics in the mouse: implications for potential stroke therapy.
Kendall, DA; Ray, D; Wong, R, 2012
)
0.38
"A new passive dosing method was developed to determine aqueous solubility of hydrophobic chemicals."( Measuring aqueous solubility in the presence of small cosolvent volume fractions by passive dosing.
Kwon, HC; Kwon, JH, 2012
)
0.38
"Low-volume protein dosage forms for subcutaneous injection pose unique challenges to the pharmaceutical scientist."( Polar solvents decrease the viscosity of high concentration IgG1 solutions through hydrophobic solvation and interaction: formulation and biocompatibility considerations.
Danilenko, DM; Gokarn, YR; Kamerzell, TJ; Li, M; McDowell, M; Pace, AL; Wang, YJ, 2013
)
0.39
" We developed a cisplatin dose-response curve using a transgenic line of zebrafish that expresses membrane-targeted green fluorescent protein under the control of the Brn3c promoter/enhancer."( Dimethyl sulfoxide (DMSO) exacerbates cisplatin-induced sensory hair cell death in zebrafish (Danio rerio).
Cotanche, DA; Gleichman, JS; Kramer, MD; Matsui, JI; Mueller, MA; Sibrian-Vazquez, M; Steyger, PS; Strongin, RM; Uribe, PM; Wang, Q, 2013
)
1.83
" Various reaction parameters such as reaction time, reaction temperature, solvent and catalyst dosage were investigated in detail."( Efficient conversion of cellulose into biofuel precursor 5-hydroxymethylfurfural in dimethyl sulfoxide-ionic liquid mixtures.
Fang, Z; Liu, B; Wang, Y; Xiao, S; Zhang, Z, 2014
)
0.63
" Here, we demonstrate that DMSO induces retinal apoptosis in vivo at low concentrations (5 μl intravitreally dosed DMSO in rat from a stock concentration of 1, 2, 4, and 8% v/v)."( Unexpected low-dose toxicity of the universal solvent DMSO.
Cordeiro, MF; Davis, B; Duchen, MR; Galvao, J; Normando, E; Tilley, M, 2014
)
0.4
" This limitation can probably be addressed by a dosage increase over the first 4 weeks and by extending treatment by 1 or 2 months."( Co-analgesic therapy for arthroscopic supraspinatus tendon repair pain using a dietary supplement containing Boswellia serrata and Curcuma longa: a prospective randomized placebo-controlled study.
Dellabiancia, F; Ingardia, A; Merolla, G; Paladini, P; Porcellini, G, 2015
)
0.42
" Vehicles were dosed orally once daily to HanWistar rats for a minimum of 28 days and a wide range of toxicological parameters were assessed."( Safety data on 19 vehicles for use in 1 month oral rodent pre-clinical studies: administration of hydroxypropyl-ß-cyclodextrin causes renal toxicity.
Burdett, L; Cotton, P; Finney, R; Garner, C; Hargreaves, A; Harris, J; Healing, G; Kirk, S; Pivette, P; Schramm, C; Sulemann, T, 2016
)
0.43
"Combination therapy, which reduces the dosage intensity of the individual drugs while increasing their efficacy, is not a novel approach for the treatment of cancer."( The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts.
Chang, SH; Cho, BW; Darvin, P; Hwang, TS; Joung, YH; Kang, DY; Kim, DN; Kim, HS; Kim, SY; Kim, WS; Lee, HK; Park, JH; Park, KD; S P, N; Yang, YM; Yoo, YB, 2015
)
0.42
" Dose-response assays with 1 from the HTS sample, as well as commercial material, yielded similar confirmatory results."( Oxidative Reactivities of 2-Furylquinolines: Ubiquitous Scaffolds in Common High-Throughput Screening Libraries.
Abate-Pella, D; Carpenter, MA; Harki, DA; Harris, RS; Li, M; Olson, ME; Perkins, AL; Rathore, A, 2015
)
0.42
" Additional studies are recommended that examine the anxiolytic and antidepressant effects of curcumin through alternate dosing regimens, modulation of other subunits on the GABAA receptor, and interactions with other central nervous system neurotransmitter systems."( Investigation of the Anxiolytic and Antidepressant Effects of Curcumin, a Compound From Turmeric (Curcuma longa), in the Adult Male Sprague-Dawley Rat.
Ceremuga, TE; Golder, J; Helmrick, K; Keller, B; Kelley, J; Kufahl, Z; Padrón, G; Philippe, F,
)
0.13
" The dosage form for Mef is mostly available as adult tablets, and thus children under the age of 5 suffer from poor medication adherence."( Development of a Rapidly Dissolvable Oral Pediatric Formulation for Mefloquine Using Liposomes.
Chen, WC; Diako, C; Li, SD; Ross, CF; Tang, WH; Tang, WL, 2017
)
0.46
" We found that dose-response curves for phenol were unaffected by DMSO concentrations up to 10% (v/v) and that DMSO (5% v/v) did not affect the degree of bacterial growth inhibition for any of the other test compounds in short-term experiments (3."( Evaluation of dimethyl sulfoxide (DMSO) as a co-solvent for toxicity testing of hydrophobic organic compounds.
Brandt, KK; Christensen, JH; Modrzyński, JJ, 2019
)
0.87
" The pharmacokinetics of the constituents of these supplements when dosed in combination with methylsulfonylmethane were compared to being administered alone."( Pharmacokinetic assessment of constituents of Boswellia serrata, pine bark extracts, curcumin in combination including methylsulfonylmethane in healthy volunteers.
Adiwidjaja, J; Eagles, SK; Eyles, J; Hunter, DJ; Liu, X; McLachlan, AJ; Wang, X, 2020
)
0.56
" The concentration in the residual DMSO solution was multiplied by the solution volume and divided by the dosage to calculate the recovery rate of DMSO."( Phase I study of KRP-116D, a 50% w/w dimethyl sulfoxide aqueous solution, on the systemic absorption from bladder by intravesical instillation in healthy Japanese subjects.
Hamamura, Y; Hojo, Y; Ootsuki, A; Shimada, H; Yono, M, 2020
)
0.83
" Furthermore, careful consideration should be given to different methods of storing diluted pharmaceutical drugs and use of DMSO controls due to the potential risk of evaporation and the subsequent effect on dose-response curves."( Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens.
Biermann, J; Engqvist, H; Forssell-Aronsson, E; Helou, K; Karlsson, P; Kovács, A; Larsson, P; Parris, TZ; Werner Rönnerman, E, 2020
)
0.56
" Passive dosing promises to have an advantage over traditional 'solvent spiking' exposure methods and involves the establishment and maintenance of known chemical concentrations in the in vitro medium, and therefore aqueous phase."( Comparison of passive-dosed and solvent spiked exposures of pro-carcinogen, benzo[a]pyrene, to human lymphoblastoid cell line, MCL-5.
Chapman, FM; Chapman, KE; Doak, SH; Hastie, C; Jenkins, GJS; Sanders, DJ; Scott, AD; Sparham, C; van Egmond, R, 2020
)
0.56
" Dose-response experiments across several cell lines showed a large range of sensitivity to DHT, prompting us to treat selected cell lines with 45 Environmental Protection Agency (EPA)-provided chemicals that include many endocrine-disrupting chemicals (EDCs); data from six of the compounds were then integrated with orthogonal assays."( Single-Cell Distribution Analysis of AR Levels by High-Throughput Microscopy in Cell Models: Application for Testing Endocrine-Disrupting Chemicals.
Johnson, HL; Mancini, MA; Mancini, MG; Mistry, RM; Singh, PK; Stossi, F; Szafran, AT, 2020
)
0.56
" Three days prior to and one day after a race, the daily dosage was doubled."( Optimized Curcumin, Pomegranate Extract, and Methylsulfonylmethane Reduce Acute, Systemic Inflammatory Response to a Half-marathon Race.
Davis, AA; Gary, MA; McFarlin, BK; Michalik, S; Tanner, EA, 2022
)
0.72
" Thus, in this study, we evaluated the dosage and temporal effects of RS-1 on porcine embryo development and viability."( Effects of RAD51-stimulatory compound 1 (RS-1) and its vehicle, DMSO, on pig embryo culture.
Chen, PR; Lucas, CG; Prather, RS; Redel, BK; Spate, LD; Wells, KD, 2021
)
0.62
" Intra-VTA infusion of SB334867 throughout the extinction phase could remarkably facilitate the extinction process and decrease the maintenance of reinforcing effects of METH at the highest dosage (10 nmol; p < 0."( The role of orexin-1 receptors within the ventral tegmental area in the extinction and reinstatement of methamphetamine place preference.
Amirteymori, H; Fattahi, M; Haghparast, A; Mousavi, Z; Zamanirad, F, 2023
)
0.91
" In order to sustain the targeted dosage over time, the use of a biocompatible local drug delivery system using low molecular mass gelators is preferred as a potential approach to reduce its side effects."( Facile one-pot multicomponent synthesis of peptoid based gelators as novel scaffolds for drug incorporation and pH-sensitive release.
Bhardwaj, P; Gupta, MK; Kumar, D; Maruthi, M; Sebastian, S; Yadav, E, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (8)

RoleDescription
alkylating agentHighly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases.
polar aprotic solventA solvent with a comparatively high relative permittivity (or dielectric constant), greater than ca. 15, and a sizable permanent dipole moment, that cannot donate suitably labile hydrogen atoms to form strong hydrogen bonds.
radical scavengerA role played by a substance that can react readily with, and thereby eliminate, radicals.
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
antidoteAny protective agent counteracting or neutralizing the action of poisons.
MRI contrast agentnull
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
sulfoxideAn organosulfur compound having the structure R2S=O or R2C=S=O (R =/= H).
volatile organic compoundAny organic compound having an initial boiling point less than or equal to 250 degreeC (482 degreeF) measured at a standard atmospheric pressure of 101.3 kPa.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (10)

PathwayProteinsCompounds
Dimethyl Sulfoxide Electron Transfer2210
dimethyl sulfoxide degradation06
dimethyl sulfone degradation06
superpathway of dimethylsulfone degradation219
dimethyl sulfide degradation III (oxidation)36
dimethyl sulfide degradation II (oxidation)814
hydrogen to dimethyl sulfoxide electron transfer1015
formate to dimethyl sulfoxide electron transfer914
NADH to dimethyl sulfoxide electron transfer168
respiration (anaerobic)-- electron acceptors reaction list021

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency68.58960.000714.592883.7951AID1259369; AID1259392
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency61.53610.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency19,952.59960.000817.505159.3239AID588544
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.01380.023723.228263.5986AID743223
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency61.13060.000627.21521,122.0200AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cereblon isoform 4Magnetospirillum gryphiswaldenseIC50 (µMol)20.80003.53006.31007.8000AID1685006
Cereblon isoform 4Magnetospirillum gryphiswaldenseKi5,570.23330.64203.94289.6000AID1685002; AID1685003; AID1685006
Choline O-acetyltransferase Rattus norvegicus (Norway rat)Ki25,000.00000.00020.00130.0030AID30246
Protein cereblonHomo sapiens (human)IC50 (µMol)264.00000.28601.70663.0000AID1685005
Protein cereblonHomo sapiens (human)Ki68,568.50001.49006.580010.0000AID1685001; AID1685005
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (36)

Processvia Protein(s)Taxonomy
regulation of cell growthInsulin-like growth factor-binding protein 5Homo sapiens (human)
osteoblast differentiationInsulin-like growth factor-binding protein 5Homo sapiens (human)
signal transductionInsulin-like growth factor-binding protein 5Homo sapiens (human)
female pregnancyInsulin-like growth factor-binding protein 5Homo sapiens (human)
negative regulation of smooth muscle cell migrationInsulin-like growth factor-binding protein 5Homo sapiens (human)
negative regulation of translationInsulin-like growth factor-binding protein 5Homo sapiens (human)
negative regulation of cell migrationInsulin-like growth factor-binding protein 5Homo sapiens (human)
hair follicle morphogenesisInsulin-like growth factor-binding protein 5Homo sapiens (human)
intracellular signal transductionInsulin-like growth factor-binding protein 5Homo sapiens (human)
glucose homeostasisInsulin-like growth factor-binding protein 5Homo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathwayInsulin-like growth factor-binding protein 5Homo sapiens (human)
negative regulation of insulin-like growth factor receptor signaling pathwayInsulin-like growth factor-binding protein 5Homo sapiens (human)
type B pancreatic cell proliferationInsulin-like growth factor-binding protein 5Homo sapiens (human)
negative regulation of osteoblast differentiationInsulin-like growth factor-binding protein 5Homo sapiens (human)
negative regulation of growthInsulin-like growth factor-binding protein 5Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayInsulin-like growth factor-binding protein 5Homo sapiens (human)
lung alveolus developmentInsulin-like growth factor-binding protein 5Homo sapiens (human)
negative regulation of smooth muscle cell proliferationInsulin-like growth factor-binding protein 5Homo sapiens (human)
striated muscle cell differentiationInsulin-like growth factor-binding protein 5Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionInsulin-like growth factor-binding protein 5Homo sapiens (human)
mammary gland involutionInsulin-like growth factor-binding protein 5Homo sapiens (human)
response to growth hormoneInsulin-like growth factor-binding protein 5Homo sapiens (human)
cellular response to cAMPInsulin-like growth factor-binding protein 5Homo sapiens (human)
cellular response to organic cyclic compoundInsulin-like growth factor-binding protein 5Homo sapiens (human)
negative regulation of muscle tissue developmentInsulin-like growth factor-binding protein 5Homo sapiens (human)
negative regulation of skeletal muscle hypertrophyInsulin-like growth factor-binding protein 5Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationInsulin-like growth factor-binding protein 5Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell migrationInsulin-like growth factor-binding protein 5Homo sapiens (human)
regulation of insulin-like growth factor receptor signaling pathwayInsulin-like growth factor-binding protein 5Homo sapiens (human)
protein ubiquitinationProtein cereblonHomo sapiens (human)
positive regulation of Wnt signaling pathwayProtein cereblonHomo sapiens (human)
negative regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
positive regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
negative regulation of monoatomic ion transmembrane transportProtein cereblonHomo sapiens (human)
locomotory exploration behaviorProtein cereblonHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
protein bindingInsulin-like growth factor-binding protein 5Homo sapiens (human)
insulin-like growth factor I bindingInsulin-like growth factor-binding protein 5Homo sapiens (human)
fibronectin bindingInsulin-like growth factor-binding protein 5Homo sapiens (human)
insulin-like growth factor II bindingInsulin-like growth factor-binding protein 5Homo sapiens (human)
protein bindingProtein cereblonHomo sapiens (human)
transmembrane transporter bindingProtein cereblonHomo sapiens (human)
metal ion bindingProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
extracellular regionInsulin-like growth factor-binding protein 5Homo sapiens (human)
endoplasmic reticulum lumenInsulin-like growth factor-binding protein 5Homo sapiens (human)
insulin-like growth factor binding protein complexInsulin-like growth factor-binding protein 5Homo sapiens (human)
insulin-like growth factor ternary complexInsulin-like growth factor-binding protein 5Homo sapiens (human)
extracellular spaceInsulin-like growth factor-binding protein 5Homo sapiens (human)
nucleusProtein cereblonHomo sapiens (human)
cytoplasmProtein cereblonHomo sapiens (human)
cytosolProtein cereblonHomo sapiens (human)
membraneProtein cereblonHomo sapiens (human)
perinuclear region of cytoplasmProtein cereblonHomo sapiens (human)
Cul4A-RING E3 ubiquitin ligase complexProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (123)

Assay IDTitleYearJournalArticle
AID1678775Antibacterial activity against Staphylococcus aureus ATCC 43300 by broth microdilution method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID252085Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 100 mg/mL after incubation for 98 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID565857Cell cycle arrest in human NCI-H460 cells assessed as accumulation at S phase at GI50 after 48 hrs by flow cytometry2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of tumor cell growth inhibition of methyl 3-amino-6-[(hetero)arylethynyl]thieno[3,2-b]pyridine-2-carboxylates. Structure-activity relationships, effects on the cell cycle and apoptosis.
AID82481Percent of viability for HL-60 cells was determined by dividing number of viable differentiated cells by total number of viable cells, at concentration of 64 mM1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Chemical differentiating agents. Differentiation of HL-60 cells by hexamethylenebis[acetamide] analogues.
AID203282Antibacterial activity against Staphylococcus aureus MTCC 1430 measured through zone of inhibition; Inactive2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Amidine derived 1,3-diazabuta-1,3-dienes as potential antibacterial and antifungal agents.
AID93235Dissociation constant in binding to Insulin-like growth factor binding protein 5 at the residue L812002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
In silico and NMR identification of inhibitors of the IGF-I and IGF-binding protein-5 interaction.
AID1678774Antibacterial activity against Enterococcus faecalis ATCC 51299 by broth microdilution method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID1309935Antiproliferative activity against human THP1 cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 09-01, Volume: 24, Issue:17
N,N-Bis(glycityl)amines as anti-cancer drugs.
AID82492Differentiation studies was conducted with the HL-60 human myeloid leukemia cell line and total cells were counted with a Coulter counter, at a concentration of 38 mM1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Chemical differentiating agents. Differentiation of HL-60 cells by hexamethylenebis[acetamide] analogues.
AID1657465Antibacterial activity against Bacillus subtilis 1064 by CLSI based susceptibility test method2020Journal of natural products, 04-24, Volume: 83, Issue:4
Proximicins F and G and Diproximicin A: Aminofurans from the Marine-Derived
AID135485Number of animals survived when the compound was tested at a dose of 30 mgkg/day in 5 Swiss mice1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
Synthesis and biological properties of 5-o-carboranyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil.
AID252072Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 1 mg/mL after incubation for 24 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID252073Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 1 mg/mL after incubation for 48 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID565858Cell cycle arrest in human NCI-H460 cells assessed as accumulation at G2/M phase at GI50 after 48 hrs by flow cytometry2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of tumor cell growth inhibition of methyl 3-amino-6-[(hetero)arylethynyl]thieno[3,2-b]pyridine-2-carboxylates. Structure-activity relationships, effects on the cell cycle and apoptosis.
AID174678Serum concentration of estradiol 24 days after intravenous administration in Orchidectomized rats1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Sustained brain-specific delivery of estradiol causes long-term suppression of luteinizing hormone secretion.
AID288696Growth inhibition of human MCF7 cells after 48 hrs2007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Alkylation potency and protein specificity of aromatic urea derivatives and bioisosteres as potential irreversible antagonists of the colchicine-binding site.
AID93239Dissociation constant in binding to Insulin-like growth factor binding protein 5 at the residue Y862002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
In silico and NMR identification of inhibitors of the IGF-I and IGF-binding protein-5 interaction.
AID252075Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 1 mg/mL after incubation for 98 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID70559Percent benzidine-positive cell differentiation in friend erythroleukemia cells1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Purine and 8-substituted purine arabinofuranosyl and ribofuranosyl nucleoside derivatives as potential inducers of the differentiation of the Friend erythroleukemia.
AID1552497Immunosuppressive activity in MOG (35 to 55 residues)/pertussis toxin-induced experimental allergic encephalomyelitis C57BL/6J mouse model assessed as reduction in disease severity score at 15 mg/kg, po bid measured at day 23 relative to dexamethasone2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.
AID252080Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 10 mg/mL after incubation for 98 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID1723071Growth inhibition of MDCK2 cells after 72 hrs by MTT assay
AID1657463Antibacterial activity against Staphylococcus aureus ATCC 29213 by CLSI based susceptibility test method2020Journal of natural products, 04-24, Volume: 83, Issue:4
Proximicins F and G and Diproximicin A: Aminofurans from the Marine-Derived
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID82488Differentiation studies was conducted with the HL-60 human myeloid leukemia cell line and Total cells were counted with a Coulter counter, at a concentration of 64 mM1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Chemical differentiating agents. Differentiation of HL-60 cells by hexamethylenebis[acetamide] analogues.
AID1374901Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 100 uM by FluoZin-3 based fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID139293Percentage of weight gained or lost in 4th week in normal swiss mice at a dose of 30 mg/kg/day1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
Synthesis and biological properties of 5-o-carboranyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil.
AID40332Antibacterial activity against Bacillus cereus MTCC 1272 measured through zone of inhibition; Inactive2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Amidine derived 1,3-diazabuta-1,3-dienes as potential antibacterial and antifungal agents.
AID71661Cell growth of friend erythroleukemia cells measured as percentage of control on day 6 at a concentration of 105 mM1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Cyclic urea and thiourea derivatives as inducers of murine erythroleukemia differentiation.
AID565859Induction of apoptosis in human NCI-H460 cells at GI50 after 48 hrs by V-FITC/propidium iodide staining-based flow cytometry2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of tumor cell growth inhibition of methyl 3-amino-6-[(hetero)arylethynyl]thieno[3,2-b]pyridine-2-carboxylates. Structure-activity relationships, effects on the cell cycle and apoptosis.
AID252084Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 100 mg/mL after incubation for 72 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID71652The degree of erythroid maturation was measured by assessing the proportion of benzidine-positive cells at a concentration of 210 mM1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Cyclic urea and thiourea derivatives as inducers of murine erythroleukemia differentiation.
AID139291Percentage of weight gained or lost in 2nd week in normal swiss mice at a dose of 30 mg/kg/day1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
Synthesis and biological properties of 5-o-carboranyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil.
AID251652Zone of inhibition of Escherichia coli after treatment with the compound2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Synthesis and antibacterial activities of 5-hydroxy-4-amino-2(5H)-furanones.
AID1657464Antibacterial activity against methicillin-resistant Staphylococcus aureus shhsA1 by CLSI based susceptibility test method2020Journal of natural products, 04-24, Volume: 83, Issue:4
Proximicins F and G and Diproximicin A: Aminofurans from the Marine-Derived
AID1136156Induction of erythroid differentiation in DBA/2J mouse Friend erythroleukemia cells assessed as hemoglobin level per 10'7 cells after 3 to 6 days relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Pyridine derivatives as potent inducers of erythroid differentiation in Friend leukemia cells.
AID251680Zone of inhibition of Pseudomonas aeruginosa after treatment with the compound2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Synthesis and antibacterial activities of 5-hydroxy-4-amino-2(5H)-furanones.
AID139292Percentage of weight gained or lost in 3rd week in normal swiss mice at a dose of 30 mg/kg/day1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
Synthesis and biological properties of 5-o-carboranyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil.
AID1678773Antibacterial activity against Escherichia coli ATCC 25922 by broth microdilution method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID1678771Antibacterial activity against Pseudomonas aeruginosa ATCC 27893 by broth microdilution method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID1374297Inhibition of chymotrypsin-like activity of human 20S proteasome at 100 nM using Suc-Leu-Leu-Val-Tyr-AMC as substrate by fluorescence assay relative to control2018Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5
Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.
AID1136155Induction of erythroid differentiation in DBA/2J mouse Friend erythroleukemia cells assessed as benzidine positive cells after 6 days relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Pyridine derivatives as potent inducers of erythroid differentiation in Friend leukemia cells.
AID93236Dissociation constant in binding to Insulin-like growth factor binding protein 5 at the residue R872002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
In silico and NMR identification of inhibitors of the IGF-I and IGF-binding protein-5 interaction.
AID82482Percent of viability for HL-60 cells was determined by dividing number of viable differentiated cells by total number of viable cells, at concentration of 77 mM1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Chemical differentiating agents. Differentiation of HL-60 cells by hexamethylenebis[acetamide] analogues.
AID71667Effect on the replication and erythroid differentiation of friend leukemia cells on day 6 at a concentration of 210 mM1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Cyclic urea and thiourea derivatives as inducers of murine erythroleukemia differentiation.
AID1685006Binding affinity to Magnetospirillum gryphiswaldense cereblon isoform 4 by measuring baseline corrected normalized fluorescence by MST based assay2021ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
AID70300Antibacterial activity against Escherichia coli MTCC 42 measured through zone of inhibition; Inactive2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Amidine derived 1,3-diazabuta-1,3-dienes as potential antibacterial and antifungal agents.
AID93234Dissociation constant in binding to Insulin-like growth factor binding protein 5 at the residue L732002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
In silico and NMR identification of inhibitors of the IGF-I and IGF-binding protein-5 interaction.
AID252083Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 100 mg/mL after incubation for 48 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID1678772Antibacterial activity against Acinetobacter baumannii ATCC 19606 by broth microdilution method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID251676Zone of inhibition of Staphylococcus aureus after treatment with the compound2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Synthesis and antibacterial activities of 5-hydroxy-4-amino-2(5H)-furanones.
AID1306202Antibacterial activity against Escherichia coli ATCC 25922 after 18 hrs by microbroth dilution assay2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
The influence of halogen substituents on the biological properties of sulfur-containing flavonoids.
AID30246Compound was evaluated for reversible inhibition of hydrolysis acetylcholine by acetylcholinesterase and represented as KI(com)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Effects of charge, volume, and surface on binding of inhibitor and substrate moieties to acetylcholinesterase.
AID174673Serum concentration of LH 12 days after intravenous administration in Orchidectomized rats1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Sustained brain-specific delivery of estradiol causes long-term suppression of luteinizing hormone secretion.
AID146720Effect on cell cycle (G0/G1 phase) progression by flow cytometry against NUGC3 human cancer cells after 24 hours2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents.
AID71654The degree of erythroid maturation was measured by assessing the proportion of benzidine-positive cells at a concentration of 4 mM1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Cyclic urea and thiourea derivatives as inducers of murine erythroleukemia differentiation.
AID71666Effect on the replication and erythroid differentiation of friend leukemia cells on day 3 at a concentration of 210 mM1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Cyclic urea and thiourea derivatives as inducers of murine erythroleukemia differentiation.
AID252077Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 10 mg/mL after incubation for 24 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID252078Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 10 mg/mL after incubation for 48 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID1309933Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 09-01, Volume: 24, Issue:17
N,N-Bis(glycityl)amines as anti-cancer drugs.
AID1306201Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by microbroth dilution assay2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
The influence of halogen substituents on the biological properties of sulfur-containing flavonoids.
AID1309937Antiproliferative activity against human SVGp12 cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 09-01, Volume: 24, Issue:17
N,N-Bis(glycityl)amines as anti-cancer drugs.
AID146722Effect on cell cycle (S-phase) progression by flow cytometry against NUGC3 human cancer cells after 24 hours2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID82143Percent of differentiated HL-60 cells was determined by dividing number of viable differentiated cells by total number of viable cells, at a concentration of 38 mM1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Chemical differentiating agents. Differentiation of HL-60 cells by hexamethylenebis[acetamide] analogues.
AID1321514Dissociation constant, pKa of the compound2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering.
AID82145Percent of differentiated HL-60 cells was determined by dividing number of viable differentiated cells by total number of viable cells, at a concentration of 64 mM1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Chemical differentiating agents. Differentiation of HL-60 cells by hexamethylenebis[acetamide] analogues.
AID1685005Binding affinity to human CRBN-thalidomide binding domain expressed in Escherichia coli by measuring baseline corrected normalized fluorescence by MST based assay2021ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
AID1374902Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 100 uM by FluoZin-3 based fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1320763Toxicity in last instar larval stage of Galleria mellonella assessed as decrease in survival at 0.33% after 96 hrs2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Synthesis of novel tetrazole derivatives and evaluation of their antifungal activity.
AID40616Effect on Bacillus subtilis in plate diffusion test; No growth inhibition2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
Solid-phase synthesis of new saphenamycin analogues with antimicrobial activity.
AID252079Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 10 mg/mL after incubation for 72 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID81817Differentiating activity of compound in HL60 cells at conc 5.6 ug/mL1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Retinoic acid conjugates as potential antitumor agents: synthesis and biological activity of conjugates with Ara-A, Ara-C, 3(2H)-furanone, and aniline mustard moieties.
AID71669Percent of untreated control cell growth evaluated in friend leukemia cells on day 3 at a concentration of 105 mM1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
Cyclic urea and thiourea derivatives as inducers of murine erythroleukemia differentiation.
AID1309939Selectivity index, ratio of IC50 for human SVGp12 cells to IC50 for human LN18 cells2016Bioorganic & medicinal chemistry, 09-01, Volume: 24, Issue:17
N,N-Bis(glycityl)amines as anti-cancer drugs.
AID288695Growth inhibition of human M21 cells after 48 hrs2007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Alkylation potency and protein specificity of aromatic urea derivatives and bioisosteres as potential irreversible antagonists of the colchicine-binding site.
AID1678770Antibacterial activity against Klebsiella pneumoniae ATCC 700603 by broth microdilution method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID40793Minimum inhibitory concentration against Bacillus subtilis; n.d.=not determined2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
Solid-phase synthesis of new saphenamycin analogues with antimicrobial activity.
AID93237Dissociation constant in binding to Insulin-like growth factor binding protein 5 at the residue S852002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
In silico and NMR identification of inhibitors of the IGF-I and IGF-binding protein-5 interaction.
AID1685003Competitive binding affinity to Magnetospirillum gryphiswaldense cereblon isoform 4 by measuring baseline corrected normalized fluorescence by MST based assay2021ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
AID174675Serum concentration of LH 24 days after intravenous administration in Orchidectomized rats1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Sustained brain-specific delivery of estradiol causes long-term suppression of luteinizing hormone secretion.
AID1309934Antiproliferative activity against human LN18 cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 09-01, Volume: 24, Issue:17
N,N-Bis(glycityl)amines as anti-cancer drugs.
AID40954Antibacterial activity against Bacillus subtilis MTCC 121 measured through zone of inhibition; Inactive2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Amidine derived 1,3-diazabuta-1,3-dienes as potential antibacterial and antifungal agents.
AID174674Serum concentration of LH 18 days after intravenous administration in Orchidectomized rats1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Sustained brain-specific delivery of estradiol causes long-term suppression of luteinizing hormone secretion.
AID252074Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 1 mg/mL after incubation for 72 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID148819Inhibition against Opioid receptor kappa 1 using selective ligand [3H]U-695931998Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26
Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine.
AID1685001Competitive binding affinity to human CRBN-thalidomide binding domain expressed in Escherichia coli by FRET assay2021ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
AID605243Agonist activity at TrkB in E17 rat primary cortical neurons assessed as AKT phosphorylation at Ser 473 at 500 nM after 15 mins by ELISA2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect.
AID174676Serum concentration of estradiol 12 days after intravenous administration in Orchidectomized rats1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Sustained brain-specific delivery of estradiol causes long-term suppression of luteinizing hormone secretion.
AID70686Optimum concentration for differentiation of friend erythroleukemia cells1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Purine and 8-substituted purine arabinofuranosyl and ribofuranosyl nucleoside derivatives as potential inducers of the differentiation of the Friend erythroleukemia.
AID1136153Induction of erythroid differentiation in DBA/2J mouse Friend erythroleukemia cells assessed as concentration required for maximum proportion of benzidine positive cells after 6 days1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Pyridine derivatives as potent inducers of erythroid differentiation in Friend leukemia cells.
AID1723070Growth inhibition of MDCK2 cells over expressing human ABCG2 after 72 hrs by MTT assay
AID93238Dissociation constant in binding to Insulin-like growth factor binding protein 5 at the residue Y502002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
In silico and NMR identification of inhibitors of the IGF-I and IGF-binding protein-5 interaction.
AID1657466Antibacterial activity against Micrococcus luteus SCSIO ML01 by CLSI based susceptibility test method2020Journal of natural products, 04-24, Volume: 83, Issue:4
Proximicins F and G and Diproximicin A: Aminofurans from the Marine-Derived
AID93219Dissociation constant in BS binding to Insulin-like growth factor binding protein 5 at the residue K912002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
In silico and NMR identification of inhibitors of the IGF-I and IGF-binding protein-5 interaction.
AID1685002Binding affinity to Magnetospirillum gryphiswaldense cereblon isoform by FRET assay2021ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
AID82489Differentiation studies was conducted with the HL-60 human myeloid leukemia cell line and Total cells were counted with a Coulter counter, at a concentration of 77 mM1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Chemical differentiating agents. Differentiation of HL-60 cells by hexamethylenebis[acetamide] analogues.
AID625294Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID71651Inhibitory activity against cellular differentiation in Friend erythroleukemia cells as optimal concentration required for maximum activity.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
8-Substituted guanosine and 2'-deoxyguanosine derivatives as potential inducers of the differentiation of Friend erythroleukemia cells.
AID1309936Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 09-01, Volume: 24, Issue:17
N,N-Bis(glycityl)amines as anti-cancer drugs.
AID174677Serum concentration of estradiol 18 days after intravenous administration in Orchidectomized rats1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Sustained brain-specific delivery of estradiol causes long-term suppression of luteinizing hormone secretion.
AID146721Effect on cell cycle (G2/M phase) progression by flow cytometry against NUGC3 human cancer cells after 24 hours2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents.
AID139290Percentage of weight gained or lost in 1 week in normal swiss mice at a dose of 30 mg/kg/day1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
Synthesis and biological properties of 5-o-carboranyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil.
AID46907Antifungal activity against Candida albicans MTCC 183 measured through zone of inhibition; Inactive2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Amidine derived 1,3-diazabuta-1,3-dienes as potential antibacterial and antifungal agents.
AID1136154Induction of erythroid differentiation in DBA/2J mouse Friend erythroleukemia cells assessed as cell growth after 3 days relative to control1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Pyridine derivatives as potent inducers of erythroid differentiation in Friend leukemia cells.
AID288694Growth inhibition of human HT29 cells after 48 hrs2007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Alkylation potency and protein specificity of aromatic urea derivatives and bioisosteres as potential irreversible antagonists of the colchicine-binding site.
AID565856Cell cycle arrest in human NCI-H460 cells assessed as accumulation at G0/G1 phase at GI50 after 48 hrs by flow cytometry2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of tumor cell growth inhibition of methyl 3-amino-6-[(hetero)arylethynyl]thieno[3,2-b]pyridine-2-carboxylates. Structure-activity relationships, effects on the cell cycle and apoptosis.
AID82479Percent of viability for HL-60 cells was determined by dividing number of viable differentiated cells by total number of viable cells, at concentration of 38 mM1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Chemical differentiating agents. Differentiation of HL-60 cells by hexamethylenebis[acetamide] analogues.
AID252082Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 100 mg/mL after incubation for 24 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID71649Inhibitory activity against cellular differentiation in Friend erythroleukemia cells as percentage of benzidine - positive cells.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
8-Substituted guanosine and 2'-deoxyguanosine derivatives as potential inducers of the differentiation of Friend erythroleukemia cells.
AID82146Percent of differentiated HL-60 cells was determined by dividing number of viable differentiated cells by total number of viable cells, at a concentration of 77 mM1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Chemical differentiating agents. Differentiation of HL-60 cells by hexamethylenebis[acetamide] analogues.
AID163761Antibacterial activity against Pseudomonas aeruginosa MTCC 1034. measured through zone of inhibition; Inactive2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Amidine derived 1,3-diazabuta-1,3-dienes as potential antibacterial and antifungal agents.
AID37570Antifungal activity against Aspergillus niger MTCC 404 measured through zone of inhibition; Inactive2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Amidine derived 1,3-diazabuta-1,3-dienes as potential antibacterial and antifungal agents.
AID81812Differentiating activity of compound in HL60 cells at conc 1.4 ug/mL1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Retinoic acid conjugates as potential antitumor agents: synthesis and biological activity of conjugates with Ara-A, Ara-C, 3(2H)-furanone, and aniline mustard moieties.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1309938Selectivity index, ratio of IC50 for HEK293 cells to IC50 for human HL60 cells2016Bioorganic & medicinal chemistry, 09-01, Volume: 24, Issue:17
N,N-Bis(glycityl)amines as anti-cancer drugs.
AID69151Compound was tested for its ability to inhibit DNA strand scission induced by resveratrol and Cu2+, at concentration 50 mM1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Resveratrol as a new type of DNA-cleaving agent.
AID81815Differentiating activity of compound in HL60 cells at conc 2.8 ug/mL1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Retinoic acid conjugates as potential antitumor agents: synthesis and biological activity of conjugates with Ara-A, Ara-C, 3(2H)-furanone, and aniline mustard moieties.
AID552438Cytotoxicity against mouse HII4E cells after 48 hrs by MTT assay2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Synthesis of sugars embodying conjugated carbonyl systems and related triazole derivatives from carboxymethyl glycoside lactones. Evaluation of their antimicrobial activity and toxicity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347054Inhibition of BCRP-mediated mitoxantrone efflux in human myeloid leukemia PLB985 cells measured by flow cytometry2017SLAS discovery : advancing life sciences R & D, 01, Volume: 22, Issue:1
Virtual Screening of DrugBank Reveals Two Drugs as New BCRP Inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14,829)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905858 (39.50)18.7374
1990's2553 (17.22)18.2507
2000's2713 (18.30)29.6817
2010's2785 (18.78)24.3611
2020's920 (6.20)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.57 (24.57)
Research Supply Index9.68 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index139.39 (26.88)
Search Engine Supply Index3.15 (0.95)

This Compound (49.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials292 (1.85%)5.53%
Reviews428 (2.72%)6.00%
Case Studies472 (2.99%)4.05%
Observational5 (0.03%)0.25%
Other14,566 (92.41%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (33)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination With Dual BRAF/MEK Inhibition in Patients With BRAF- Mutated Metastatic Melanoma Who Progressed on Prior BRAF/MEK Inhibitor Therapy [NCT04557956]Phase 1/Phase 258 participants (Anticipated)Interventional2021-08-19Recruiting
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma [NCT02196181]Phase 2280 participants (Anticipated)Interventional2014-09-19Active, not recruiting
Bladder Capacity as an Objective Measure of Response to Intravesical Treatment of Newly Diagnosed Interstitial Cystitis: a Prospective, Randomized Trial [NCT05223244]Phase 483 participants (Actual)Interventional2011-10-01Completed
MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E or V600K Mutations (Excluding Melanoma, Thyroid Cancer, Colorectal Adenocarcinoma, and Non-Small Cell Lung Cancer) [NCT04439292]Phase 235 participants (Anticipated)Interventional2015-08-12Active, not recruiting
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial [NCT02224781]Phase 3300 participants (Anticipated)Interventional2015-09-08Active, not recruiting
MATCH Treatment Subprotocol S2: Phase II Study of Trametinib in Patients With Tumors With GNAQ or GNA11 Mutations [NCT04439357]Phase 24 participants (Actual)Interventional2016-02-25Active, not recruiting
A Phase 1, Dose Escalating, Single Centre, Double Blind Study of the Safety and Immunogenicity of Opal-HIV-Gag Clade C in HIV Positive Subjects [NCT01123915]Phase 122 participants (Actual)Interventional2010-05-31Terminated
MELADERM-trial: Melatonin Cream Against Acute Radiation Dermatitis in Patients With Early Breast Cancer: a Pivotal Phase 2, Double-blind, Randomized, Placebo-controlled Trial [NCT03716583]Phase 248 participants (Actual)Interventional2019-04-30Completed
Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study [NCT03814343]Phase 419 participants (Actual)Interventional2019-01-15Completed
A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600 Mutation Positive Lesions in Erdheim Chester Disease [NCT03794297]Phase 20 participants (Actual)Interventional2019-01-04Withdrawn(stopped due to Inadequate accrual rate)
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer [NCT02101788]Phase 2/Phase 3260 participants (Actual)Interventional2014-02-27Active, not recruiting
[NCT02206477]Phase 2/Phase 3110 participants (Anticipated)Interventional2014-08-31Not yet recruiting
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG) [NCT03919071]Phase 258 participants (Anticipated)Interventional2020-02-20Recruiting
Comparison Between Hyperbaric Oxygen Therapy (HBOT) and Intravesical Dimethyl Sulfoxide (DMSO) Instillation for the Treatment of Interstitial Cystitis - a Prospective, Randomized Cross-over Trial [NCT01069263]60 participants (Anticipated)Interventional2010-02-28Recruiting
Efficacy of DMSO Cocktail Treatment in Interstitial Cystitis Patients During and After Treatment [NCT01074567]50 participants (Anticipated)Interventional2009-12-31Recruiting
Experimental Protocol for the Infusion of Platelets,Cryopreserved With Dimethyl Sulphoxide (DMSO) and Obtained From Multiple Donors Buffy Coats, in Patients With Severe Thrombocytopenia [NCT02032134]Phase 45 participants (Actual)Interventional2015-07-31Terminated(stopped due to recruitment failure within the interval of available CRY BC-PLTs for the study)
Evaluation of the Efficacy of Botulinum-A Toxin/DMSO Instillation in the Treatment of Women With Over Active Bladder (OAB) Syndrome and/or Urinary Urge Incontinence [NCT00667095]Phase 325 participants (Actual)Interventional2008-04-30Terminated(stopped due to Study terminated early due to PI's extended medical leave.)
MATCH Treatment Subprotocol S1: Phase II Study of Trametinib in Patients With Tumors With NF1 Mutations [NCT04439318]Phase 250 participants (Actual)Interventional2016-02-25Active, not recruiting
Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults [NCT04201457]Phase 1/Phase 275 participants (Anticipated)Interventional2020-01-17Recruiting
Botulin-A Toxin/Dimethyl Sulfoxide Bladder Instillations for Treatment of Voiding Dysfunction Secondary to Detrusor Hyperreflexia and Detrusor Instability in Women [NCT00583219]Phase 1/Phase 225 participants (Actual)Interventional2006-03-31Completed
Double-blind Randomized Clinical Study on Topical Diclofenac Efficacy in Symptomatic Relief of Temporomandibular Degenerative Joint Disease in Women. [NCT00471393]28 participants (Actual)Interventional2006-05-31Completed
Evaluation of Different Adjuvants for the Transdermal Administration of a Peptide-Based Vaccine in Participants With High-Risk Melanoma [NCT00118313]Phase 10 participants Interventional2004-11-04Completed
Evaluation of Clinical Efficacy of Locally Injected Vitamin D3 (Calcitriol or 1,25 Dihidroxicolecalciferol) in Accelerating Orthodontic Tooth Movement (A Randomized Controlled Trial) [NCT05560919]Phase 2/Phase 318 participants (Actual)Interventional2021-09-20Completed
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer [NCT01902173]Phase 1/Phase 227 participants (Actual)Interventional2013-07-19Active, not recruiting
A Randomized Controlled Trial to Evaluate the Efficacy and Tolerability of Intravesical Cocktail and Comparison With Intravesical Dimethyl Sulfoxide (DMSO) for the Treatment of Painful Bladder Syndrome Including Interstitial Cystitis (PBS/IC) [NCT00317070]Phase 210 participants (Actual)Interventional2006-04-30Terminated(stopped due to Poor recruitment, poor patient compliance, lack of funding)
In Vivo Clinical Evaluation of Dimethyl Sulfoxide Dentin Pre-treatment Prior to a Two-step Etch and Rinse Adhesive: Randomized Controlled Trial [NCT04492306]24 participants (Actual)Interventional2020-11-17Completed
A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease [NCT02281760]Phase 29 participants (Actual)Interventional2014-11-01Completed
Impact of Different DMSO Concentrations in Cryopreservation Mixture on Hematopoietic Recovery After Autologous Transplantation of Hematopoietic Stem Cells. [NCT02452099]150 participants (Actual)Interventional2014-01-31Completed
A Study to Assess the Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Osteoarthritis Patients [NCT01980940]Phase 1/Phase 270 participants (Actual)Interventional2013-12-23Completed
The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma [NCT04527549]Phase 284 participants (Anticipated)Interventional2021-06-01Active, not recruiting
An Open-label, Randomized, 2-treatment, 2-period, 2-way Crossover, Single-dose Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies [NCT01725100]Phase 180 participants (Actual)Interventional2013-02-05Completed
MATCH Treatment Subprotocol R: Phase II Study of Trametinib in Patients With BRAF Fusions, or With NonV600E, Non-V600K BRAF Mutations [NCT04439279]Phase 235 participants (Actual)Interventional2015-08-12Active, not recruiting
Dose Escalation Study Evaluating the Safety of Dimethyl Sulfoxide Cryopreserved Platelets Compared With Liquid Stored Platelets in Patients With Uncontrolled Bleeding [NCT02078284]Phase 128 participants (Actual)Interventional2014-11-05Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00583219 (14) [back to overview]Urinary Urgency at 1 Month
NCT00583219 (14) [back to overview]Urine Culture
NCT00583219 (14) [back to overview]Urinary Urgency at Baseline
NCT00583219 (14) [back to overview]Urinary Urgency at 3 Months
NCT00583219 (14) [back to overview]Blaivas-Groutz Anti-Incontinence Score at 1 Month
NCT00583219 (14) [back to overview]Blaivas-Groutz Anti-Incontinence Score at 3 Months
NCT00583219 (14) [back to overview]Blaivas-Groutz Anti-Incontinence Score at Baseline
NCT00583219 (14) [back to overview]Bothersomeness
NCT00583219 (14) [back to overview]Incontinence Impact Questionnaire-short Form (IIQ-7) Scores
NCT00583219 (14) [back to overview]Mean Number of Pads Per Day
NCT00583219 (14) [back to overview]Median 24 Hour Pad Weight
NCT00583219 (14) [back to overview]Median Number of Incontinent Episodes During 24 Hours
NCT00583219 (14) [back to overview]Median Urogenital Distress Inventory (UDI-6) Scores
NCT00583219 (14) [back to overview]Postvoid Residual
NCT00667095 (6) [back to overview]Number of Participants With a Decrease in Urinary Urgency at 1 Month and 3 Months
NCT00667095 (6) [back to overview]Change in Incontinence Impact Questionnaire Short Form (IIQ-7)
NCT00667095 (6) [back to overview]Change in Incontinence Quality of Life (I-QoL) Score
NCT00667095 (6) [back to overview]Change in International Consultation on Incontinence Questionnaire - Short Form Score (ICIQ-SF)
NCT00667095 (6) [back to overview]Change in Urogenital Distress Inventory (UDI-6)
NCT00667095 (6) [back to overview]Number of Participants With Decrease in Blaivas-Groutz Anti-Incontinence Score at 1 Month and 3 Months
NCT01902173 (2) [back to overview]Maximum-tolerated Dose (MTD) of Akt Inhibitor GSK2141795 in Combination With Dabrafenib.
NCT01902173 (2) [back to overview]Maximum-tolerated Dose (MTD) of Akt Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib.
NCT01980940 (9) [back to overview]Study Part 2: Change From Baseline in Mean Participant Score on the WOMAC VA 3.1 Physical Functioning Scale
NCT01980940 (9) [back to overview]Study Part 2: Change From Baseline in Mean Participant Score on the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Visual Analog (VA) 3.1 Pain Scale
NCT01980940 (9) [back to overview]Study Parts 1 and 2: Number of Participants Who Experienced at Least One Adverse Event
NCT01980940 (9) [back to overview]Study Parts 1 and 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event
NCT01980940 (9) [back to overview]Study Part 1: Time to Maximum Concentration (Tmax) of ETOR After Single Dosing
NCT01980940 (9) [back to overview]Study Part 1: Maximum Concentration (Cmax) of ETOR After Single Dosing
NCT01980940 (9) [back to overview]Study Part 1: Area Under the Concentration-time Curve of ETOR From Time 0 to Last (AUC0-last) After Single Dosing
NCT01980940 (9) [back to overview]Study Part 2: Change From Baseline in Mean Participant Score on the WOMAC VA 3.1 Stiffness Scale
NCT01980940 (9) [back to overview]Study Part 2: Percentage of Participants by Category on Patient Global Assessment of Response to Therapy (PGART)
NCT02078284 (5) [back to overview]Number of Subject Who Experienced Adverse Events (AEs) for a Specific Severity
NCT02078284 (5) [back to overview]Number of Subject With Thrombotic Events
NCT02078284 (5) [back to overview]Adverse Events (AEs) by Level of Severity
NCT02078284 (5) [back to overview]Corrected Count Increments (CCI)
NCT02078284 (5) [back to overview]Count Increment
NCT02101788 (7) [back to overview]Patient Reported Acute Peripheral Neuropathy Symptoms
NCT02101788 (7) [back to overview]Progression-free Survival (PFS)
NCT02101788 (7) [back to overview]Progression Free Survival
NCT02101788 (7) [back to overview]Overall Survival
NCT02101788 (7) [back to overview]Objective Tumor Response Rate (Complete Response and Partial Response)
NCT02101788 (7) [back to overview]Incidence of Adverse Events (AEs)
NCT02101788 (7) [back to overview]Patients Reported Acute Quality of Life
NCT02281760 (7) [back to overview]Disease Resistance to Dabrafenib/Trametinib Combination Therapy in a Cohort of Patients With BRAFV600E Positive Erdheim Chester Disease
NCT02281760 (7) [back to overview]Number of Participants With Adverse Events to Dabrafenib and/or Trametinib
NCT02281760 (7) [back to overview]Number of Participants With Partial Response to Dabrafenib and Trametinib
NCT02281760 (7) [back to overview]Overall Survival in a Cohort of Patients With BRAFV600E Positive Erdheim Chester Disease
NCT02281760 (7) [back to overview]Progression-free Survival in a Cohort of Patients With BRAFV600E Positive Erdheim Chester Disease
NCT02281760 (7) [back to overview]Time Response to Dabrafenib/Trametinib Combination Therapy in a Cohort of Patients With BRAFV600E Positive Erdheim Chester Disease.
NCT02281760 (7) [back to overview]Clinical Response Rate to Dabrafenib/Trametinib Combination Therapy in a Cohort of Patients With BRAFV600E Positive Erdheim Chester Disease.
NCT04439279 (3) [back to overview]Overall Response Rate (ORR)
NCT04439279 (3) [back to overview]Progression-free Survival
NCT04439279 (3) [back to overview]6-month Progression-free Survival (PFS) Rate
NCT04439318 (3) [back to overview]Progression Free Survival (PFS)
NCT04439318 (3) [back to overview]Objective Response Rate (ORR)
NCT04439318 (3) [back to overview]6-month Progression-free Survival (PFS) Rate
NCT04439357 (3) [back to overview]Progression Free Survival (PFS)
NCT04439357 (3) [back to overview]Objective Response Rate (ORR)
NCT04439357 (3) [back to overview]6-month Progression-free Survival (PFS) Rate

Urinary Urgency at 1 Month

"Urinary urgency was measured by the Indevus Urgency Severity Scale (IUSS). The IUSS asks patients to assess the severity of 'urgency' at each void. The scale employs the following wording: Degree of urgency is meant to describe your urge to urinate. Sometimes you may feel a very strong urge to urinate and at other times, you may feel a milder urge prior to the onset of a toilet void. Rate this feeling by circling 0, 1, 2, or 3, defined as: 0: NONE - no urgency, 1: MILD - awareness of urgency, but it is easily tolerated and you can continue with your usual activity or tasks, 2: MODERATE - enough urgency discomfort that it interferes with or shortens your usual activity or tasks, 3: SEVERE - extreme urgency discomfort that abruptly stops all activity or tasks." (NCT00583219)
Timeframe: 1 month after treatment

Interventionparticipants (per category) (Number)
NoneMildModerateSevere
Botox/DMSO Solution01371

[back to top]

Urine Culture

(NCT00583219)
Timeframe: baseline, 1 month, 3 months

Interventionparticipants (Number)
baseline negativebaseline positive1 month negative1 month positive3 months negative3 months positive
Botox/DMSO Solution165165138

[back to top]

Urinary Urgency at Baseline

"Urinary urgency was measured by the Indevus Urgency Severity Scale (IUSS). The IUSS asks patients to assess the severity of 'urgency' at each void. The scale employs the following wording: Degree of urgency is meant to describe your urge to urinate. Sometimes you may feel a very strong urge to urinate and at other times, you may feel a milder urge prior to the onset of a toilet void. Rate this feeling by circling 0, 1, 2, or 3, defined as: 0: NONE - no urgency, 1: MILD - awareness of urgency, but it is easily tolerated and you can continue with your usual activity or tasks, 2: MODERATE - enough urgency discomfort that it interferes with or shortens your usual activity or tasks, 3: SEVERE - extreme urgency discomfort that abruptly stops all activity or tasks." (NCT00583219)
Timeframe: baseline

Interventionparticipants (per category) (Number)
NoneMildModerateSevere
Botox/DMSO Solution02811

[back to top]

Urinary Urgency at 3 Months

"Urinary urgency was measured by the Indevus Urgency Severity Scale (IUSS). The IUSS asks patients to assess the severity of 'urgency' at each void. The scale employs the following wording: Degree of urgency is meant to describe your urge to urinate. Sometimes you may feel a very strong urge to urinate and at other times, you may feel a milder urge prior to the onset of a toilet void. Rate this feeling by circling 0, 1, 2, or 3, defined as: 0: NONE - no urgency, 1: MILD - awareness of urgency, but it is easily tolerated and you can continue with your usual activity or tasks, 2: MODERATE - enough urgency discomfort that it interferes with or shortens your usual activity or tasks, 3: SEVERE - extreme urgency discomfort that abruptly stops all activity or tasks." (NCT00583219)
Timeframe: 3 months after treatment

Interventionparticipants (per category) (Number)
NoneMildModerateSevere
Botox/DMSO Solution01173

[back to top]

Blaivas-Groutz Anti-Incontinence Score at 1 Month

The Blaivas-Groutz Anti-incontinence scale was used as a measure of urinary incontinence. This scale combines information on the number of incontinent episodes in a 24-hour period, 24-hour pad weights, and a qualitative rating by the patient into a single score ranging from 0 to 6. This score is then used to categorize incontinence as none (0), mild (1-2), moderate (3-4), or severe (5-6). (NCT00583219)
Timeframe: 1 month after treatment

Interventionparticipants (per category) (Number)
NoneMildModerateSevere
Botox/DMSO Solution15510

[back to top]

Blaivas-Groutz Anti-Incontinence Score at 3 Months

The Blaivas-Groutz Anti-incontinence scale was used as a measure of urinary incontinence. This scale combines information on the number of incontinent episodes in a 24-hour period, 24-hour pad weights, and a qualitative rating by the patient into a single score ranging from 0 to 6. This score is then used to categorize incontinence as none (0), mild (1-2), moderate (3-4), or severe (5-6). (NCT00583219)
Timeframe: 3 months after treatment

Interventionparticipants (per category) (Number)
NoneMildModerateSevere
Botox/DMSO Solution02613

[back to top]

Blaivas-Groutz Anti-Incontinence Score at Baseline

The Blaivas-Groutz Anti-incontinence scale was used as a measure of urinary incontinence. This scale combines information on the number of incontinent episodes in a 24-hour period, 24-hour pad weights, and a qualitative rating by the patient into a single score ranging from 0 to 6. This score is then used to categorize incontinence as none (0), mild (1-2), moderate (3-4), or severe (5-6). (NCT00583219)
Timeframe: baseline

Interventionparticipants (per category) (Number)
NoneMildModerateSevere
Botox/DMSO Solution04116

[back to top]

Bothersomeness

The bothersomeness refers to the question: On a scale of 1-10 (0 is not at all; 10 is intolerable), how badly does loss of urinary control bother you? (NCT00583219)
Timeframe: baseline, 1 month, 3 months

Interventionunits on a scale (Median)
Baseline1 month3 months
Botox/DMSO Solution955

[back to top]

Incontinence Impact Questionnaire-short Form (IIQ-7) Scores

The IIQ-7 was one measure of urinary-associated quality of life. The IIQ-7 questionnaire has 7 items, scored from 0 (not at all) to 3 (greatly), with total scores ranging from 0 to 21, a higher score indicating greater distress. (NCT00583219)
Timeframe: baseline, 1 month, 3 months

Interventionunits on a scale (Median)
Baseline1 month3 months
Botox/DMSO Solution1376

[back to top]

Mean Number of Pads Per Day

(NCT00583219)
Timeframe: baseline, 1 month, 3 months

Interventionpads per day (Mean)
Baseline1 month3 months
Botox/DMSO Solution433

[back to top]

Median 24 Hour Pad Weight

Prior to baseline and follow-up visits, the study coordinator weighed standard pads provided to the subject for the study time period. The study coordinator instructed the subject to bring in any pads used during the 24-hour period prior to baseline and follow up visits. The study coordinator recorded the 24-hour pad weights into the study dataset. (NCT00583219)
Timeframe: baseline, 1 month, 3 months

Interventiong (Median)
Baseline1 month3 months
Botox/DMSO Solution1354655

[back to top]

Median Number of Incontinent Episodes During 24 Hours

The study coordinator instructed the subject to keep record of any incontinence episodes during the 24-hour period prior to their baseline and follow-up visits. (NCT00583219)
Timeframe: baseline, 1 month, 3 months

Interventionnumber of incontinent episodes (Median)
Baseline1 month3 months
Botox/DMSO Solution424

[back to top]

Median Urogenital Distress Inventory (UDI-6) Scores

The UDI-6 was one measure of urinary-associated quality of life. The UDI-6 questionnaire has 6 items, scored from 0 (not at all) to 3 (greatly), with total scores ranging from 0 to 18, a higher score indicating greater distress. (NCT00583219)
Timeframe: baseline, 1 month, 3 months

Interventionunits on a scale (Median)
Baseline1 month3 months
Botox/DMSO Solution1056

[back to top]

Postvoid Residual

(NCT00583219)
Timeframe: baseline, 1 month, 3 months

InterventionmL (Median)
Baseline1 month3 months
Botox/DMSO Solution81924

[back to top]

Number of Participants With a Decrease in Urinary Urgency at 1 Month and 3 Months

"Urinary urgency was measured by the Indevus Urgency Severity Scale (IUSS). The IUSS asks patients to assess the severity of 'urgency' at each void. The scale employs the following wording: Degree of urgency is meant to describe your urge to urinate. Sometimes you may feel a very strong urge to urinate and at other times, you may feel a milder urge prior to the onset of a toilet void. Rate this feeling by circling 0, 1, 2, or 3, defined as: 0: NONE - no urgency, 1: MILD - awareness of urgency, but it is easily tolerated and you can continue with your usual activity or tasks, 2: MODERATE - enough urgency discomfort that it interferes with or shortens your usual activity or tasks, 3: SEVERE - extreme urgency discomfort that abruptly stops all activity or tasks." (NCT00667095)
Timeframe: Baseline, 1 month, 3 months

,
Interventionparticipants (Number)
1 month3 months (n=11, 9)
Botox and DMSO Instillation45
DMSO Instillation10

[back to top]

Change in Incontinence Impact Questionnaire Short Form (IIQ-7)

"The IIQ-7 measures the effect of urinary incontinence on quality of life. It is comprised of 7 items, each with the response scale from 0=Not at all to 3=Greatly. The scores can range from 0 to 21; a low score indicates less impact of incontinence on quality of life." (NCT00667095)
Timeframe: baseline, 1 month, 3 months

,
Interventionunits on a scale (Mean)
Change from baseline to 1 monthChange from baseline to 3 months (n=11, 9)
Botox and DMSO Instillation-2.5-1.8
DMSO Instillation2.01.1

[back to top]

Change in Incontinence Quality of Life (I-QoL) Score

"The I-QoL measures the effect of urinary incontinence on quality of life. It is divided into 3 subscales: 1) avoidance and limiting behavior, 2) psychosocial impact, and 3) social embarrassment. The I-QOL is comprised of 22 items, each with the response scale from '1= Extremely' to '5= Not at all'.~A mean score for each subscale is calculated (averaging the scores for the items in each subscale) as well as a total score for all 22 items (sum of all subscale scores). The scores are then transformed to a 'Scale score' ranging from 0-100 points for ease of interpretation: Scale score = (sum of the items - lowest possible score)/possible raw score range X 100. Higher scores indicate less impact of incontinence on quality of life." (NCT00667095)
Timeframe: Baseline, 1 month, 3 months

,
Interventionunits on a scale (Mean)
Change from baseline to 1 monthChange from baseline to 3 months (n=11, 9)
Botox and DMSO Instillation9.68.6
DMSO Instillation-3.9-4.0

[back to top]

Change in International Consultation on Incontinence Questionnaire - Short Form Score (ICIQ-SF)

The ICIQ-SF provides a brief and robust measure to assess the impact of symptoms of incontinence on quality of life and outcome of treatment. The questionnaire has 4 items and the score can range from 0 to 21, with greater values indicating increased severity of symptoms and lower quality of life. (NCT00667095)
Timeframe: baseline, 1 month, 3 months

,
Interventionunits on a scale (Mean)
Change from baseline to 1 monthChange from baseline to 3 months (n=11, 9)
Botox and DMSO Instillation-2.4-2.5
DMSO Instillation-0.50.8

[back to top]

Change in Urogenital Distress Inventory (UDI-6)

"The UDI-6 measures the effect of urinary incontinence on quality of life. It consists of 6 items, each with the response scale from 0=Not at all to 3=Greatly. The scores can range from 0 to 18; a low score indicates less impact of incontinence on quality of life." (NCT00667095)
Timeframe: baseline, 1 month, 3 months

,
Interventionunits on a scale (Mean)
Change from baseline to 1 monthChange from baseline to 3 months (n=11, 9)
Botox and DMSO Instillation-1.9-0.9
DMSO Instillation-0.1-0.4

[back to top]

Number of Participants With Decrease in Blaivas-Groutz Anti-Incontinence Score at 1 Month and 3 Months

The Blaivas-Groutz Anti-incontinence scale was used as a measure of urinary incontinence. This scale combines information on the number of incontinent episodes in a 24-hour period, 24-hour pad weights, and a qualitative rating by the patient into a single score ranging from 0 to 6. this score is then used to categorize incontinence as none (0), mild (1-2), moderate (3-4), or severe (5-6). (NCT00667095)
Timeframe: baseline, 1 month, 3 months

,
Interventionparticipants (Number)
1 month3 months (n=11, 9)
Botox and DMSO Instillation66
DMSO Instillation42

[back to top]

Maximum-tolerated Dose (MTD) of Akt Inhibitor GSK2141795 in Combination With Dabrafenib.

MTD was evaluated by testing increasing doses up to 75 mg once a day, given in combination with dabrafenib dosed at 150 mg twice daily. MTD reflects the highest dose that did not cause a DLT. DLTs were defined as treatment regimen related: febrile neutropenia; Grade 4 neutropenia lasting more than 7 days; Grade 4 platelet count decrease; Grade 3-4 rash, fever, or hyperglycemia > 14 days, e) Grade 3-4 non-hematologic adverse events lasting greater than 7 days. Adverse events were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. (NCT01902173)
Timeframe: Every 2 weeks during days 1-56 of treatment.

Interventionmg (Number)
Phase 1 Doublet Regimen75

[back to top]

Maximum-tolerated Dose (MTD) of Akt Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib.

"MTD was evaluated by testing increasing doses up to 75 mg once a day, given in combination with dabrafenib dosed at 150 mg twice daily and trametinib at either 1.5 mg or 2 mg once a day. MTD reflects the highest dose that did not cause a dose-limiting toxicity (DLT). DLTs were defined as treatment regimen related: febrile neutropenia; Grade 4 neutropenia lasting more than 7 days; Grade 4 platelet count decrease; Grade 3-4 rash, fever, or hyperglycemia > 14 days, e) Grade 3-4 non-hematologic adverse events lasting greater than 7 days. Adverse events were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.~Note: MTD for the triplet regimen could not be determined due to the end of supply of the study drug. Number reported is the maximum dose of GSK2141795 that was assessed in combination with 150 mg Dabrafenib and 2 mg trametinib." (NCT01902173)
Timeframe: Every 2 weeks during days 1-56 of treatment.

Interventionmg (Number)
Phase 1 Triplet Regimen75

[back to top]

Study Part 2: Change From Baseline in Mean Participant Score on the WOMAC VA 3.1 Physical Functioning Scale

The WOMAC VA 3.1 Physical Functioning subscale is a self-administered questionnaire assessing lower extremity physical function due to osteoarthritis that was completed by participants 2 to 3 hours post morning dose. The WOMAC Physical Functioning subscale had 17 questions with answers to each item assessed on a 100 mm VA scale (0 = no difficulty; 100 = extreme difficulty). The score for each item was summed and the overall score ranged from 0 to 1700 (increasing severity). The time weighted average up to day x was calculated as the sum of rectangles under the curve for successive intervals prior to day x as defined by timepoints at which assessments were made. The time weighted change from baseline was calculated. A negative mean change from baseline indicates improvement in physical function. (NCT01980940)
Timeframe: Baseline (Day -1), Day 2, Day 4, Day 7, Day 11, Day 14

,
InterventionUnits on a scale (Mean)
BL to Day 2BL to Day 4BL to Day 7BL to Day 11BL to Day 14
ETOR 50 DMSO-117.13-147.71-172.94-214.87-250.82
Placebo (Pt 2)-153.54-171.35-199.88-245.05-280.29

[back to top]

Study Part 2: Change From Baseline in Mean Participant Score on the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Visual Analog (VA) 3.1 Pain Scale

The WOMAC VA 3.1 Pain subscale is a self-administered questionnaire assessing lower extremity pain due to osteoarthritis that was completed by participants 2 to 3 hours post morning dose. The WOMAC Pain Subscale had five questions with answers to each item assessed on a 100 mm VA scale (0 = no pain; 100 = extreme pain). The score for each item was summed and the overall score ranged from 0 to 500 (increasing severity). The time weighted average up to day x was calculated as the sum of rectangles under the curve for successive intervals prior to day x as defined by timepoints at which assessments were made. The time weighted change from baseline was calculated. A negative mean change from baseline indicates improvement in pain. (NCT01980940)
Timeframe: Baseline (Day -1), Day 2, Day 4, Day 7, Day 11, Day 14

,
InterventionUnits on a scale (Mean)
BL to Day 2BL to Day 4BL to Day 7BL to Day 11BL to Day 14
ETOR 50 DMSO-24.21-34.29-45.81-59.42-69.60
Placebo (Pt 2)-37.21-43.92-54.11-63.60-72.60

[back to top]

Study Parts 1 and 2: Number of Participants Who Experienced at Least One Adverse Event

An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure. (NCT01980940)
Timeframe: Study Part 1: up to Day 47; Study Part 2: up to Day 28

InterventionParticipants (Number)
ETOR 75 DMSO1
ETOR 75 PG (Pt 1)1
ETOR 150 DMSO (Pt 1)1
ETOR 150 PG (Pt 1)1
ETOR OD (Pt 1)2
Placebo (Pt 1) (Deviation)0
ETOR 50 DMSO (Pt 2)6
Placebo (Pt 2)5

[back to top]

Study Parts 1 and 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event

An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure. (NCT01980940)
Timeframe: Study Part 1: up to Day 47; Study Part 2: up to Day 28

InterventionParticipants (Number)
ETOR 75 DMSO0
ETOR 75 PG (Pt 1)0
ETOR 150 DMSO (Pt 1)0
ETOR 150 PG (Pt 1)0
ETOR OD (Pt 1)0
Placebo (Pt 1) (Deviation)0
ETOR 50 DMSO (Pt 2)0
Placebo (Pt 2)0

[back to top]

Study Part 1: Time to Maximum Concentration (Tmax) of ETOR After Single Dosing

Tmax determined for the period up to 72 hours post-single application. (NCT01980940)
Timeframe: Predose and 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, 24, 36, 48, and 72 hours post-application

Interventionhour (Median)
ETOR 75 DMSO30.0
ETOR 75 PG48.0
ETOR 150 DMSO24.0
ETOR 150 PG48
ETOR OD36.0

[back to top]

Study Part 1: Maximum Concentration (Cmax) of ETOR After Single Dosing

Cmax determined for the period up to 72 hours post-single application. Descriptive statistics are expressed as the geometric least squares mean (GLSM). Cmax with value 0 included in calculation of GLSMs with a value of 0.5*LLOQ (=0.5 h*ng/ml). (NCT01980940)
Timeframe: Predose and 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, 24, 36, 48, and 72 hours post-application

Interventionmg (Least Squares Mean)
ETOR 75 DMSO12.39
ETOR 75 PG2.43
ETOR 150 DMSO27.30
ETOR 150 PG3.74

[back to top]

Study Part 1: Area Under the Concentration-time Curve of ETOR From Time 0 to Last (AUC0-last) After Single Dosing

Area under the observed concentration-time curve from time zero to the last quantifiable time point determined for the period up to 72 hours post-single application. The area was calculated according to the linear up/log down trapezoidal rule. AUC0-last is an estimate of total plasma exposure. Descriptive statistics are expressed as the GLSM. AUC with value 0 included in calculation of GLSMs with a value of 0.5*LLOQ (=0.5 h*ng/ml). (NCT01980940)
Timeframe: Predose and 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, 24, 36, 48, and 72 hours post-application

Interventionmg (Least Squares Mean)
ETOR 75 DMSO611.3
ETOR 75 PG65.6
ETOR 150 DMSO1309.7
ETOR 150 PG161.3

[back to top]

Study Part 2: Change From Baseline in Mean Participant Score on the WOMAC VA 3.1 Stiffness Scale

The WOMAC VA 3.1 Stiffness subscale is a self-administered questionnaire assessing lower extremity stiffness due to osteoarthritis that was completed by participants 2 to 3 hours post morning dose. The WOMAC Stiffness subscale had two questions with answers to each item assessed on a 100 mm VA scale (0 = no stiffness; 100 = extreme stiffness). The score for each item was summed and the overall score ranged from 0 to 200 (increasing severity). The time weighted average up to day x was calculated as the sum of rectangles under the curve for successive intervals prior to day x as defined by timepoints at which assessments were made. The time weighted change from baseline was calculated. A negative mean change from baseline indicates improvement in stiffness. (NCT01980940)
Timeframe: Baseline (Day -1), Day 2, Day 4, Day 7, Day 11, Day 14

,
InterventionUnits on a scale (Mean)
BL to Day 2BL to Day 4BL to Day 7BL to Day 11BL to Day 14
ETOR 50 DMSO-9.17-14.69-19.34-24.44-29.22
Placebo (Pt 2)-16.79-18.79-23.08-26.87-30.52

[back to top]

Study Part 2: Percentage of Participants by Category on Patient Global Assessment of Response to Therapy (PGART)

The PGART is a self-administered questionnaire completed by participants. Participant assessment of response of arthritis to study medication was assessed on a 5-point Likert scale ('very well', 'well', 'fair', 'poor', and 'very poor'). (NCT01980940)
Timeframe: Day 2, Day 4, Day 7, Day 11, Day 14, post-trial (up to Day 28)

,
InterventionPercentage of participants (Number)
Day 2: Very wellDay 2: WellDay 2: FairDay 2: PoorDay 2: Very poorDay 4: Very wellDay 4: WellDay 4: FairDay 4: PoorDay 4: Very poorDay 7: Very wellDay 7: WellDay 7: FairDay 7: PoorDay 7: Very poorDay 11: Very wellDay 11: WellDay 11: FairDay 11: PoorDay 11: Very poorDay 14: Very wellDay 14: WellDay 14: FairDay 14: PoorDay 14: Very poorPost-trial: Very wellPost-trial: WellPost-trial: FairPost-trial: PoorPost-trial: Very poor
ETOR 50 DMSO0.020.825.037.516.70.020.845.829.24.20.025.050.025.00.00.037.545.816.70.00.054.241.74.20.08.362.529.200.0
Placebo (Pt 2)0.033.325.033.38.30.033.337.525.04.20.037.537.525.00.00.050.037.512.50.08.350.033.38.30.08.350.029.212.50.0

[back to top]

Number of Subject Who Experienced Adverse Events (AEs) for a Specific Severity

Number of subjects who experienced AEs at specific levels of severity. Clinical laboratory [chemistry (serum creatinine, lactate dehydrogenase (LDH), and troponin, and hematology (hemoglobin and hematocrit)] parameters, physical examination findings, electrocardiogram (ECG)] and vital signs were evaluated. (NCT02078284)
Timeframe: day of thru 6 days after transfusion

,,,,
InterventionParticipants (Count of Participants)
Total Patients with Any AETotal Patients with Mild AEsTotal Patients with Moderate AEsTotal Patients with Severe AEssTotal Patients with Life-threatening or Fatal AEsRelated to Investigational Product
1 Unit of LSP1110000
Cohort 1 With 0.5 Units of CPP4441011
Cohort 2 With 1 Unit of CPP6641112
Cohort 3 With 2 Units of CPP3313022
Cohort 4 With 3 Units of CPP5551122

[back to top]

Number of Subject With Thrombotic Events

Subjects with any signs or symptoms of thrombotic events. (NCT02078284)
Timeframe: 6 days after transfusion

InterventionParticipants (Count of Participants)
Cohort 1 With 0.5 Units of CPP0
Cohort 2 With 1 Unit of CPP0
Cohort 3 With 2 Units of CPP0
Cohort 4 With 3 Units of CPP0
1 Unit of LSP0

[back to top]

Adverse Events (AEs) by Level of Severity

Clinical laboratory [chemistry (serum creatinine, lactate dehydrogenase (LDH), and troponin, and hematology (hemoglobin and hematocrit)] parameters, physical examination findings, electrocardiogram (ECG)] and vital sign AEs summarized by severity. (NCT02078284)
Timeframe: day of thru 6 days after transfusion

,,,,
Interventionadverse events (Number)
Total number of AEsTotal mild AEsTotal moderate AEsTotal Severe AEsTotal Life-threatening or Fatal AEs
1 Unit of LSP55000
Cohort 1 With 0.5 Units of CPP86101
Cohort 2 With 1 Unit of CPP1811313
Cohort 3 With 2 Units of CPP61500
Cohort 4 With 3 Units of CPP219516

[back to top]

Corrected Count Increments (CCI)

Corrected Count Increments Expressed in units of mm^2/(µL*10¹¹ platelets) (CCI) in the 6 hour period after the study platelet transfusion and on Day 2 (approximately 24 hours after the study platelet transfusion) (NCT02078284)
Timeframe: Day 1 up to 6 hrs after transfusion and Day 2 approx 24 hrs after transfusion

,,,,
Interventionmm^2/(μL*1011 platelets) (Mean)
CII: Day 1 up to 6 hrs afterCII: Day 2
1 Unit of LSP14.84.13
Cohort 1 With 0.5 Units of CPP2.405.19
Cohort 2 With 1 Unit of CPP3.10-2.05
Cohort 3 With 2 Units of CPP2.735.63
Cohort 4 With 3 Units of CPP3.702.35

[back to top]

Count Increment

Count Increment expressed in units of platelets (x10^3 µL) (CI) (NCT02078284)
Timeframe: On Day 1 up to 6 hours after transfusion and on Day 2 approximately 24 hours after transfusion

,,,,
Interventionplatelets*10^3 µL (Mean)
Day 1 Up to 6 Hours AfterDay 2
1 Unit of LSP30.58.75
Cohort 1 With 0.5 Units of CPP1.202.80
Cohort 2 With 1 Unit of CPP3.67-2.57
Cohort 3 With 2 Units of CPP6.5012.5
Cohort 4 With 3 Units of CPP13.210.7

[back to top]

Patient Reported Acute Peripheral Neuropathy Symptoms

Patient reported peripheral neuropathy symptoms was measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 4 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). According to the FACIT measurement system, the Ntx score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the scale. The Ntx score ranges 0-16 with a large score suggesting less peripheral neuropathy symptoms (NCT02101788)
Timeframe: Up to 52 weeks

,
Interventionscore on a scale (Mean)
Baseline12 Weeks24 Weeks36 Weeks52 Weeks
Arm A (Letrozole, Tamoxifen, Paclitaxel, PLD, Topotecan)13.212.512.412.312.8
Arm B (Trametinib)12.812.612.112.612.4

[back to top]

Progression-free Survival (PFS)

Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last followup were censored on the date of last CT Scan.Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the PFS endpoint definition. (NCT02101788)
Timeframe: Time from study entry to time of progression or death, an average of 7 months for arm A and 13 months for arm B

Interventionmonths (Median)
Arm A - Control Arm7.2
Arm B - Experimental Arm13.0

[back to top]

Progression Free Survival

Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last followup were censored on the date of last CT Scan. RECIST v1.1 defines progression as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. (NCT02101788)
Timeframe: Time from study entry to time of progression or death, an average of 7 months for SOC and 13 months for the treatment (Trametinib) arm.

InterventionMonths (Median)
KRAS/BRAF/NRAS Mutant Group (MAPK Pathway) (Trametinib)13.2
KRAS/BRAF/NRAS Mutant Group (MAPK Pathway) (SOC)11.4
KRAS/BRAF/NRAS Wild-type (MAPK Pathway) (Trametinib)7.3
KRAS/BRAF/NRAS Wild-type (MAPK Pathway) (SOC)6.3

[back to top]

Overall Survival

Overall survival (OS) was defined as the number of months between study enrollment and death from any cause. Patients still alive at the last follow-up were censored on the date of last contact. Patients with disease progression on the Control arm were allowed to cross over to the trametinib arm. Per the protocol, the intent-to-treat OS analysis was not adjusted for crossover. (NCT02101788)
Timeframe: Time from study entry to time of death or date of last contact, an average of 29 months for arm A and 37 months for arm B

InterventionMonths (Median)
Arm A - Control Arm29.2
Arm B - Experimental Arm37.0

[back to top]

Objective Tumor Response Rate (Complete Response and Partial Response)

The Response Rates were estimated as the binomial proportion of patients with Best Overall Response of Complete or Partial response according to RECIST 1.1 criteria. (NCT02101788)
Timeframe: Time from study entry to time of progression or death, an average of 7 months for arm A and 13 months for arm B

Interventionparticipants (Number)
Arm A - Control Arm8
Arm B - Experimental Arm34

[back to top]

Incidence of Adverse Events (AEs)

Number of treated patients with Adverse Events (grade 3 or higher) observed while receiving randomized therapy. Excludes AEs observed among control patients treated with trametinib after crossover.Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the AE endpoint definition. (NCT02101788)
Timeframe: During treatment period and up to 100 days after stopping the study treatment

,
Interventionparticipants (Number)
Abdominal painAnemiaDiarrheaFatigueHypertensionNauseaNeutrophil count decreasedRash maculo-papularSmall Intestinal ObstructionVomiting
Arm A - Control Arm22124561410910
Arm B - Experimental Arm7161310151289169

[back to top]

Patients Reported Acute Quality of Life

Patient reported quality of life was measured with the Treatment Outcome Index (TOI) of the Functional Assessment of Cancer Therapy for ovarian cancer (FACT-O TOI). The FACT-O TOI is a scale for assessing general QOL of ovarian cancer patients. It consists of three subscales: Physical Well Being (7 items), Functional Well Being (7 items), and Ovarian Cancer subscale (11 items). . The FACT-O TOI score is calculated as the sum of the subscale scores if more than 80% of the FACT-O TOI items provide valid answers and all of the component subscales have valid scores. The FACT-O TOI score ranges 0-100 with a large score suggesting better QOL. Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the quality of life endpoint definition (NCT02101788)
Timeframe: 1. baseline (prior to cycle 1), 12 weeks (prior to cycle 4), 24 weeks (4 weeks post cycle 6), 36 weeks post cycle 1, 52 weeks post cycle 1.

,
Interventionscore on a scale (Mean)
Baseline12 Weeks24 Weeks36 Weeks52 Weeks
Arm A (Letrozole, Tamoxifen, Paclitaxel, PLD, Topotecan)74.574.270.269.372.1
Arm B (Trametinib)74.570.673.072.673.3

[back to top]

Disease Resistance to Dabrafenib/Trametinib Combination Therapy in a Cohort of Patients With BRAFV600E Positive Erdheim Chester Disease

Disease resistance to the combination therapy during the active treatment phase of the study. Resistance is defined as evidence of disease progression per RECIST 1.1 in a participant previously exhibiting stable disease or at least a partial response according to RECIST 1.1 criteria. Also, disease progression is defined as the requirement of dosage escalation in order to maintain current efficacy. (NCT02281760)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Combination Therapy With Dabrafenib and Trametinib in Patients With ECD0

[back to top]

Number of Participants With Adverse Events to Dabrafenib and/or Trametinib

Safety of dabrafenib and trametinib as combination therapy, or either drug as single-agent therapy among participants, as measured by the adverse event characteristics of participants. See the adverse event table for list of specific adverse events experienced. (NCT02281760)
Timeframe: 24 months

InterventionParticipants (Count of Participants)
Combination Therapy With Dabrafenib and Trametinib in Patients With ECD6

[back to top]

Number of Participants With Partial Response to Dabrafenib and Trametinib

Efficacy of dabrafenib and trametinib as combination therapy in patients with BRAFV600E positive Erdheim Chester Disease based on RECIST 1.1 criteria of a partial response greater than or equal to 30% decrease in at least one target lesion size. (NCT02281760)
Timeframe: 24 months

InterventionParticipants (Count of Participants)
Combination Therapy With Dabrafenib and Trametinib in Patients With ECD4

[back to top]

Overall Survival in a Cohort of Patients With BRAFV600E Positive Erdheim Chester Disease

Overall survival rate among participants defined as the number of patients alive at the end of the 24-month study period. (NCT02281760)
Timeframe: 24 months

InterventionParticipants (Count of Participants)
Combination Therapy With Dabrafenib and Trametinib in Patients With ECD6

[back to top]

Progression-free Survival in a Cohort of Patients With BRAFV600E Positive Erdheim Chester Disease

Progression free survival rate using RECIST 1.1 criteria among participants during the entire study period of 24 months. Progression is defined as a 20% increase in the diameter of target lesions, or a significant increase in a non-target lesion, or the appearance of new lesions. (NCT02281760)
Timeframe: 24 months

InterventionParticipants (Count of Participants)
Combination Therapy With Dabrafenib and Trametinib in Patients With ECD5

[back to top]

Time Response to Dabrafenib/Trametinib Combination Therapy in a Cohort of Patients With BRAFV600E Positive Erdheim Chester Disease.

Time to response to combination therapy defined as the minimum length of time elapsed during the active treatment phase to reach at least a partial response, as defined by RECIST 1.1 criteria. (NCT02281760)
Timeframe: 12 months

Interventionmonths (Mean)
Combination Therapy With Dabrafenib and Trametinib in Patients With ECD5.5

[back to top]

Clinical Response Rate to Dabrafenib/Trametinib Combination Therapy in a Cohort of Patients With BRAFV600E Positive Erdheim Chester Disease.

Clinical response rate to dabrafenib and trametinib combination therapy in patients as measured by the percentage of patients who met RECIST 1.1 criteria for a partial response. (NCT02281760)
Timeframe: 24 months

InterventionParticipants (Count of Participants)
Combination Therapy With Dabrafenib and Trametinib in Patients With ECD4

[back to top]

Overall Response Rate (ORR)

Overall response rate was defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) among all eligible and treated patients. Best overall response was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. The 90% two-sided binomial exact confidence interval was calculated for ORR. (NCT04439279)
Timeframe: assessed at baseline, then every 2 cycles until disease progression, up to 3 years post registration

Interventionpercentage of participants (Number)
Subprotocol R3

[back to top]

Progression-free Survival

PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. (NCT04439279)
Timeframe: assessed at baseline, then every 2 cycles until disease progression, up to 3 years post registration

Interventionmonths (Median)
Subprotocol R1.8

[back to top]

6-month Progression-free Survival (PFS) Rate

PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. The 6-month PFS rate was estimated using the Kaplan-Meier method which can provide a point estimate for any specific time point. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. (NCT04439279)
Timeframe: assessed at baseline, then every 2 cycles until disease progression, up to 3 years post registration

Interventionpercentage of participants (Number)
Subprotocol R20

[back to top]

Progression Free Survival (PFS)

PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression. (NCT04439318)
Timeframe: Assessed at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration

Interventionmonths (Median)
Treatment (Trametinib)1.9

[back to top]

Objective Response Rate (ORR)

Overall response rate was defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) among all eligible and treated patients. Best overall response was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for the detailed definitions of response criteria. The 90% two-sided binomial exact confidence interval was calculated for ORR. (NCT04439318)
Timeframe: Tumor assessments occurred at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration

Interventionpercentage of participants (Number)
Treatment (Trametinib)4.3

[back to top]

6-month Progression-free Survival (PFS) Rate

Progression free survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression. 6 month PFS rate was estimated using the Kaplan-Meier method, which can provide a point estimate for any specific time point. (NCT04439318)
Timeframe: Assessed at baseline, then every 2 cycles for the first 26 cycles, and every 3 cycles thereafter until disease progression, up to 3 years post registration, from which 6-month PFS rate is determined

Interventionpercentage of participants (Number)
Treatment (Trametinib)21

[back to top]

Progression Free Survival (PFS)

PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression. (NCT04439357)
Timeframe: Assessed at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration

Interventionmonths (Median)
Treatment (Trametinib)6.5

[back to top]

Objective Response Rate (ORR)

Overall response rate was defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) among all eligible and treated patients. Best overall response was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for the detailed definitions of response criteria. The 90% two-sided binomial exact confidence interval was calculated for ORR. (NCT04439357)
Timeframe: Tumor assessments occurred at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration

Interventionpercentage of participants (Number)
Treatment (Trametinib)25

[back to top]

6-month Progression-free Survival (PFS) Rate

Progression free survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression. 6 month PFS rate was estimated using the Kaplan-Meier method, which can provide a point estimate for any specific time point. (NCT04439357)
Timeframe: Assessed at baseline, then every 2 cycles for the first 26 cycles, and every 3 cycles thereafter until disease progression, up to 3 years post registration, from which 6-month PFS rate is determined

Interventionpercentage of participants (Number)
Treatment (Trametinib)50

[back to top]